Irs2-targeted oligonucleotides

IRS2-targeted oligonucleotides provide a selective and effective means to inhibit IRS2 expression in breast cancer cells, addressing the limitations of current breast cancer therapies by reducing tumor growth without hyperglycemia.

WO2026236639A1PCT designated stage Publication Date: 2026-11-12UNIV OF MASSACHUSETTS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027321
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current efforts to target the insulin and insulin-like growth factor signaling pathway in breast cancer have shown limited efficacy and often lead to hyperglycemia, highlighting the need for selective targeting of IRS2 to prevent tumor progression without adverse metabolic effects.

Method used

Development of IRS2-targeted oligonucleotides, specifically double-stranded RNA (dsRNA), which are designed to selectively silence IRS2 expression in breast cancer cells while minimizing impact on IRS1, using chemically modified strands and conjugation to enhance delivery.

Benefits of technology

The IRS2-targeted oligonucleotides effectively inhibit IRS2 expression, slowing breast tumor progression without causing hyperglycemia, and modulate tumor cell-intrinsic and extrinsic processes, reducing tumor growth and vascularization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027321_12112026_PF_FP_ABST
    Figure US2026027321_12112026_PF_FP_ABST
Patent Text Reader

Abstract

This disclosure relates to oligonucleotides targeting insulin receptor substrate 2 (IRS2) and methods of treating diseases such as breast cancer with the same.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Atorney Docket No.: UM9-328PC (776088)

[0002] IRS2-TARGETED OLIGONUCLEOTIDES

[0003] Related application

[0004] This application claims the benefit of U.S. Provisional Application Serial No.

[0005] 63 / 802,716, filed May 9, 2025, the entire disclosure of which is incorporated herein by reference.

[0006] Statement of Government Interest

[0007] This invention was made with government support under CA290778 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0008] Background

[0009] Breast cancer is a leading cause of cancer death worldwide. Dysregulation of the insulin and insulin-like growth factor signaling (IIS) pathway promotes breast cancer progression. Efforts to target the IIS pathway, however, have shown little efficacy and often lead to hyperglycemia in patients. Insulin receptor substrate (IRS) proteins are downstream adaptors of IIS receptors and represent unexplored therapeutic targets in breast cancer. IRS2 expression and activity is increased in aggressive breast tumors. Selectively targeting IRS2, therefore, may prevent tumor progression in breast cancers for which there are fewer effective therapies.

[0010] Summary

[0011] In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to any one of SEQ ID NOs: 1-17. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 1. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 2. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 3. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 4. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 5. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50

[0012] 82690703v1 1Atorney Docket No.: UM9-328PC (776088)

[0013] bases in length comprising substantial complementary to SEQ ID NO: 6. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 7. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 8. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 9. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 10. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 11. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 12. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 13. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 14. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 15. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 16. In one aspect, the disclosure provides an oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to SEQ ID NO: 17.

[0014] In certain embodiments, the oligonucleotide compound comprises substantial complementary to any one of SEQ IDNOs: 18-34. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 18. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 19. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 20. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 21. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 22. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 23. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 24. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 25. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 26. In certain embodiments, the

[0015] 82690703v1 2Atorney Docket No.: UM9-328PC (776088)

[0016] oligonucleotide compound comprises substantial complementary to SEQ ID NO: 27. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 28. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 29. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 30. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 31. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 32. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 33. In certain embodiments, the oligonucleotide compound comprises substantial complementary to SEQ ID NO: 34.

[0017] In certain embodiments, the oligonucleotide compound is a double stranded RNA (dsRNA), an antisense oligonucleotide (ASO), a microRNA (miRNA), or a short hairpin RNA (shRNA).

[0018] In certain embodiments, the oligonucleotide compound is a dsRNA comprising an antisense strand with substantial complementary to any one of SEQ ID NOs: 1-34 and a sense strand.

[0019] In certain embodiments, the antisense strand comprises no more than 3 mismatches with any one of SEQ ID NOs: 1-34. In certain embodiments, the antisense strand comprises full complementarity with any one of SEQ ID NOs: 1-34. In certain embodiments, no more than 2 mismatches are present between nucleotides 1-8 from the 5’ end the antisense strand and any one of SEQ ID NOs: 1-34.

[0020] In certain embodiments, the antisense strand is 15 nucleotides to 25 nucleotides in length. In certain embodiments, the antisense strand is 20 nucleotides in length. In certain embodiments, the antisense strand is 21 nucleotides in length. In certain embodiments, the antisense strand is 22 nucleotides in length.

[0021] In certain embodiments, the sense strand is 15 nucleotides to 25 nucleotides in length. In certain embodiments, the sense strand is 15 nucleotides in length. In certain embodiments, the sense strand is 16 nucleotides in length. In certain embodiments, the sense strand is 18 nucleotides in length. In certain embodiments, the sense strand is 20 nucleotides in length.

[0022] In certain embodiments, the dsRNA comprises a double-stranded region of 15 base pairs to 20 base pairs, optionally 15, 16, 18, or 20 base pairs.

[0023] In certain embodiments, the dsRNA comprises a blunt-end.

[0024] In certain embodiments, the dsRNA comprises at least one single stranded nucleotide overhang, optionally about a 2-nucleotide to 5-nucleotide single stranded nucleotide overhang.

[0025] 82690703v1 3Atorney Docket No.: UM9-328PC (776088)

[0026] In certain embodiments, the dsRNA comprises at least one modified nucleotide. In certain embodiments, the modified nucleotide comprises a 2'-O-methyl modified nucleotide, a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, or a mixture thereof.

[0027] In certain embodiments, the dsRNA comprises at least one modified internucleotide linkage. In certain embodiments, the modified intemucleotide linkage comprises a phosphorothioate internucleotide linkage. In certain embodiments, the dsRNA comprises 4-16 phosphorothioate intemucleotide linkages. In certain embodiments, the dsRNA comprises 8-13 phosphorothioate intemucleotide linkages.

[0028] In certain embodiments, the nucleotides at positions 1-2 to 1-7 from the 3’ end of the antisense strand are connected to each other via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1-2 from the 5’ end of the antisense strand are connected to each other via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1-2 from the 5’ end of the sense strand are connected to each other via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1-2 from the 3’ end of the sense strand are connected to each other via phosphorothioate intemucleotide linkages.

[0029] In certain embodiments, the dsRNA comprises at least 80% chemically modified nucleotides. In certain embodiments, the dsRNA is fully chemically modified.

[0030] In certain embodiments, the antisense strand comprises a 5’ phosphate, a 5 ’-alkyl phosphonate, a 5’ alkylene phosphonate, or a 5’ alkenyl phosphonate. In certain embodiments, the antisense strand comprises a 5’ vinyl phosphonate.

[0031] In certain embodiments: i) the antisense strand comprises or consists of the sequence of SEQ ID NO: 35, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 36, or a chemically modified variant thereof; ii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 37, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 38, or a chemically modified variant thereof; iii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 39, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 40, or a chemically modified variant thereof; iv) the antisense strand comprises or consists of the sequence of SEQ ID NO: 41, or a chemically modified variant thereof, and the senses strand comprises or

[0032] 82690703v1 4Atorney Docket No.: UM9-328PC (776088)

[0033] consists of the sequence of SEQ ID NO: 42, or a chemically modified variant thereof; v) the antisense strand comprises or consists of the sequence of SEQ ID NO: 43, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 44, or a chemically modified variant thereof; vi) the antisense strand comprises or consists of the sequence of SEQ ID NO: 45, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 46, or a chemically modified variant thereof; vii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 47, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 48, or a chemically modified variant thereof; viii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 49, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 50, or a chemically modified variant thereof; ix) the antisense strand comprises or consists of the sequence of SEQ ID NO: 51, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 52, or a chemically modified variant thereof; x) the antisense strand comprises or consists of the sequence of SEQ ID NO: 53, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 54, or a chemically modified variant thereof; xi) the antisense strand comprises or consists of the sequence of SEQ ID NO: 55, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 56, or a chemically modified variant thereof; xii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 57, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 58, or a chemically modified variant thereof; xiii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 59, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 60, or a chemically modified variant thereof; xiv) the antisense strand comprises or consists of the sequence of SEQ ID NO: 61, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 62, or a chemically modified variant thereof; xv) the antisense strand comprises or consists of the sequence of SEQ ID NO: 63, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 64, or a chemically modified variant thereof; xvi) the antisense strand comprises or consists of the sequence of SEQ ID NO: 65, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 66, or a chemically modified variant thereof; or xvii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 67, or a chemically

[0034] 82690703v1 5Atorney Docket No.: UM9-328PC (776088)

[0035] modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 68, or a chemically modified variant thereof.

[0036] In certain embodiments, a functional moiety is linked to the 5’ end and / or 3’ end of the antisense strand.

[0037] In certain embodiments, a functional moiety is linked to the 5’ end and / or 3’ end of the sense strand.

[0038] In certain embodiments, a functional moiety is linked to the 3’ end of the sense strand. In certain embodiments, the functional moiety comprises a dendron that comprises an end group, a phosphate group, and / or a hydrophobic chain.

[0039] In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NOs: 1-34. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 1. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to IRS2 nucleic acid sequence of SEQ ID NO: 2. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 3. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 4. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 5. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 6. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to IRS2 nucleic acid sequence of SEQ ID NO: 7. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 8. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially

[0040] 82690703v1 6Atorney Docket No.: UM9-328PC (776088)

[0041] complementary to IRS2 nucleic acid sequence of SEQ ID NO: 9. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 10. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 11. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 12. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to aIRS2 nucleic acid sequence of SEQ ID NO: 13. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 14. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 15. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 16. In one aspect, the disclosure provides a vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ ID NO: 17.

[0042] In certain embodiments, the RNA molecule inhibits the expression of said IRS2 gene by at least 20%. In certain embodiments, the RNA molecule inhibits the expression of said IRS 2 gene by at least 50%.

[0043] In one aspect, the disclosure provides a cell comprising the vector described herein. In one aspect, the disclosure provides a recombinant adeno-associated virus (rAAV) comprising the vector described herein and an AAV capsid.

[0044] In one aspect, the disclosure provides a branched RNA compound comprising two or more oligonucleotides described herein (e.g., dsRNA), wherein the two or more oligonucleotides are connected to one another by one or more moieties independently selected from a linker, a spacer and a branching point.

[0045] In certain embodiments, linker comprises an ethylene glycol chain, an alkyl chain, a peptide, an RNA, a DNA, a phosphate, a phosphonate, a phosphoramidate, an ester, an amide,

[0046] 82690703v1 7Atorney Docket No.: UM9-328PC (776088)

[0047] a triazole, or combinations thereof.

[0048] Brief Description of the Drawings

[0049] The foregoing and other features and advantages of the present disclosure will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0050] FIG. 1A - FIG. IK depict the identification of IRS2-selective siRNAs. In vitro screening of siRNAs in human MDA-MB-231 (FIG. 1A) and mouse 4T1 (FIG. IB) cells. Cells were treated with fully chemically modified siRNAs conjugated to cholesterol at 0.1875 pM (MDA-MB-231) and 1 ,5pM (4T1) for 72hr (n=3 independent samples). Seven-point doseresponse curves of lead / / :s2 siRNAs 5967, 6530, and 1110 in MDA-MB-231 cells (FIG. 1C) and Irs2 siRNAs 6548, 6696, and 6530 in 4T1 cells (FIG. ID) (n=3 independent samples). IRS2 and IRS1 protein expression in MDA-MB-231 cells (FIG. IE) and 4T1 cells (FIG. IF) after 72hr siRNA treatment (n=3-5 independent experiments). FIG. 1H shows Irs2 mRNA expression in skeletal muscle and FIG. II shows protein expression in liver 2 weeks after treatment with PBS, NTC DCA-siRNA, or Irs2 DCA-siRNA 6548 (n=5 mice / group). UNT = untreated control, NTC = nontargeting control. Data presented as means ±SD. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001 by one-way ANOVA. FIG. 1J and FIG. IK depict Irs2 mRNA (FIG. 1 J) and Irs2 and Irsl protein (FIG. IK) expression after treatment with speciesspecific, Irs2 -targeting siRNAs in the FL83B mouse hepatocyte cell line. n=6 independent samples (FIG. 1J) or n=3 independent experiments (FIG. IK) **p<0.01 ***p<0.001 ****p<0.0001 by one-way ANOVA.

[0051] FIG. 2A - FIG. 2J depict the effects of several conjugates on siRNA delivery to mammary tumors. FIG. 2A depicts a schematic of siRNA chemical modifications and the docosanoic acid (DCA), phosphocholine-docosanoic acid (PCDCA), and dendrimer (DENDR) conjugates. FIG. 2B and FIG. 2C depict whole-tissue (FIG. 2B) and confocal fluorescence microscopy (FIG. 2C) images of mammary tumors from mice subcutaneously injected with a single 40 mg / kg dose of Cy3-labeled unconjugated, DCA-conjugated, PCDCA-conjugated, or dendrimer-conjugated siRNAs targeting Htt (n=5 mice / group). FIG. 2D depicts tumor accumulation levels of Cy3-labeled siRNA 48hr after subcutaneous siRNA administration (n=4-5 mice / group). UNC unconjugated, DENDR dendrimer. **p<0.01***p<0.001****p<0.0001 by one-way ANOVA. FIG. 2E depicts representative

[0052] 82690703v1 8Atorney Docket No.: UM9-328PC (776088)

[0053] images of mammary fat pads from mice 48hr after one subcutaneous injection of PBS or 40mg / kg Cy3-labeled unconjugated (UNC), DCA-conjugated, or PCDCA-conjugated siRNAs targeting Htt (n=4 mice / group). FIG.2F depicts fluorescence microscopy images of mammary fat pad tissue in PBS- and siRNA-treated mice. siRNA antisense accumulation (FIG. 2G) and silencing efficacy (FIG. 2H) of unconjugated and lipid-conjugated siRNAs targeting Htt in mammary fat pad tissue 2 weeks after subcutaneous injection of PBS or 40mg / kg siRNA (n=5 mice / group) are also depicted. UNC unconjugated, NTC nontargeting control. ns=nonsignificant, *p<0.05**p<01***p<0.001 by one-way ANOVA. FIG. 21 depicts representative fluorescence microscopy images of mammary tumors 48hr after intratumoral injection of PBS or 40mg / kg unconjugated (UNC), DCA-conjugated, PCDCA-conjugated, or dendrimer-conjugated (DENDR) siRNAs. FIG. 2J depicts representative fluorescence microscopy images of tumor-associated mammary fat pad tissue 48hr after subcutaneous injection of PBS or 40mg / kg siRNA. n=5 mice / group.

[0054] FIG. 3A - FIG. 3G depict Dendrimer-conjugated siRNA internalization by all cell types within mammary tumors. FIG. 3A depicts a schematic of the assay, specifically 4T1 tumor-bearing mice were injected twice with 40mg / kg Cy3-labeled unconjugated or dendrimer-conjugated siRNA across 6 days to determine cell-specific siRNA delivery in mammary tumors. FIG. 3B depicts flow cytometric gating strategy of mammary tumors to identify primary tumor cells and tumor stromal and immune populations. Representative histograms (FIG. 3C) and quantification (FIG. 3D) of Cy3 median fluorescence intensity (MFI) in mammary tumor cell populations are depicted. FIG. 3E depicts quantification of the proportion of tumor cell populations with Cy3 fluorescence after siRNA administration. Analysis of n=4 tumors / group; UNC unconjugated, DENDR dendrimer. *p<0.05**p<0.01***p<0.001****p<0.0001 by two-way ANOVA. Tumor initiation (FIG.3F) and growth (FIG. 3G) curves of untreated 4T1 tumors are depicted.

[0055] FIG. 4A - FIG. 4M depict effects of administration of siRNAs targeting Irs2 on tumor gene silencing and tumor growth. FIG. 4A depicts tumor volumes before and after NTC and Irs2 siRNA administration. FIG. 4B depicts change in tumor volume after siRNA injection.

[0056] FIG. 4C depicts tumor volumes before and after NTC and Irs2 siRNA administration. FIG.

[0057] 4D depicts representative fluorescence microscopy of mammary tumors from mice subcutaneously injected with dendrimer-conjugated siRNAs targeting Irs2, Jakl, or nontargeting control (NTC). FIG. 4E depicts accumulation of Cy3-labeled siRNA targeting Irs2 in mammary tumor, pancreas, and liver tissue after subcutaneous administration of two 40mg / kg doses across 6 days. FIG. 4F depicts Irs2 mRNA expression in mammary tumor

[0058] 82690703v1 9Atorney Docket No.: UM9-328PC (776088)

[0059] biopsies. FIG. 4G depicts terminal serum glucose concentrations in 4T1 tumor-bearing mice after treatment with PBS, NTC siRNA, or Irs2 siRNA. FIG. 4H depicts representative H&E images and FIG. 41 depicts quantification of pancreatic islet number and size in PBS and siRNA-treated mice. Analysis of n=8-10mice / group. NTC nontargeting control, scale bar = 20 pm. Data are presented as means ±SD. ns=nonsignificant *p<0.05**p<0.01 by Student’s t-test (FIG. 4B, FIG. 4F); ns=nonsignificant *p<0.05****p<0.0001 by two-way ANOVA (FIG.

[0060] 4C, FIG. 4E); ns=nonsignificant by one-way ANOVA (FIG. 4G, FIG. 41). FIG. 4J and FIG.

[0061] 4K depict tumor volumes before and after NTC and Jakl siRNA administration. FIG. 4L depicts Cy3 -labeled Jakl siRNA antisense strand accumulation in tumor and secondary tissues.

[0062] FIG. 4M depicts Jakl expression in mammary tumor biopsies. Data are presented as means ±SD. ns=nonsignificant *p<0.05**p<0.01 by Student’s t-test (FIG. 4M); ns=nonsignificant *p<0.05****p<0.0001 by two-way ANOVA (FIG. 4K and 4L).

[0063] FIG. 5A - FIG. 5K depict the characterization of primary mammary tumors after treatment with / / :s2-targeting siRNA. FIG. 5A depicts quantification of mitotic counts in tumors from siRNA-treated mice. FIG. 5B depicts schematic of tumor-associated macrophage subsets. FIG. 5C and FIG. 5D depict flow cytometric analysis of the proportion of immune cell subsets (FIG. 5C) and macrophage subsets (FIG. 5D) within mammary tumors from mice treated with NTC orlrs2 siRNA. FIG. 5E depicts quantification of the ratio of Ml-like to NC-like macrophages in siRNA-treated tumors. FIG. 5F depicts representative images and quantification of CD31-positive blood vessels in mammary tumors from NTC or Irs2 siRNA-treated mice. FIG. 5G depicts representative immunofluorescence images of mammary tumor blood vessels (top row) and macrophages (bottom row) after siRNA administration. Analysis of n=10 mice / group (FIG. 5A, FIG. 5F) and of n=4 tumors / group (FIG. 5C-E, FIG. 5G).

[0064] NTC nontargeting control, M macrophage, scale bars 100pm (FIG. 5F), and 10pm (FIG.

[0065] 5G). Data presented as means ±SD (FIG. 5A, FIG. 5F). Line in box-and-whisker plots (FIG.

[0066] 5C-E) represents median value, while whiskers represent minimum-to-maximum values. ns=nonsignificant *p<0.05****p<0.0001 by Student’s t-test. Comparison of serum glucose levels and relative Irs2 mRNA expression in NTC (FIG.5H) and Irs2 (FIG.51) siRNA-treated mice are depicted. Relative Irs2 expression is presented as a percentage of average Irs2 mRNA expression in NTC siRNA-treated mice. Analysis of n=8-10 mice / group. R2 determined by simple linear regression. Representative H&E images (FIG. 5J) and quantification of the percent tumor necrosis (FIG. 5K) in mammary tumors from mice treated with either NTC or Irs2 siRNA are depicted. Analysis of n=10 mice / group. FIG. 5J scale bars = 10pm (left) and 250pm (right). Data are presented as means ±SD. ns=nonsignificant by Student’s t-test.

[0067] 82690703v1 10Atorney Docket No.: UM9-328PC (776088)

[0068] FIG. 6A - FIG. 6G depict the effect of Irs2 silencing in mammary tumors on the epithelial to mesenchymal transition (EMT). Frequency of metastatic lesion density (FIG. 6A) and cross-sectional lesion area (FIG. 6B) in lungs from tumor-bearing mice treated with NTC or Irs2 siRNA are depicted. FIG. 6C depicts representative immunohistochemistry images (left) and quantification (right) of vimentin expression in tumors from siRNA-treated mice. Vimentin mRNA (FIG. 6D) and protein (FIG. 6E) expression in PyV-MT Irsl / 2- / - cells expressing either empty vector (EV) control or Irs2. FIG. 6F depicts representative western blot (left) and quantification (right) of vimentin expression in PyV-MT Irsl / 2- / -:Irs2 cells after treatment with shRNAs targeting vimentin. FIG.6H depicts transwell migration assay of PyV-MT Irsl / 2- / - cells expressing either empty vector (EV) or Irs2 after treatment with shGFP or vimentin shRNA. n=10 mice / group (FIG.6A-D). n=6 (FIG.6E) or n=4 (FIG.6F) independent experiments. FIG. 6H is representative of 3 independent experiments. Scale bar 100pm (FIG.

[0069] 6B) or 20pm (FIG. 6C). Data presented as means ±SD. ns=nonsignificant **p<0.01****p<0.0001 by Student’s t-test (FIG. 6A-F) *p<0.05 by one-way ANOVA (FIG.

[0070] 6H)

[0071] FIG. 7A - FIG. 7B depicts Irs2 siRNA tissue accumulation (FIG. 7A) and safety data (FIG. 7B) in naive, non-tumor-bearing mice.

[0072] Detailed Description

[0073] The disclosure relates to oligonucleotides that target and robustly silence the expression of human IRS2, including in breast cancer cells in mammary tissue. Uniquely, the exemplified dsRNA (e.g., siRNA) targeting IRS2 disclosed herein effectively silence IRS2 expression in a selective fashion, leaving IRS1 expression intact. Selective silencing of IRS2 using the exemplified dsRNA slowed breast tumor progression without causing hyperglycemia. Conjugation of the exemplified dsRNA to a dendron promoted robust mammary tissue delivery, useful for the treatment of breast cancer originating in mammary tissue. Treatment with IRS2-targeting dsRNA in a syngeneic model of triple negative breast cancer reduced tumor growth but did not impact serum glucose concentrations. Suppression of Irs2 reduced vimentin expression in tumor cells, reduced tumor vascularization, and decreased M2-like macrophages, suggesting that the dsRNA modulated tumor cell-intrinsic and -extrinsic processes.

[0074] 82690703v1 11Atorney Docket No.: UM9-328PC (776088)

[0075] Unless otherwise specified, nomenclature used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. Unless otherwise specified, the methods and techniques provided herein are performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. Enzymatic reactions and purification techniques are performed according to manufacturer’s specifications, as commonly accomplished in the art or as described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, delivery, and treatment of patients.

[0076] Unless otherwise defined herein, scientific and technical terms used herein have the meanings that are commonly understood by those of ordinary skill in the art. In the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The use of “or” means “and / or” unless stated otherwise. The use of the term “including,” as well as other forms, such as “includes” and “included,” is not limiting.

[0077] So that the invention may be more readily understood, certain terms are first defined. The term “nucleoside” refers to a molecule having a purine or pyrimidine base covalently linked to a ribose or deoxyribose sugar. Exemplary nucleosides include adenosine, guanosine, cytidine, uridine and thymidine. Additional exemplary nucleosides include inosine, 1 -methyl inosine, pseudouridine, 5,6-dihydrouridine, ribothymidine, 2N-methylguanosine and N2,N2-dimethylguanosine (also referred to as “rare” nucleosides). The term “nucleotide” refers to a nucleoside having one or more phosphate groups joined in ester linkages to the sugar moiety. Exemplary nucleotides include nucleoside monophosphates, diphosphates and triphosphates. The terms “polynucleotide” and “nucleic acid molecule” are used interchangeably herein and refer to a polymer of nucleotides joined together by a phosphodiester or phosphorothioate linkage between 5' and 3' carbon atoms.

[0078] 82690703v1 12Atorney Docket No.: UM9-328PC (776088)

[0079] The term “RNA” or “RNA molecule” or “ribonucleic acid molecule” refers to a polymer of ribonucleotides (e.g., 2, 3, 4, 5, 10, 15, 20, 25, 30, or more ribonucleotides). The term “DNA” or “DNA molecule” or “deoxyribonucleic acid molecule" refers to a polymer of deoxyribonucleotides. DNA and RNA can be synthesized naturally (e.g., by DNA replication or transcription of DNA, respectively). RNA can be post-transcriptionally modified. DNA and RNA can also be chemically synthesized. DNA and RNA can be single-stranded (i.e., ssRNA and ssDNA, respectively) or multi -stranded (e.g., double stranded, i.e., dsRNA and dsDNA, respectively). “Messenger RNA” or “mRNA” is single-stranded RNA that specifies the amino acid sequence of one or more polypeptide chains. This information is translated during protein synthesis when ribosomes bind to the mRNA.

[0080] As used herein, the term “small interfering RNA” (“siRNA”) refers to an RNA (or RNA analog) comprising between about 10-50 nucleotides (or nucleotide analogs), which is capable of directing or mediating RNA interference. In certain embodiments, an siRNA comprises between about 15-30 nucleotides or nucleotide analogs, or between about 16-25 nucleotides (or nucleotide analogs), or between about 18-23 nucleotides (or nucleotide analogs), or between about 19-22 nucleotides (or nucleotide analogs) (e.g., 19, 20, 21 or 22 nucleotides or nucleotide analogs). The term “short” siRNA refers to a siRNA comprising about 21 nucleotides (or nucleotide analogs), for example, 19, 20, 21 or 22 nucleotides. The term “long” siRNA refers to a siRNA comprising about 24-25 nucleotides, for example, 23, 24, 25 or 26 nucleotides. Short siRNAs may, in some instances, include fewer than 19 nucleotides, e.g., 16, 17 or 18 nucleotides, provided that the shorter siRNA retains the ability to mediate RNAi. Likewise, long siRNAs may, in some instances, include more than 26 nucleotides, provided that the longer siRNA retains the ability to mediate RNAi absent further processing, e.g., enzymatic processing, to a short siRNA.

[0081] The term “nucleotide analog” or “altered nucleotide” or “modified nucleotide’ refers to a non-standard nucleotide, including non-naturally occurring ribonucleotides or deoxyribonucleotides. Exemplary nucleotide analogs are modified at any position so as to alter certain chemical properties of the nucleotide yet retain the ability of the nucleotide analog to perform its intended function. Examples of positions of the nucleotide, which may be derivatized include: the 5 position, e.g., 5-(2-amino)propyl uridine, 5-bromo uridine, 5-propyne uridine, 5-propenyl uridine, etc.; the 6 position, e.g., 6-(2-amino)propyl uridine; and the 8-position for adenosine and / or guanosines, e.g., 8-bromo guanosine, 8-chloro guanosine, 8-fluoroguanosine, etc. Nucleotide analogs also include deaza nucleotides, e.g., 7-deaza-

[0082] 82690703v1 13Atorney Docket No.: UM9-328PC (776088)

[0083] adenosine; O- and N-modified (e.g., alkylated, e.g., N6-methyl adenosine, or as otherwise known in the art) nucleotides; and other heterocyclically modified nucleotide analogs, such as those described in Herdewijn, Antisense Nucleic Acid Drug Dev., 2000 Aug. 10(4):297-310.

[0084] Nucleotide analogs may also comprise modifications to the sugar portion of the nucleotides. For example, the 2' OH-group may be replaced by a group selected from H, OR, R, F, Cl, Br, I, SH, SR, NH2, NHR, NR2, COOR, or, wherein R is substituted or unsubstituted Ci-Ce alkyl, alkenyl, alkynyl, aryl, etc. Other possible modifications include those described in U.S. Pat. Nos. 5,858,988, and 6,291,438.

[0085] The phosphate group of the nucleotide may also be modified, e.g., by substituting one or more of the oxygens of the phosphate group with sulfur (e.g., phosphorothioates), or by making other substitutions, which allow the nucleotide to perform its intended function, such as described in, for example, Eckstein, Antisense Nucleic Acid Drug Dev. 2000 Apr.

[0086] 10(2): 117-21, Rusckowski et al. Antisense Nucleic Acid Drug Dev. 2000 Oct. 10(5):333-45, Stein, Antisense Nucleic Acid Drug Dev. 2001 Oct. 11(5): 317-25, Vorobjev et al. Antisense Nucleic Acid Drug Dev. 2001 Apr. 11(2):77-85, and U.S. Pat. No. 5,684,143. Certain of the above-referenced modifications (e.g., phosphate group modifications) decrease the rate of hydrolysis of, for example, polynucleotides comprising said analogs in vivo or in vitro.

[0087] The term "oligonucleotide" refers to a short polymer of nucleotides and / or nucleotide analogs.

[0088] The term "RNA analog" refers to a polynucleotide (e.g., a chemically synthesized polynucleotide) having at least one altered or modified nucleotide as compared to a corresponding unaltered or unmodified RNA, but retaining the same or similar nature or function as the corresponding unaltered or unmodified RNA. As discussed above, the oligonucleotides may be linked with linkages, which result in a lower rate of hydrolysis of the RNA analog as compared to an RNA molecule with phosphodiester linkages. For example, the nucleotides of the analog may comprise methylenediol, ethylene diol, oxymethylthio, oxyethylthio, oxycarbonyloxy, phosphorodiamidate, phosphoroamidate, and / or phosphorothioate linkages. Some RNA analogues include sugar- and / or backbone-modified ribonucleotides and / or deoxyribonucleotides. Such alterations or modifications can further include addition of non-nucleotide material, such as to the end(s) of the RNA or internally (at one or more nucleotides of the RNA). An RNA analog need only be sufficiently similar to natural RNA that it has the ability to mediate RNA interference.

[0089] 82690703v1 14Atorney Docket No.: UM9-328PC (776088)

[0090] As used herein, the term "RNA interference" ("RNAi") refers to a selective intracellular degradation of RNA. RNAi occurs in cells naturally to remove foreign RNAs (e.g., viral RNAs). Natural RNAi proceeds via fragments cleaved from free dsRNA, which direct the degradative mechanism to other similar RNA sequences. Alternatively, RNAi can be initiated by the hand of man, for example, to silence the expression of target genes.

[0091] An RNAi agent, e.g., an RNA silencing agent, having a strand, which is "sequence sufficiently complementary to a target mRNA sequence to direct target-specific RNA interference (RNAi)" means that the strand has a sequence sufficient to trigger the destruction of the target mRNA by the RNAi machinery or process.

[0092] As used herein, the term “isolated RNA” (e.g., "isolated siRNA" or "isolated siRNA precursor") refers to RNA molecules, which are substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

[0093] As used herein, the term “RNA silencing” refers to a group of sequence-specific regulatory mechanisms (e.g. RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), quelling, co-suppression, and translational repression) mediated by RNA molecules, which result in the inhibition or "silencing" of the expression of a corresponding protein-coding gene. RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.

[0094] The term "discriminatory RNA silencing" refers to the ability of an RNA molecule to substantially inhibit the expression of a "first" or "target" polynucleotide sequence while not substantially inhibiting the expression of a "second" or "non-target" polynucleotide sequence," e.g., when both polynucleotide sequences are present in the same cell. In certain embodiments, the target polynucleotide sequence corresponds to a target gene, while the non-target polynucleotide sequence corresponds to a non-target gene. In other embodiments, the target polynucleotide sequence corresponds to a target allele, while the non-target polynucleotide sequence corresponds to a non-target allele. In certain embodiments, the target polynucleotide sequence is the DNA sequence encoding the regulatory region (e.g. promoter or enhancer elements) of a target gene. In other embodiments, the target polynucleotide sequence is a target mRNA encoded by a target gene.

[0095] The term "in vitro" has its art recognized meaning, e.g., involving purified reagents or extracts, e.g., cell extracts. The term "in vivo" also has its art recognized meaning, e.g.,

[0096] 82690703v1 15Atorney Docket No.: UM9-328PC (776088)

[0097] involving living cells, e.g., immortalized cells, primary cells, cell lines, and / or cells in an organism.

[0098] As used herein, the term "transgene" refers to any nucleic acid molecule, which is inserted by artifice into a cell, and becomes part of the genome of the organism that develops from the cell. Such a transgene may include a gene that is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism. The term "transgene" also means a nucleic acid molecule that includes one or more selected nucleic acid sequences, e.g., DNAs, that encode one or more engineered RNA precursors, to be expressed in a transgenic organism, e.g., animal, which is partly or entirely heterologous, i.e., foreign, to the transgenic animal, or homologous to an endogenous gene of the transgenic animal, but which is designed to be inserted into the animal's genome at a location which differs from that of the natural gene. A transgene includes one or more promoters and any other DNA, such as introns, necessary for expression of the selected nucleic acid sequence, all operably linked to the selected sequence, and may include an enhancer sequence.

[0099] A gene "involved" in a disease or disorder includes a gene, the normal or aberrant expression or function of which effects or causes the disease or disorder or at least one symptom of said disease or disorder.

[0100] As used herein, the term "target gene" is a gene whose expression is to be substantially inhibited or "silenced." This silencing can be achieved by RNA silencing, e.g., by cleaving the mRNA of the target gene or translational repression of the target gene. The term "non-target gene" is a gene whose expression is not to be substantially silenced. In one embodiment, the polynucleotide sequences of the target and non-target gene (e.g. mRNA encoded by the target and non-target genes) can differ by one or more nucleotides. In another embodiment, the target and non-target genes can differ by one or more polymorphisms (e.g., Single Nucleotide Polymorphisms or SNPs). In another embodiment, the target and non-target genes can share less than 100% sequence identity. In another embodiment, the non-target gene may be a homologue (e.g. an orthologue or paralogue) of the target gene.

[0101] As used herein, the term "RNA silencing agent" refers to an RNA, which is capable of inhibiting or "silencing" the expression of a target gene. In certain embodiments, the RNA silencing agent is capable of preventing complete processing (e.g., the full translation and / or expression) of a mRNA molecule through a post-transcriptional silencing mechanism. RNA

[0102] 82690703v1 16Atorney Docket No.: UM9-328PC (776088)

[0103] silencing agents include small (<50 b.p.), noncoding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small noncoding RNAs can be generated. Exemplary RNA silencing agents include siRNAs, miRNAs, siRNA-like duplexes, antisense oligonucleotides, GAPMER molecules, and dual-function oligonucleotides, as well as precursors thereof. In one embodiment, the RNA silencing agent is capable of inducing RNA interference. In another embodiment, the RNA silencing agent is capable of mediating translational repression.

[0104] As used herein, the term "rare nucleotide" refers to a naturally occurring nucleotide that occurs infrequently, including naturally occurring deoxyribonucleotides or ribonucleotides that occur infrequently, e.g., a naturally occurring ribonucleotide that is not guanosine, adenosine, cytosine, or uridine. Examples of rare nucleotides include, but are not limited to, inosine, 1-methyl inosine, pseudouridine, 5,6-dihydrouridine, ribothymidine, 2N-methylguanosine and 2,2N,N-dimethylguanosine.

[0105] The term "engineered," as in an engineered RNA precursor, or an engineered nucleic acid molecule, indicates that the precursor or molecule is not found in nature, in that all or a portion of the nucleic acid sequence of the precursor or molecule is created or selected by a human. Once created or selected, the sequence can be replicated, translated, transcribed, or otherwise processed by mechanisms within a cell. Thus, an RNA precursor produced within a cell from a transgene that includes an engineered nucleic acid molecule is an engineered RNA precursor.

[0106] As used herein, the term "microRNA" ("miRNA"), also known in the art as "small temporal RNAs" ("stRNAs"), refers to a small (10-50 nucleotide) RNA, which are genetically encoded (e.g., by viral, mammalian, or plant genomes) and are capable of directing or mediating RNA silencing.

[0107] As used herein, the term "dual functional oligonucleotide" refers to a RNA silencing agent having the formula T-L-p, wherein T is an mRNA targeting moiety, Lisa linking moiety, and p is a miRNA recruiting moiety. As used herein, the terms "mRNA targeting moiety," "targeting moiety," "mRNA targeting portion" or "targeting portion" refer to a domain, portion or region of the dual functional oligonucleotide having sufficient size and sufficient complementarity to a portion or region of an mRNA chosen or targeted for silencing (i.e., the moiety has a sequence sufficient to capture the target mRNA).

[0108] 82690703v1 17Atorney Docket No.: UM9-328PC (776088)

[0109] As used herein, the term "linking moiety" or "linking portion" refers to a domain, portion or region of the RNA-silencing agent which covalently joins or links the mRNA.

[0110] As used herein, the term "antisense strand" of an RNA silencing agent, e.g., an siRNA or RNA silencing agent, refers to a strand that is substantially complementary to a section of about 10-50 nucleotides, e.g., about 15-30, 16-25, 18-23 or 19-22 nucleotides of the mRNA of the gene targeted for silencing. The antisense strand or first strand has sequence sufficiently complementary to the desired target mRNA sequence to direct target-specific silencing, e.g., complementarity sufficient to trigger the destruction of the desired target mRNA by the RNAi machinery or process (RNAi interference) or complementarity sufficient to trigger translational repression of the desired target mRNA. The antisense strand contains a seed region consisting of nucleotides 2-8 from the antisense strand 5’ end which plays a role in on-target mRNA silencing. In certain embodiments, the antisense strand seed region has perfect complementarity to the target mRNA. In certain embodiments, the antisense strand seed region has perfect complementarity to the target mRNA and 1, 2, 3, 4, or 5 mismatches outside of the seed region to the target mRNA. In certain embodiments, the antisense strand seed region has no more than one mismatch to the target mRNA. In certain embodiments, no more than 2 mismatches are present between nucleotides 1-8 from the 5’ end the antisense strand and the target mRNA. In certain embodiments, the antisense strand comprises a 5’ terminal U or A nucleotide.

[0111] The term "sense strand" or "second strand" of an RNA silencing agent, e.g., an siRNA or RNA silencing agent, refers to a strand that is complementary to the antisense strand or first strand. Antisense and sense strands can also be referred to as first or second strands, the first or second strand having complementarity to the target sequence and the respective second or first strand having complementarity to said first or second strand. miRNA duplex intermediates or siRNA-like duplexes include a miRNA strand having sufficient complementarity to a section of about 10-50 nucleotides of the mRNA of the gene targeted for silencing and a miRNA* strand having sufficient complementarity to form a duplex with the miRNA strand.

[0112] As used herein, the term "guide strand" refers to a strand of an RNA silencing agent, e.g., an antisense strand of an siRNA duplex or siRNA sequence, that enters into the RISC complex and directs cleavage of the target mRNA.

[0113] As used herein, the term "asymmetry," as in the asymmetry of the duplex region of an RNA silencing agent (e.g., the stem of an shRNA), refers to an inequality of bond strength or

[0114] 82690703v1 18Atorney Docket No.: UM9-328PC (776088)

[0115] base pairing strength between the termini of the RNA silencing agent (e.g., between terminal nucleotides on a first strand or stem portion and terminal nucleotides on an opposing second strand or stem portion), such that the 5' end of one strand of the duplex is more frequently in a transient unpaired, e.g., single- stranded, state than the 5' end of the complementary strand. This structural difference determines that one strand of the duplex is preferentially incorporated into a RISC complex. The strand whose 5' end is less tightly paired to the complementary strand will preferentially be incorporated into RISC and mediate RNAi.

[0116] As used herein, the term "bond strength" or "base pair strength" refers to the strength of the interaction between pairs of nucleotides (or nucleotide analogs) on opposing strands of an oligonucleotide duplex (e.g., an siRNA duplex), due primarily to H-bonding, van der Waals interactions, and the like, between said nucleotides (or nucleotide analogs).

[0117] As used herein, the "5' end," as in the 5' end of an antisense strand, refers to the 5' terminal nucleotides, e.g., between one and about 5 nucleotides at the 5' terminus of the antisense strand. As used herein, the "3' end," as in the 3' end of a sense strand, refers to the region, e.g., a region of between one and about 5 nucleotides, that is complementary to the nucleotides of the 5' end of the complementary antisense strand.

[0118] As used herein the term "destabilizing nucleotide" refers to a first nucleotide or nucleotide analog capable of forming a base pair with second nucleotide or nucleotide analog such that the base pair is of lower bond strength than a conventional base pair (i.e., Watson-Crick base pair). In certain embodiments, the destabilizing nucleotide is capable of forming a mismatch base pair with the second nucleotide. In other embodiments, the destabilizing nucleotide is capable of forming a wobble base pair with the second nucleotide. In yet other embodiments, the destabilizing nucleotide is capable of forming an ambiguous base pair with the second nucleotide.

[0119] As used herein, the term "base pair" refers to the interaction between pairs of nucleotides (or nucleotide analogs) on opposing strands of an oligonucleotide duplex (e.g., a duplex formed by a strand of an RNA silencing agent and a target mRNA sequence), due primarily to H-bonding, van der Waals interactions, and the like between said nucleotides (or nucleotide analogs). As used herein, the term "bond strength" or "base pair strength" refers to the strength of the base pair.

[0120] As used herein, the term "mismatched base pair" refers to a base pair consisting of non-complementary or non-Watson-Crick base pairs, for example, not normal complementary G:C,

[0121] 82690703v1 19Atorney Docket No.: UM9-328PC (776088)

[0122] A:T or A:U base pairs. As used herein the term "ambiguous base pair" (also known as a non-discriminatory base pair) refers to a base pair formed by a universal nucleotide.

[0123] As used herein, term "universal nucleotide" (also known as a "neutral nucleotide") include those nucleotides (e.g. certain destabilizing nucleotides) having a base (a "universal base" or "neutral base") that does not significantly discriminate between bases on a complementary polynucleotide when forming a base pair. Universal nucleotides are predominantly hydrophobic molecules that can pack efficiently into antiparallel duplex nucleic acids (e.g., double-stranded DNA or RNA) due to stacking interactions. The base portion of universal nucleotides typically comprise a nitrogen-containing aromatic heterocyclic moiety.

[0124] As used herein, the terms "sufficient complementarity" or "sufficient degree of complementarity" mean that the RNA silencing agent has a sequence (e.g. in the antisense strand, mRNA targeting moiety or miRNA recruiting moiety), which is sufficient to bind the desired target RNA, respectively, and to trigger the RNA silencing of the target mRNA.

[0125] As used herein, the term "translational repression" refers to a selective inhibition of mRNA translation. Natural translational repression proceeds via miRNAs cleaved from shRNA precursors. Both RNAi and translational repression are mediated by RISC. Both RNAi and translational repression occur naturally or can be initiated by the hand of man, for example, to silence the expression of target genes.

[0126] Various methodologies of the instant invention include a step that involves comparing a value, level, feature, characteristic, property, etc. to a "suitable control," referred to interchangeably herein as an "appropriate control." A "suitable control" or "appropriate control" is any control or standard familiar to one of ordinary skill in the art useful for comparison purposes. In one embodiment, a "suitable control" or "appropriate control" is a value, level, feature, characteristic, property, etc. determined prior to performing an RNAi methodology, as described herein. For example, a transcription rate, mRNA level, translation rate, protein level, biological activity, cellular characteristic or property, genotype, phenotype, etc. can be determined prior to introducing an RNA silencing agent of the invention into a cell or organism. In another embodiment, a "suitable control" or "appropriate control" is a value, level, feature, characteristic, property, etc. determined in a cell or organism, e.g., a control or normal cell or organism, exhibiting, for example, normal traits. In yet another embodiment, a "suitable control" or "appropriate control" is a predefined value, level, feature, characteristic, property, etc.

[0127] 82690703v1 20Atorney Docket No.: UM9-328PC (776088)

[0128] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and example are illustrative only and not intended to be limiting.

[0129] Various aspects of the invention are described in further detail in the following subsections.

[0130] Insulin Receptor Substrate 2 (IRS2)

[0131] Insulin receptor substrate 2 (IRS2), encoded by the IRS2 gene, is one of three insulin receptor substrate (IRS) proteins in humans. The IRS proteins are cytoplasmic docking proteins that function as signaling intermediates downstream of activated cell surface receptors, such as the insulin receptor and IGF-1R (Gibson et al. Cell Cycle. 2007. 6: 631-37). Similar to other IRS proteins, IRS2 phosphorylation initiates an intracellular pro-growth signaling cascade. IRS2 expression and activity is increased in aggressive breast tumors. The human IRS2 mRNA is under RefSeq accession number NM 003749. The mouselrs2 mRNA tale lais under RefSeq accession number NM_001081212.

[0132] I. siRNA Design

[0133] In some embodiments, siRNAs are designed as follows. First, a portion of the target gene (e.g., the IRS2 gene) is selected, such as the 5’ untranslated region (UTR), one or more exons, one or more introns, or the 3’ UTR. Cleavage of mRNA at these sites should eliminate translation of corresponding protein. Antisense strands were designed based on the target sequence and sense strands were designed to be complementary to the antisense strand. Hybridization of the antisense and sense strands forms the siRNA duplex. The antisense strand includes about 19 to 25 nucleotides, e.g., 19, 20, 21, 22, 23, 24 or 25 nucleotides. In other embodiments, the antisense strand includes 20, 21, 22 or 23 nucleotides. The sense strand includes about 14 to 25 nucleotides, e.g., 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. In other embodiments, the sense strand is 15 nucleotides. In other embodiments,

[0134] 82690703v1 21Atorney Docket No.: UM9-328PC (776088)

[0135] the sense strand is 18 nucleotides. In other embodiments, the sense strand is 20 nucleotides. The skilled artisan will appreciate, however, that siRNAs having a length of less than 19 nucleotides or greater than 25 nucleotides can also function to mediate RNAi. Accordingly, siRNAs of such length are also within the scope of the instant invention, provided that they retain the ability to mediate RNAi. Longer RNAi agents have been demonstrated to elicit an interferon or PKR response in certain mammalian cells, which may be undesirable. In certain embodiments, the RNAi agents of the invention do not elicit a PKR response (i.e., are of a sufficiently short length). However, longer RNAi agents may be useful, for example, in cell types incapable of generating a PKR response or in situations where the PKR response has been down-regulated or dampened by alternative means.

[0136] The sense strand sequence can be designed such that the target sequence is essentially in the middle of the strand. Moving the target sequence to an off-center position can, in some instances, reduce efficiency of cleavage by the siRNA. Such compositions, i.e., less efficient compositions, may be desirable for use if off-silencing of the wild-type mRNA is detected.

[0137] The antisense strand can be the same length as the sense strand and includes complementary nucleotides. In one embodiment, the strands are fully complementary, i.e., the strands are blunt-ended when aligned or annealed. In another embodiment, the strands align or anneal such that 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-nucleotide overhangs are generated, i.e., the 3' end of the sense strand extends 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides further than the 5' end of the antisense strand and / or the 3' end of the antisense strand extends 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides further than the 5' end of the sense strand. Overhangs can comprise (or consist of) nucleotides corresponding to the target gene sequence (or complement thereof). Alternatively, overhangs can comprise (or consist of) deoxyribonucleotides, for example dTs, or nucleotide analogs, or other suitable non-nucleotide material.

[0138] To facilitate entry of the antisense strand into RISC (and thus increase or improve the efficiency of target cleavage and silencing), the base pair strength between the 5' end of the sense strand and 3' end of the antisense strand can be altered, e.g., lessened or reduced, as described in detail in U.S. Patent Nos. 7,459,547, 7,772,203 and 7,732,593, entitled “Methods and Compositions for Controlling Efficacy of RNA Silencing” (filed Jun. 2, 2003) and U.S. Patent Nos. 8,309,704, 7,750,144, 8,304,530, 8,329,892 and 8,309,705, entitled “Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi” (filed Jun. 2, 2003), the contents of which are incorporated in their entirety by this reference. In one embodiment of these aspects of the invention, the base-pair strength is less due to fewer G:C base pairs between

[0139] 82690703v1 22Atorney Docket No.: UM9-328PC (776088)

[0140] the 5' end of the first or antisense strand and the 3' end of the second or sense strand than between the 3' end of the first or antisense strand and the 5' end of the second or sense strand. In another embodiment, the base pair strength is less due to at least one mismatched base pair between the 5' end of the first or antisense strand and the 3' end of the second or sense strand. In certain exemplary embodiments, the mismatched base pair is selected from the group consisting of G:A, C:A, C:U, G:G, A:A, C:C and U:U. In another embodiment, the base pair strength is less due to at least one wobble base pair, e.g., G:U, between the 5' end of the first or antisense strand and the 3' end of the second or sense strand. In another embodiment, the base pair strength is less due to at least one base pair comprising a rare nucleotide, e.g., inosine (I). In certain exemplary embodiments, the base pair is selected from the group consisting of an I:A, I:U and I:C. In yet another embodiment, the base pair strength is less due to at least one base pair comprising a modified nucleotide. In certain exemplary embodiments, the modified nucleotide is selected from the group consisting of 2-amino-G, 2-amino-A, 2,6-diamino-G, and 2,6-diamino-A.

[0141] The design of siRNAs suitable for targeting the IRS2 gene is described in detail below. siRNAs can be designed according to the above exemplary teachings for any other target sequences found in the IRS2 gene. Moreover, the technology is applicable to targeting any other target sequences, e.g., non-disease-causing target sequences.

[0142] To validate the effectiveness by which siRNAs destroy mRNAs (e.g., IRS2 mRNA), the siRNA can be incubated with cDNA (e.g., IRS2 cDNA) in a Drosophila-\) s in vitro mRNA expression system. Radiolabeled with32P, newly synthesized mRNAs (e.g., IRS2 mRNA) are detected autoradiographically on an agarose gel. The presence of cleaved mRNA indicates mRNA nuclease activity. Suitable controls include omission of siRNA. Alternatively, control siRNAs are selected having the same nucleotide composition as the selected siRNA, but without significant sequence complementarity to the appropriate target gene. Such negative controls can be designed by randomly scrambling the nucleotide sequence of the selected siRNA; a homology search can be performed to ensure that the negative control lacks homology to any other gene in the appropriate genome. In addition, negative control siRNAs can be designed by introducing one or more base mismatches into the sequence. Sites of siRNA-mRNA complementation are selected which result in optimal mRNA specificity and maximal mRNA cleavage.

[0143] 82690703v1 23Atorney Docket No.: UM9-328PC (776088)

[0144] II, RNAi Agents

[0145] The present invention includes siRNA molecules designed, for example, as described above. The siRNA molecules of the invention can be chemically synthesized, or can be transcribed in vitro from a DNA template, or in vivo from e.g., shRNA, or by using recombinant human DICER enzyme, to cleave in vitro transcribed dsRNA templates into pools of 20-, 21-or 23 -bp duplex RNA mediating RNAi. The siRNA molecules can be designed using any method known in the art.

[0146] In one aspect, instead of the RNAi agent being an interfering ribonucleic acid, e.g., an siRNA or shRNA as described above, the RNAi agent can encode an interfering ribonucleic acid, e.g., an shRNA, as described above. In other words, the RNAi agent can be a transcriptional template of the interfering ribonucleic acid. Thus, RNAi agents of the present invention can also include small hairpin RNAs (shRNAs), and expression constructs engineered to express shRNAs. Transcription of shRNAs is initiated at a polymerase III (pol III) promoter, and is thought to be terminated at position 2 of a 4-5-thymine transcription termination site. Upon expression, shRNAs are thought to fold into a stem-loop structure with 3' UU-overhangs; subsequently, the ends of these shRNAs are processed, converting the shRNAs into siRNA-like molecules of about 21-23 nucleotides (Brummelkamp et al., 2002; Lee et al., 2002, Supra, Miyagishi et al., 2002; Paddison et al., 2002, supra, Paul et al., 2002, supra, Sui et al., 2002 supra, Yu et al., 2002, supra. More information about shRNA design and use can be found on the internet at the following addresses: katandin.cshl.org:9331 / RNAi / docs / BseRI-BamHI Strategy.pdf and katandin.cshl.org:9331 / RNAi / docs / W eb_version_of_PCR_strategy 1.pdf).

[0147] Expression constructs of the present invention include any construct suitable for use in the appropriate expression system and include, but are not limited to, retroviral vectors, linear expression cassettes, plasmids and viral or virally-derived vectors, as known in the art. Such expression constructs can include one or more inducible promoters, RNA Pol III promoter systems, such as U6 snRNA promoters or Hl RNA polymerase III promoters, or other promoters known in the art. The constructs can include one or both strands of the siRNA. Expression constructs expressing both strands can also include loop structures linking both strands, or each strand can be separately transcribed from separate promoters within the same construct. Each strand can also be transcribed from a separate expression construct. (Tuschl, T., 2002, Supra).

[0148] 82690703v1 24Atorney Docket No.: UM9-328PC (776088)

[0149] Synthetic siRNAs can be delivered into cells by methods known in the art, including cationic liposome transfection and electroporation. To obtain longer term suppression of the target genes (e.g., IRS2 gene) and to facilitate delivery under certain circumstances, one or more siRNA can be expressed within cells from recombinant DNA constructs. Such methods for expressing siRNA duplexes within cells from recombinant DNA constructs to allow longer-term target gene suppression in cells are known in the art, including mammalian Pol III promoter systems (e.g., Hl or U6 / snRNA promoter systems (Tuschl, T., 2002, supra) capable of expressing functional double-stranded siRNAs; (Bagella et al., 1998; Lee et al., 2002, supra, Miyagishi et al., 2002, supra, Paul et al., 2002, supra, Yu et al., 2002, supra, Sui et al., 2002, supra). Transcriptional termination by RNA Pol III occurs at runs of four consecutive T residues in the DNA template, providing a mechanism to end the siRNA transcript at a specific sequence. The siRNA is complementary to the sequence of the target gene in 5'-3' and 3'-5' orientations, and the two strands of the siRNA can be expressed in the same construct or in separate constructs. Hairpin siRNAs, driven by Hl or U6 snRNA promoter and expressed in cells, can inhibit target gene expression (Bagella et al., 1998; Lee et al., 2002, supra, Miyagishi et al., 2002, supra, Paul et al., 2002, supra, Yu et al., 2002), supra, Sui et al., 2002, supra). Constructs containing siRNA sequence under the control of T7 promoter also make functional siRNAs when co-transfected into the cells with a vector expressing T7 RNA polymerase (Jacque et al., 2002, supra). A single construct may contain multiple sequences coding for siRNAs targeting the same gene or multiple genes, and can be driven, for example, by separate PolIII promoter sites.

[0150] Animal cells express a range of noncoding RNAs of approximately 22 nucleotides termed micro RNA (miRNAs), which can regulate gene expression at the post transcriptional or translational level during animal development. One common feature of miRNAs is that they are all excised from an approximately 70 nucleotide precursor RNA stem-loop, probably by Dicer, an RNase Ill-type enzyme, or a homolog thereof. By substituting the stem sequences of the miRNA precursor with sequence complementary to the target mRNA, a vector construct that expresses the engineered precursor can be used to produce siRNAs to initiate RNAi against specific mRNA targets in mammalian cells (Zeng et al., 2002, supra). When expressed by DNA vectors containing polymerase III promoters, micro-RNA designed hairpins can silence gene expression (McManus et al., 2002, supra). MicroRNAs targeting polymorphisms may also be useful for blocking translation of mutant proteins, in the absence of siRNA-mediated

[0151] 82690703v1 25Atorney Docket No.: UM9-328PC (776088)

[0152] gene-silencing. Such applications may be useful in situations, for example, where a designed siRNA caused off-target silencing of wild type protein.

[0153] Viral-mediated delivery mechanisms can also be used to induce specific silencing of targeted genes through expression of siRNA, for example, by generating recombinant adenoviruses harboring siRNA under RNA Pol II promoter transcription control (Xia et al., 2002, supra). Infection of HeLa cells by these recombinant adenoviruses allows for diminished endogenous target gene expression. Injection of the recombinant adenovirus vectors into transgenic mice expressing the target genes of the siRNA results in in vivo reduction of target gene expression. Id. In an animal model, whole-embryo electroporation can efficiently deliver synthetic siRNA into post-implantation mouse embryos (Calegari et al., 2002). In adult mice, efficient delivery of siRNA can be accomplished by "high-pressure" delivery technique, a rapid injection (within 5 seconds) of a large volume of siRNA containing solution into animal via the tail vein (Liu et al., 1999, supra, McCaffrey et al., 2002, supra, Lewis et al., 2002. Nanoparticles and liposomes can also be used to deliver siRNA into animals. In certain exemplary embodiments, recombinant adeno-associated viruses (rAAVs) and their associated vectors can be used to deliver one or more siRNAs into cells, e.g., neural cells (e.g., brain cells) (US Patent Applications 2014 / 0296486, 2010 / 0186103, 2008 / 0269149, 2006 / 0078542 and 2005 / 0220766).

[0154] The nucleic acid compositions of the invention include both unmodified siRNAs and modified siRNAs, such as crosslinked siRNA derivatives or derivatives having non-nucleotide moieties linked, for example to their 3' or 5' ends. Modifying siRNA derivatives in this way may improve cellular uptake or enhance cellular targeting activities of the resulting siRNA derivative, as compared to the corresponding siRNA, and are useful for tracing the siRNA derivative in the cell, or improving the stability of the siRNA derivative compared to the corresponding siRNA.

[0155] Engineered RNA precursors, introduced into cells or whole organisms as described herein, will lead to the production of a desired siRNA molecule. Such an siRNA molecule will then associate with endogenous protein components of the RNAi pathway to bind to and target a specific mRNA sequence for cleavage and destruction. In this fashion, the mRNA, which will be targeted by the siRNA generated from the engineered RNA precursor, and will be depleted from the cell or organism, leading to a decrease in the concentration of the protein encoded by that mRNA in the cell or organism. The RNA precursors are typically nucleic acid molecules

[0156] 82690703v1 26Atorney Docket No.: UM9-328PC (776088)

[0157] that individually encode either one strand of a dsRNA or encode the entire nucleotide sequence of an RNA hairpin loop structure.

[0158] The nucleic acid compositions of the invention can be unconjugated or can be conjugated to another moiety, such as a nanoparticle, to enhance a property of the compositions, e.g., a pharmacokinetic parameter such as absorption, efficacy, bioavailability and / or half-life. The conjugation can be accomplished by methods known in the art, e.g., using the methods of Lambert et al., Drug Deliv. Rev.: 47(1), 99-112 (2001) (describes nucleic acids loaded to polyalkylcyanoacrylate (PACA) nanoparticles); Fattal et al., J. Control Release 53(1-3): 137-43 (1998) (describes nucleic acids bound to nanoparticles); Schwab et al., Ann. Oncol.

[0159] 5 Suppl. 4:55-8 (1994) (describes nucleic acids linked to intercalating agents, hydrophobic groups, polycations or PACA nanoparticles); and Godard et al., Eur. J. Biochem. 232(2):404-10 (1995) (describes nucleic acids linked to nanoparticles).

[0160] The nucleic acid molecules of the present invention can also be labeled using any method known in the art. For instance, the nucleic acid compositions can be labeled with a fluorophore, e.g., Cy3, fluorescein, or rhodamine. The labeling can be carried out using a kit, e.g., the SILENCER™ siRNA labeling kit (Ambion). Additionally, the siRNA can be radiolabeled, e.g., using3H,32P or another appropriate isotope.

[0161] Moreover, because RNAi is believed to progress via at least one single-stranded RNA intermediate, the skilled artisan will appreciate that ss-siRNAs (e.g., the antisense strand of a ds-siRNA) can also be designed (e.g., for chemical synthesis), generated (e.g., enzymatically generated), or expressed (e.g., from a vector or plasmid) as described herein and utilized according to the claimed methodologies. Moreover, in invertebrates, RNAi can be triggered effectively by long dsRNAs (e.g., dsRNAs about 100-1000 nucleotides in length, such as about 200-500, for example, about 250, 300, 350, 400 or 450 nucleotides in length) acting as effectors of RNAi. (Brondani et al., Proc Natl Acad Sci USA. 2001 Dec. 4; 98(25): 14428-33. Epub 2001 Nov. 27.)

[0162] Ill, Anti-IRS2 gene RNA Silencing Agents

[0163] In one embodiment, the present invention provides novel anti- / AS2 gene RNA silencing agents (e.g., siRNA, shRNA, and antisense oligonucleotides), methods of making said RNA silencing agents, and methods (e.g., research and / or therapeutic methods) for using said improved RNA silencing agents (or portions thereof) for RNA silencing of IRS2 gene. The

[0164] 82690703v1 27Atorney Docket No.: UM9-328PC (776088)

[0165] RNA silencing agents comprise an antisense strand (or portions thereof), wherein the antisense strand has sufficient complementary to a target IRS2 mRNA to mediate an RNA-mediated silencing mechanism (e.g. RNAi).

[0166] In certain embodiments, siRNA compounds are provided having one or any combination of the following properties: (1) fully chemically-stabilized (i.e., no unmodified 2’-OH residues); (2) asymmetry; (3) 11-20 base pair duplexes; (4) greater than 50% 2’-methoxy modifications, although an alternating pattern of chemically-modified nucleotides (e.g., 2’-fluoro and 2’-methoxy modifications), are also contemplated; and (5) single-stranded, tails of 2-8 bases with at least two phosphorothioate internucleotide linkages. In certain embodiments, the number of phosphorothioate modifications is varied from 4 to 16 total. In certain embodiments, the number of phosphorothioate modifications is varied from 8 to 13 total.

[0167] In certain embodiments, the siRNA compounds described herein can be conjugated to a variety of targeting agents, including, but not limited to, cholesterol, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosanoic acid (DCA), phenyltropanes, cortisol, vitamin A, vitamin D, N-acetylgalactosamine (GalNac), and gangliosides.

[0168] Certain compounds of the invention having the structural properties described above and herein may be referred to as “hsiRNA-ASP” (hydrophobically-modified, small interfering RNA, featuring an advanced stabilization pattern). In addition, this hsiRNA-ASP pattern showed a dramatically improved distribution through various tissues, making them accessible for therapeutic intervention.

[0169] a) Design of Anti-IRS2 siRNA Molecules

[0170] An siRNA molecule of the application is a duplex made of a sense strand and complementary antisense strand, the antisense strand having sufficient complementary to a IRS2 mRNA to mediate RNAi. In certain embodiments, the siRNA molecule has a length from about 10-50 or more nucleotides, i.e., each strand comprises 10-50 nucleotides (or nucleotide analogs). In other embodiments, the siRNA molecule has a length from about 15-30, e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is sufficiently complementary to a target region. In certain embodiments, the strands are aligned such that there are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases at the end of the strands, which do not align (i.e., for which no complementary bases occur in the opposing

[0171] 82690703v1 28Atorney Docket No.: UM9-328PC (776088)

[0172] strand), such that an overhang of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 residues occurs at one or both ends of the duplex when strands are annealed.

[0173] Usually, siRNAs can be designed by using any method known in the art, for instance, by using the following protocol:

[0174] 1. The siRNA should be specific for a target sequence, e.g., a target sequence set forth in the Examples. The first strand should be complementary to the target sequence, and the other strand is substantially complementary to the first strand. (See Examples for exemplary sense and antisense strands.) Exemplary target sequences are selected from any region of the target gene that leads to potent gene silencing. Regions of the target gene include, but are not limited to, the 5' untranslated region (5'-UTR) of a target gene, the 3’ untranslated region (3’-UTR) of a target gene, an exon of a target gene, or an intron of a target gene. Cleavage of mRNA at these sites should eliminate translation of corresponding IRS2 protein. Target sequences from other regions of the IRS2 gene are also suitable for targeting. A sense strand is designed based on the target sequence.

[0175] 2. The sense strand of the siRNA is designed based on the sequence of the selected target site. In certain embodiments, the sense strand includes about 15 to 25 nucleotides, e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. In certain embodiments, the sense strand includes 15, 16, 17, 18, 19, or 20 nucleotides. In certain embodiments, the sense strand is 15 nucleotides in length. In certain embodiments, the sense strand is 18 nucleotides in length. In certain embodiments, the sense strand is 20 nucleotides in length. The skilled artisan will appreciate, however, that siRNAs having a length of less than 15 nucleotides or greater than 25 nucleotides can also function to mediate RNAi. Accordingly, siRNAs of such length are also within the scope of the instant invention, provided that they retain the ability to mediate RNAi. Longer RNA silencing agents have been demonstrated to elicit an interferon or Protein Kinase R (PKR) response in certain mammalian cells which may be undesirable. In certain embodiments, the RNA silencing agents of the invention do not elicit a PKR response (i.e., are of a sufficiently short length). However, longer RNA silencing agents may be useful, for example, in cell types incapable of generating a PKR response or in situations where the PKR response has been down-regulated or dampened by alternative means.

[0176] The siRNA molecules of the invention have sufficient complementarity with the target sequence such that the siRNA can mediate RNAi. In general, siRNA containing nucleotide sequences sufficiently complementary to a target sequence portion of the target gene to effect RISC-mediated cleavage of the target gene are contemplated. Accordingly, in a certain embodiment, the antisense strand of the siRNA is designed to have a sequence sufficiently

[0177] 82690703v1 29Atorney Docket No.: UM9-328PC (776088)

[0178] complementary to a portion of the target. For example, the antisense strand may have 100% complementarity to the target site. However, 100% complementarity is not required. Greater than 80% identity, e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or even 100% complementarity, between the antisense strand and the target RNA sequence is contemplated. The present application has the advantage of being able to tolerate certain sequence variations to enhance efficiency and specificity of RNAi. In one embodiment, the antisense strand has 4, 3, 2, 1, or 0 mismatched nucleotide(s) with a target region, such as a target region that differs by at least one base pair between a wild-type and mutant allele, e.g., a target region comprising the gain-of-function mutation, and the other strand is identical or substantially identical to the first strand. Moreover, siRNA sequences with small insertions or deletions of 1 or 2 nucleotides may also be effective for mediating RNAi. Alternatively, siRNA sequences with nucleotide analog substitutions or insertions can be effective for inhibition.

[0179] Sequence identity may be determined by sequence comparison and alignment algorithms known in the art. To determine the percent identity of two nucleic acid sequences (or of two amino acid sequences), the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the first sequence or second sequence for optimal alignment). The nucleotides (or amino acid residues) at corresponding nucleotide (or amino acid) positions are then compared. When a position in the first sequence is occupied by the same residue as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = number of identical positions / total number of positions x 100), optionally penalizing the score for the number of gaps introduced and / or length of gaps introduced.

[0180] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In one embodiment, the alignment generated over a certain portion of the sequence aligned having sufficient identity but not over portions having low degree of identity (i.e., a local alignment). A non-limiting example of a local alignment algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the BLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol.

[0181] 215:403-10.

[0182] 82690703v1 30Atorney Docket No.: UM9-328PC (776088)

[0183] In another embodiment, the alignment is optimized by introducing appropriate gaps and the percent identity is determined over the length of the aligned sequences (i.e., a gapped alignment). To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul etal., (1997) Nucleic Acids Res. 25(17):3389-3402. In another embodiment, the alignment is optimized by introducing appropriate gaps and percent identity is determined over the entire length of the sequences aligned (i.e., a global alignment). A nonlimiting example of a mathematical algorithm utilized for the global comparison of sequences is the algorithm of Myers and Miller, CAB IOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

[0184] 3. The antisense or guide strand of the siRNA is routinely the same length as the sense strand and includes complementary nucleotides. In one embodiment, the guide and sense strands are fully complementary, i.e., the strands are blunt-ended when aligned or annealed. In another embodiment, the strands of the siRNA can be paired in such a way as to have a 3' overhang of 1 to 7 (e.g., 2, 3, 4, 5, 6 or 7), or 1 to 4, e.g., 2, 3 or 4 nucleotides. Overhangs can comprise (or consist of) nucleotides corresponding to the target gene sequence (or complement thereof). Alternatively, overhangs can comprise (or consist of) deoxyribonucleotides, for example dTs, or nucleotide analogs, or other suitable non-nucleotide material. Thus, in another embodiment, the nucleic acid molecules may have a 3' overhang of 2 nucleotides, such as TT. The overhanging nucleotides may be either RNA or DNA. As noted above, it is desirable to choose a target region wherein the mutant:wild type mismatch is a purine:purine mismatch.

[0185] 4. Using any method known in the art, compare the potential targets to the appropriate genome database (human, mouse, rat, etc.) and eliminate from consideration any target sequences with significant homology to other coding sequences. One such method for such sequence homology searches is known as BLAST, which is available at National Center for Biotechnology Information website.

[0186] 5. Select one or more sequences that meet your criteria for evaluation.

[0187] Further general information about the design and use of siRNA may be found in "The siRNA User Guide," available at The Max-Plank-Institut fur Biophysikalische Chemie website.

[0188] Alternatively, the siRNA may be defined functionally as a nucleotide sequence (or oligonucleotide sequence) that is capable of hybridizing with the target sequence (e.g., 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50 °C or 70 °C hybridization for 12-16 hours; followed by washing). Additional hybridization conditions include hybridization at 70 °C in

[0189] 82690703v1 31Atorney Docket No.: UM9-328PC (776088)

[0190] IxSSC or 50 °C in IxSSC, 50% formamide followed by washing at 70 °C in 0.3xSSC or hybridization at 70 °C in 4xSSC or 50 °C in 4xSSC, 50% formamide followed by washing at 67 °C in IxSSC. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10 °C less than the melting temperature (Tm) of the hybrid, where Tmis determined according to the following equations. For hybrids less than 18 base pairs in length, Tm(°C)=2(# of A+T bases)+4(# of G+C bases). For hybrids between 18 and 49 base pairs in length, Tm(°C)=81.5+16.6(log 10[Na+])+0.41(% G+C)-(600 / N), where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer ([Na+] for lxSSC=0.165 M). Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

[0191] Negative control siRNAs should have the same nucleotide composition as the selected siRNA, but without significant sequence complementarity to the appropriate genome. Such negative controls may be designed by randomly scrambling the nucleotide sequence of the selected siRNA. A homology search can be performed to ensure that the negative control lacks homology to any other gene in the appropriate genome. In addition, negative control siRNAs can be designed by introducing one or more base mismatches into the sequence.

[0192] 6. To validate the effectiveness by which siRNAs destroy target mRNAs (e.g., wildtype or mutant IRS2 mRNA), the siRNA may be incubated with target cDNA (e.g., IRS2 cDNA) in a Drosophila-based in vitro mRNA expression system. Radiolabeled with32P, newly synthesized target mRNAs (e.g., IRS2 mRNA) are detected autoradiographically on an agarose gel. The presence of cleaved target mRNA indicates mRNA nuclease activity. Suitable controls include omission of siRNA and use of non-target cDNA. Alternatively, control siRNAs are selected having the same nucleotide composition as the selected siRNA, but without significant sequence complementarity to the appropriate target gene. Such negative controls can be designed by randomly scrambling the nucleotide sequence of the selected siRNA. A homology search can be performed to ensure that the negative control lacks homology to any other gene in the appropriate genome. In addition, negative control siRNAs can be designed by introducing one or more base mismatches into the sequence.

[0193] Anti-IRS2 siRNAs may be designed to target any of the target sequences described supra. Said siRNAs comprise an antisense strand, which is sufficiently complementary with

[0194] 82690703v1 32Atorney Docket No.: UM9-328PC (776088)

[0195] the target sequence to mediate silencing of the target sequence. In certain embodiments, the RNA silencing agent is a siRNA.

[0196] Sites of siRNA-mRNA complementation are selected, which result in optimal mRNA specificity and maximal mRNA cleavage.

[0197] b) siRNA-Like Molecules

[0198] siRNA-like molecules of the invention have a sequence (i.e., have a strand having a sequence) that is "sufficiently complementary" to a target sequence of an IRS2 mRNA to direct gene silencing either by RNAi or translational repression. siRNA-like molecules are designed in the same way as siRNA molecules, but the degree of sequence identity between the sense strand and target RNA approximates that observed between a miRNA and its target. In general, as the degree of sequence identity between a miRNA sequence and the corresponding target gene sequence is decreased, the tendency to mediate post-transcriptional gene silencing by translational repression rather than RNAi is increased. Therefore, in an alternative embodiment, where post-transcriptional gene silencing by translational repression of the target gene is desired, the miRNA sequence has partial complementarity with the target gene sequence. In certain embodiments, the miRNA sequence has partial complementarity with one or more short sequences (complementarity sites) dispersed within the target mRNA (e.g. within the 3'-UTR of the target mRNA) (Hutvagner and Zamore, Science, 2002; Zeng et al., Mol. Cell, 2002; Zeng et al., RNA, 2003; Doench et al., Genes & Dev., 2003). Since the mechanism of translational repression is cooperative, multiple complementarity sites (e.g., 2, 3, 4, 5, or 6) may be targeted in certain embodiments.

[0199] The capacity of a siRNA-like duplex to mediate RNAi or translational repression may be predicted by the distribution of non-identical nucleotides between the target gene sequence and the nucleotide sequence of the silencing agent at the site of complementarity. In one embodiment, where gene silencing by translational repression is desired, at least one nonidentical nucleotide is present in the central portion of the complementarity site so that duplex formed by the miRNA guide strand and the target mRNA contains a central "bulge" (Doench J G et al., Genes & Dev., 2003). In another embodiment 2, 3, 4, 5, or 6 contiguous or noncontiguous non-identical nucleotides are introduced. The non-identical nucleotide may be selected such that it forms a wobble base pair (e.g., G:U) or a mismatched base pair (G: A, C: A, C:U, G:G, A:A, C:C, U:U). In a further embodiment, the "bulge" is centered at nucleotide positions 12 and 13 from the 5' end of the miRNA molecule.

[0200] 82690703v1 33Atorney Docket No.: UM9-328PC (776088)

[0201] c) Short Hairpin RNA (shRNA) Molecules

[0202] In certain featured embodiments, the instant invention provides shRNAs capable of mediating RNA silencing of an IRS2 RNA target sequence with enhanced selectivity. In contrast to siRNAs, shRNAs mimic the natural precursors of micro RNAs (miRNAs) and enter at the top of the gene silencing pathway. For this reason, shRNAs are believed to mediate gene silencing more efficiently by being fed through the entire natural gene silencing pathway. miRNAs are noncoding RNAs of approximately 22 nucleotides, which can regulate gene expression at the post transcriptional or translational level during plant and animal development. One common feature of miRNAs is that they are all excised from an approximately 70 nucleotide precursor RNA stem-loop termed pre-miRNA, probably by Dicer, an RNase Ill-type enzyme, or a homolog thereof. Naturally-occurring miRNA precursors (pre-miRNA) have a single strand that forms a duplex stem including two portions that are generally complementary, and a loop, that connects the two portions of the stem. In typical pre-miRNAs, the stem includes one or more bulges, e.g., extra nucleotides that create a single nucleotide "loop" in one portion of the stem, and / or one or more unpaired nucleotides that create a gap in the hybridization of the two portions of the stem to each other. Short hairpin RNAs, or engineered RNA precursors, of the present application are artificial constructs based on these naturally occurring pre-miRNAs, but which are engineered to deliver desired RNA silencing agents (e.g., siRNAs of the invention). By substituting the stem sequences of the pre-miRNA with sequence complementary to the target mRNA, a shRNA is formed. The shRNA is processed by the entire gene silencing pathway of the cell, thereby efficiently mediating RNAi.

[0203] The requisite elements of a shRNA molecule include a first portion and a second portion, having sufficient complementarity to anneal or hybridize to form a duplex or doublestranded stem portion. The two portions need not be fully or perfectly complementary. The first and second "stem" portions are connected by a portion having a sequence that has insufficient sequence complementarity to anneal or hybridize to other portions of the shRNA. This latter portion is referred to as a "loop" portion in the shRNA molecule. The shRNA molecules are processed to generate siRNAs. shRNAs can also include one or more bulges, i.e., extra nucleotides that create a small nucleotide "loop" in a portion of the stem, for example a one-, two- or three-nucleotide loop. The stem portions can be the same length, or one portion can include an overhang of, for example, 1-5 nucleotides. The overhanging nucleotides can

[0204] 82690703v1 34Atorney Docket No.: UM9-328PC (776088)

[0205] include, for example, uracils (Us), e.g., all Us. Such Us are notably encoded by thymidines (Ts) in the shRNA-en coding DNA which signal the termination of transcription.

[0206] In shRNAs (or engineered precursor RNAs) of the instant invention, one portion of the duplex stem is a nucleic acid sequence that is complementary (or antisense) to the target sequence. In certain embodiments, one strand of the stem portion of the shRNA is sufficiently complementary (e.g., antisense) to a target RNA (e.g., mRNA) sequence to mediate degradation or cleavage of said target RNA via RNA interference (RNAi). Thus, engineered RNA precursors include a duplex stem with two portions and a loop connecting the two stem portions. The antisense portion can be on the 5' or 3' end of the stem. The stem portions of a shRNA are about 15 to about 50 nucleotides in length. In certain embodiments, the two stem portions are about 18 or 19 to about 21, 22, 23, 24, 25, 30, 35, 37, 38, 39, or 40 or more nucleotides in length. In certain embodiments, the length of the stem portions should be 21 nucleotides or greater. When used in mammalian cells, the length of the stem portions should be less than about 30 nucleotides to avoid provoking non-specific responses like the interferon pathway. In non-mammalian cells, the stem can be longer than 30 nucleotides. In fact, the stem can include much larger sections complementary to the target mRNA (up to, and including the entire mRNA). In fact, a stem portion can include much larger sections complementary to the target mRNA (up to, and including the entire mRNA).

[0207] The two portions of the duplex stem must be sufficiently complementary to hybridize to form the duplex stem. Thus, the two portions can be, but need not be, fully or perfectly complementary. In addition, the two stem portions can be the same length, or one portion can include an overhang of 1, 2, 3, or 4 nucleotides. The overhanging nucleotides can include, for example, uracils (Us), e.g., all Us. The loop in the shRNAs or engineered RNA precursors may differ from natural pre-miRNA sequences by modifying the loop sequence to increase or decrease the number of paired nucleotides, or replacing all or part of the loop sequence with a tetraloop or other loop sequences. Thus, the loop in the shRNAs or engineered RNA precursors can be 2, 3, 4, 5, 6, 7, 8, 9, or more, e.g., 15 or 20, or more nucleotides in length.

[0208] The loop in the shRNAs or engineered RNA precursors may differ from natural pre-miRNA sequences by modifying the loop sequence to increase or decrease the number of paired nucleotides, or replacing all or part of the loop sequence with a tetraloop or other loop sequences. Thus, the loop portion in the shRNA can be about 2 to about 20 nucleotides in length, i.e., about 2, 3, 4, 5, 6, 7, 8, 9, or more, e.g., 15 or 20, or more nucleotides in length. In certain embodiments, a loop consists of or comprises a "tetraloop" sequence. Exemplary

[0209] 82690703v1 35Atorney Docket No.: UM9-328PC (776088)

[0210] tetraloop sequences include, but are not limited to, the sequences GNRA, where N is any nucleotide and R is a purine nucleotide, GGGG, and UUUU.

[0211] In certain embodiments, shRNAs of the present application include the sequences of a desired siRNA molecule described supra. In other embodiments, the sequence of the antisense portion of a shRNA can be designed essentially as described above or generally by selecting an 18, 19, 20, 21 nucleotide, or longer, sequence from within the target RNA (e.g., IRS2 mRNA), for example, from a region 100 to 200 or 300 nucleotides upstream or downstream of the start of translation. In general, the sequence can be selected from any portion of the target RNA (e.g., mRNA) including the 5' UTR (untranslated region), coding sequence, or 3' UTR. This sequence can optionally follow immediately after a region of the target gene containing two adjacent AA nucleotides. The last two nucleotides of the nucleotide sequence can be selected to be UU. This 21 or so nucleotide sequence is used to create one portion of a duplex stem in the shRNA. This sequence can replace a stem portion of a wild-type pre-miRNA sequence, e.g., enzymatically, or is included in a complete sequence that is synthesized. For example, one can synthesize DNA oligonucleotides that encode the entire stem-loop engineered RNA precursor, or that encode just the portion to be inserted into the duplex stem of the precursor, and using restriction enzymes to build the engineered RNA precursor construct, e.g., from a wild-type pre-miRNA.

[0212] Engineered RNA precursors include, in the duplex stem, the 21-22 or so nucleotide sequences of the siRNA or siRNA-like duplex desired to be produced in vivo. Thus, the stem portion of the engineered RNA precursor includes at least 18 or 19 nucleotide pairs corresponding to the sequence of an exonic portion of the gene whose expression is to be reduced or inhibited. The two 3' nucleotides flanking this region of the stem are chosen so as to maximize the production of the siRNA from the engineered RNA precursor and to maximize the efficacy of the resulting siRNA in targeting the corresponding mRNA for translational repression or destruction by RNAi in vivo and in vitro.

[0213] In certain embodiments, shRNAs of the invention include miRNA sequences, optionally end-modified miRNA sequences, to enhance entry into RISC. The miRNA sequence can be similar or identical to that of any naturally occurring miRNA (see e.g. The miRNA Registry; Griffiths- Jones S, Nuc. Acids Res., 2004). Over one thousand natural miRNAs have been identified to date and together they are thought to comprise about 1% of all predicted genes in the genome. Many natural miRNAs are clustered together in the introns of pre-mRNAs and can be identified in silico using homology-based searches (Pasquinelli et

[0214] 82690703v1 36Atorney Docket No.: UM9-328PC (776088)

[0215] al., 2000; Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001) or computer algorithms (e.g. MiRScan, MiRSeeker) that predict the capability of a candidate miRNA gene to form the stem loop structure of a pri-mRNA (Grad et al., Mol. Cell., 2003; Lim et al., Genes Dev., 2003; Lim et al., Science, 2003; Lai E C et al., Genome Bio., 2003). An online registry provides a searchable database of all published miRNA sequences (The miRNA Registry at the Sanger Institute website; Griffiths-Jones S, Nuc. Acids Res., 2004). Exemplary, natural miRNAs include lin-4, let-7, miR-10, mirR-15, miR-16, miR-168, miR-175, miR-196 and their homologs, as well as other natural miRNAs from humans and certain model organisms including Drosophila melanogaster, Caenorhabditis elegans, zebrafish, Arabidopsis thalania, Mus musculus, and Rattus norvegicus as described in International PCT Publication No. WO 03 / 029459.

[0216] Naturally-occurring miRNAs are expressed by endogenous genes in vivo and are processed from a hairpin or stem-loop precursor (pre-miRNA or pri-miRNAs) by Dicer or other RNAses (Lagos-Quintana et al., Science, 2001; Lau et al., Science, 2001; Lee and Ambros, Science, 2001; Lagos-Quintana et al., Curr. Biol., 2002; Mourelatos et al., Genes Dev., 2002; Reinhart et al., Science, 2002; Ambros et al., Curr. Biol., 2003; Brennecke et al., 2003; Lagos-Quintana et al., RNA, 2003; Lim et al., Genes Dev., 2003; Lim et al., Science, 2003). miRNAs can exist transiently in vivo as a double-stranded duplex, but only one strand is taken up by the RISC complex to direct gene silencing. Certain miRNAs, e.g., plant miRNAs, have perfect or near-perfect complementarity to their target mRNAs and, hence, direct cleavage of the target mRNAs. Other miRNAs have less than perfect complementarity to their target mRNAs and, hence, direct translational repression of the target mRNAs. The degree of complementarity between a miRNA and its target mRNA is believed to determine its mechanism of action. For example, perfect or near-perfect complementarity between a miRNA and its target mRNA is predictive of a cleavage mechanism (Yekta et al., Science, 2004), whereas less than perfect complementarity is predictive of a translational repression mechanism. In certain embodiments, the miRNA sequence is that of a naturally-occurring miRNA sequence, the aberrant expression or activity of which is correlated with a miRNA disorder.

[0217] d) Dual Functional Oligonucleotide Tethers

[0218] In other embodiments, the RNA silencing agents of the present invention include dual functional oligonucleotide tethers useful for the intercellular recruitment of a miRNA. Animal cells express a range of miRNAs, noncoding RNAs of approximately 22 nucleotides which can regulate gene expression at the post transcriptional or translational level. By binding a miRNA

[0219] 82690703v1 37Atorney Docket No.: UM9-328PC (776088)

[0220] bound to RISC and recruiting it to a target mRNA, a dual functional oligonucleotide tether can repress the expression of genes involved e.g., in the arteriosclerotic process. The use of oligonucleotide tethers offers several advantages over existing techniques to repress the expression of a particular gene. First, the methods described herein allow an endogenous molecule (often present in abundance), a miRNA, to mediate RNA silencing. Accordingly, the methods described herein obviate the need to introduce foreign molecules (e.g., siRNAs) to mediate RNA silencing. Second, the RNA-silencing agents and the linking moiety (e.g., oligonucleotides such as the 2'-O-methyl oligonucleotide), can be made stable and resistant to nuclease activity. As a result, the tethers of the present invention can be designed for direct delivery, obviating the need for indirect delivery (e.g. viral) of a precursor molecule or plasmid designed to make the desired agent within the cell. Third, tethers and their respective moi eties, can be designed to conform to specific mRNA sites and specific miRNAs. The designs can be cell and gene product specific. Fourth, the methods disclosed herein leave the mRNA intact, allowing one skilled in the art to block protein synthesis in short pulses using the cell's own machinery. As a result, these methods of RNA silencing are highly regulatable.

[0221] The dual functional oligonucleotide tethers ("tethers") of the invention are designed such that they recruit miRNAs (e.g., endogenous cellular miRNAs) to a target mRNA so as to induce the modulation of a gene of interest. In certain embodiments, the tethers have the formula T-L-p, wherein T is an mRNA targeting moiety, L is a linking moiety, and p is a miRNA recruiting moiety. Any one or more moiety may be double stranded. In certain embodiments, each moiety is single stranded.

[0222] Moieties within the tethers can be arranged or linked (in the 5' to 3' direction) as depicted in the formula T-L-p (i.e., the 3' end of the targeting moiety linked to the 5' end of the linking moiety and the 3' end of the linking moiety linked to the 5' end of the miRNA recruiting moiety). Alternatively, the moieties can be arranged or linked in the tether as follows: p-T-L (i.e., the 3' end of the miRNA recruiting moiety linked to the 5' end of the linking moiety and the 3' end of the linking moiety linked to the 5' end of the targeting moiety).

[0223] The mRNA targeting moiety, as described above, is capable of capturing a specific target mRNA. According to the invention, expression of the target mRNA is undesirable, and, thus, translational repression of the mRNA is desired. The mRNA targeting moiety should be of sufficient size to effectively bind the target mRNA. The length of the targeting moiety will vary greatly, depending, in part, on the length of the target mRNA and the degree of

[0224] 82690703v1 38Atorney Docket No.: UM9-328PC (776088)

[0225] complementarity between the target mRNA and the targeting moiety. In various embodiments, the targeting moiety is less than about 200, 100, 50, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 nucleotides in length. In a certain embodiment, the targeting moiety is about 15 to about 25 nucleotides in length.

[0226] The miRNA recruiting moiety, as described above, is capable of associating with a miRNA. According to the present application, the miRNA may be any miRNA capable of repressing the target mRNA. Mammals are reported to have over 250 endogenous miRNAs (Lagos-Quintana et al. (2002) Current Biol. 12:735-739; Lagos-Quintana et al. (2001) Science 294:858-862; and Lim et al. (2003) Science 299:1540). In various embodiments, the miRNA may be any art-recognized miRNA.

[0227] The linking moiety is any agent capable of linking the targeting moi eties such that the activity of the targeting moieties is maintained. Linking moieties can be oligonucleotide moieties comprising a sufficient number of nucleotides, such that the targeting agents can sufficiently interact with their respective targets. Linking moieties have little or no sequence homology with cellular mRNA or miRNA sequences. Exemplary linking moieties include one or more 2'-O-methylnucleotides, e.g., 2'-P-methyladenosine, 2'-O-methylthymidine, 2'-O-methylguanosine or 2'-O-methyluridine.

[0228] V. Modified Anti-IRS2 RNA Silencing Agents

[0229] In certain aspects of the invention, an RNA silencing agent (or any portion thereof) of the present application, as described supra, may be modified, such that the activity of the agent is further improved. For example, the RNA silencing agents described in Section II supra, may be modified with any of the modifications described infra. The modifications can, in part, serve to further enhance target discrimination, to enhance stability of the agent (e.g., to prevent degradation), to promote cellular uptake, to enhance the target efficiency, to improve efficacy in binding (e.g., to the targets), to improve patient tolerance to the agent, and / or to reduce toxicity.

[0230] Notably, the antisense and sense strand sequences recited in Table IB and Table 2B may be chemically modified with any one or more of the chemical modifications described herein. As used herein, the term “chemically modified variant thereof’ refers to the specific antisense and sense strand sequences disclosed herein having one or more of the chemical modifications described herein. While the specific antisense and sense strand sequences

[0231] 82690703v1 39Atorney Docket No.: UM9-328PC (776088)

[0232] disclosed herein are shown in an unmodified form, it will be readily apparent to one of skill in the art that any of the chemical modifications described herein may be applied to these unmodified strands to form chemically modified variants thereof.

[0233] 1) Modifications to Enhance Target Discrimination

[0234] In certain embodiments, the RNA silencing agents of the present application may be substituted with a destabilizing nucleotide to enhance single nucleotide target discrimination (see U.S. application Ser. No. 11 / 698,689, filed Jan. 25, 2007 and U.S. Provisional Application No. 60 / 762,225 filed Jan. 25, 2006, both of which are incorporated herein by reference). Such a modification may be sufficient to abolish the specificity of the RNA silencing agent for a non-target mRNA (e.g. wild-type mRNA), without appreciably affecting the specificity of the RNA silencing agent for a target mRNA (e.g. gain-of-function mutant mRNA).

[0235] In certain embodiments, the RNA silencing agents of the present application are modified by the introduction of at least one universal nucleotide in the antisense strand thereof. Universal nucleotides comprise base portions that are capable of base pairing indiscriminately with any of the four conventional nucleotide bases (e.g. A, G, C, U). A universal nucleotide is contemplated because it has relatively minor effect on the stability of the RNA duplex or the duplex formed by the guide strand of the RNA silencing agent and the target mRNA. Exemplary universal nucleotides include those having an inosine base portion or an inosine analog base portion selected from the group consisting of deoxyinosine (e.g. 2'-deoxyinosine), 7-deaza-2'-deoxyinosine, 2'-aza-2'-deoxyinosine, PNA-inosine, morpholino-inosine, LNA-inosine, phosphoramidate-inosine, 2'-O-methoxyethyl-inosine, and 2'-OMe-inosine. In certain embodiments, the universal nucleotide is an inosine residue or a naturally occurring analog thereof.

[0236] In certain embodiments, the RNA silencing agents of the invention are modified by the introduction of at least one destabilizing nucleotide within 5 nucleotides from a specificitydetermining nucleotide (i.e., the nucleotide which recognizes the disease-related polymorphism). For example, the destabilizing nucleotide may be introduced at a position that is within 5, 4, 3, 2, or 1 nucleotide(s) from a specificity-determining nucleotide. In exemplary embodiments, the destabilizing nucleotide is introduced at a position which is 3 nucleotides from the specificity-determining nucleotide (i.e., such that there are 2 stabilizing nucleotides between the destablilizing nucleotide and the specificity-determining nucleotide). In RNA

[0237] 82690703v1 40Atorney Docket No.: UM9-328PC (776088)

[0238] silencing agents having two strands or strand portions (e.g. siRNAs and shRNAs), the destabilizing nucleotide may be introduced in the strand or strand portion that does not contain the specificity-determining nucleotide. In certain embodiments, the destabilizing nucleotide is introduced in the same strand or strand portion that contains the specificity-determining nucleotide.

[0239] 2) Modifications to Enhance Efficacy and Specificity

[0240] In certain embodiments, the RNA silencing agents of the invention may be altered to facilitate enhanced efficacy and specificity in mediating RNAi according to asymmetry design rules (see U.S. Patent Nos. 8,309,704, 7,750,144, 8,304,530, 8,329,892 and 8,309,705). Such alterations facilitate entry of the antisense strand of the siRNA (e.g., a siRNA designed using the methods of the present application or an siRNA produced from a shRNA) into RISC in favor of the sense strand, such that the antisense strand preferentially guides cleavage or translational repression of a target mRNA, and thus increasing or improving the efficiency of target cleavage and silencing. In certain embodiments, the asymmetry of an RNA silencing agent is enhanced by lessening the base pair strength between the antisense strand 5' end (AS 5') and the sense strand 3' end (S 3') of the RNA silencing agent relative to the bond strength or base pair strength between the antisense strand 3' end (AS 3') and the sense strand 5' end (S 5') of said RNA silencing agent.

[0241] In one embodiment, the asymmetry of an RNA silencing agent of the present application may be enhanced such that there are fewer G:C base pairs between the 5' end of the first or antisense strand and the 3' end of the sense strand portion than between the 3' end of the first or antisense strand and the 5' end of the sense strand portion. In another embodiment, the asymmetry of an RNA silencing agent of the invention may be enhanced such that there is at least one mismatched base pair between the 5' end of the first or antisense strand and the 3' end of the sense strand portion. In certain embodiments, the mismatched base pair is selected from the group consisting of G:A, C:A, C:U, G:G, A:A, C:C and U:U. In another embodiment, the asymmetry of an RNA silencing agent of the invention may be enhanced such that there is at least one wobble base pair, e.g., G:U, between the 5' end of the first or antisense strand and the 3' end of the sense strand portion. In another embodiment, the asymmetry of an RNA silencing agent of the invention may be enhanced such that there is at least one base pair comprising a rare nucleotide, e.g., inosine (I). In certain embodiments, the base pair is selected from the group consisting of an I: A, I:U and I:C. In yet another embodiment, the asymmetry of an RNA silencing agent of the invention may be enhanced such that there is at least one base pair

[0242] 82690703v1 41Atorney Docket No.: UM9-328PC (776088)

[0243] comprising a modified nucleotide. In certain embodiments, the modified nucleotide is selected from the group consisting of 2-amino-G, 2-amino-A, 2,6-diamino-G, and 2,6-diamino-A.

[0244] 3) RNA Silencing Agents with Enhanced Stability

[0245] The RNA silencing agents of the present application can be modified to improve stability in serum or in growth medium for cell cultures. In order to enhance the stability, the 3'-residues may be stabilized against degradation, e.g., they may be selected such that they consist of purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNA interference.

[0246] In a one aspect, the present application features RNA silencing agents that include first and second strands wherein the second strand and / or first strand is modified by the substitution of internal nucleotides with modified nucleotides, such that in vivo stability is enhanced as compared to a corresponding unmodified RNA silencing agent. As defined herein, an "internal" nucleotide is one occurring at any position other than the 5' end or 3' end of nucleic acid molecule, polynucleotide or oligonucleotide. An internal nucleotide can be within a single-stranded molecule or within a strand of a duplex or double-stranded molecule. In one embodiment, the sense strand and / or antisense strand is modified by the substitution of at least one internal nucleotide. In another embodiment, the sense strand and / or antisense strand is modified by the substitution of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more internal nucleotides. In another embodiment, the sense strand and / or antisense strand is modified by the substitution of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of the internal nucleotides. In yet another embodiment, the sense strand and / or antisense strand is modified by the substitution of all of the internal nucleotides.

[0247] In one aspect, the present application features RNA silencing agents that are at least 80% chemically modified. In certain embodiments, the RNA silencing agents may be fully chemically modified, i.e., 100% of the nucleotides are chemically modified. In another aspect, the present application features RNA silencing agents comprising 2’ -OH ribose groups that are at least 80% chemically modified. In certain embodiments, the RNA silencing agents comprise 2’-OH ribose groups that are about 80%, 85%, 90%, 95%, or 100% chemically modified.

[0248] In certain embodiments, the RNA silencing agents may contain at least one modified nucleotide analogue. The nucleotide analogues may be located at positions where the target-

[0249] 82690703v1 42Atorney Docket No.: UM9-328PC (776088)

[0250] specific silencing activity, e.g., the RNAi mediating activity or translational repression activity is not substantially affected, e.g., in a region at the 5'-end and / or the 3'-end of the siRNA molecule. Moreover, the ends may be stabilized by incorporating modified nucleotide analogues.

[0251] Exemplary nucleotide analogues include sugar- and / or backbone-modified ribonucleotides (i.e., include modifications to the phosphate-sugar backbone). For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. In exemplary backbone-modified ribonucleotides, the phosphodiester group connecting to adjacent ribonucleotides is replaced by a modified group, e.g., of phosphorothioate group. In exemplary sugar-modified ribonucleotides, the 2' OH-group is replaced by a group selected from H, OR, R, halo, SH, SR, NEh, NHR, NR2 or ON, wherein R is Ci-Ce alkyl, alkenyl or alkynyl and halo is F, Cl, Br or I.

[0252] In certain embodiments, the modifications are 2'-fluoro, 2'-amino and / or 2'-thio modifications. Modifications include 2'-fluoro-cytidine, 2'-fluoro-uridine, 2'-fluoro-adenosine, 2'-fluoro-guanosine, 2'-amino-cytidine, 2'-amino-uridine, 2'-amino-adenosine, 2'-amino-guanosine, 2,6-diaminopurine, 4-thio-uridine, and / or 5-amino-allyl-uridine. In a certain embodiment, the 2'-fluoro ribonucleotides are every uridine and cytidine. Additional exemplary modifications include 5-bromo-uridine, 5-iodo-uridine, 5-methyl-cytidine, ribothymidine, 2-aminopurine, 2'-amino-butyryl-pyrene-uridine, 5-fluoro-cytidine, and 5-fluoro-uridine. 2'-deoxy-nucleotides and 2'-0me nucleotides can also be used within modified RNA-silencing agents moieties of the instant invention. Additional modified residues include, deoxy-abasic, inosine, N3-methyl-uridine, N6,N6-dimethyl-adenosine, pseudouridine, purine ribonucleoside and ribavirin. In a certain embodiment, the 2' moiety is a methyl group such that the linking moiety is a 2'-O-methyl oligonucleotide.

[0253] In a certain embodiment, the RNA silencing agent of the present application comprises Locked Nucleic Acids (LNAs). LNAs comprise sugar-modified nucleotides that resist nuclease activities (are highly stable) and possess single nucleotide discrimination for mRNA (Elmen et al., Nucleic Acids Res., (2005), 33(1): 439-447; Braasch et al. (2003) Biochemistry 42:7967-7975, Petersen et al. (2003) Trends Biotechnol 21:74-81). These molecules have 2'-O,4'-C-ethylene-bridged nucleic acids, with possible modifications such as 2'-deoxy-2"-fluorouridine. Moreover, LNAs increase the specificity of oligonucleotides by constraining the sugar moiety into the 3'-endo conformation, thereby pre-organizing the nucleotide for base

[0254] 82690703v1 43Atorney Docket No.: UM9-328PC (776088)

[0255] pairing and increasing the melting temperature of the oligonucleotide by as much as 10 °C per base.

[0256] In another exemplary embodiment, the RNA silencing agent of the present application comprises Peptide Nucleic Acids (PNAs). PNAs comprise modified nucleotides in which the sugar-phosphate portion of the nucleotide is replaced with a neutral 2-amino ethylglycine moiety capable of forming a polyamide backbone, which is highly resistant to nuclease digestion and imparts improved binding specificity to the molecule (Nielsen, et al., Science, (2001), 254: 1497-1500).

[0257] Also contemplated are nucleobase-modified ribonucleotides, i.e., ribonucleotides, containing at least one non-naturally occurring nucleobase instead of a naturally occurring nucleobase. Bases may be modified to block the activity of adenosine deaminase. Exemplary modified nucleobases include, but are not limited to, uridine and / or cytidine modified at the 5-position, e.g., 5-(2-amino)propyl uridine, 5-bromo uridine; adenosine and / or guanosines modified at the 8 position, e.g., 8-bromo guanosine; deaza nucleotides, e.g., 7-deaza-adenosine; O- and N-alkylated nucleotides, e.g., N6-methyl adenosine are suitable. It should be noted that the above modifications may be combined.

[0258] In other embodiments, cross-linking can be employed to alter the pharmacokinetics of the RNA silencing agent, for example, to increase half-life in the body. Thus, the present application includes RNA silencing agents having two complementary strands of nucleic acid, wherein the two strands are crosslinked. The present application also includes RNA silencing agents which are conjugated or unconjugated (e.g., at its 3' terminus) to another moiety (e.g. a non-nucleic acid moiety such as a peptide), an organic compound (e.g., a dye), or the like). Modifying siRNA derivatives in this way may improve cellular uptake or enhance cellular targeting activities of the resulting siRNA derivative as compared to the corresponding siRNA, are useful for tracing the siRNA derivative in the cell, or improve the stability of the siRNA derivative compared to the corresponding siRNA.

[0259] Other exemplary modifications include: (a) 2' modification, e.g., provision of a 2' OMe moiety on a U in a sense or antisense strand, but especially on a sense strand, or provision of a 2' OMe moiety in a 3' overhang, e.g., at the 3' terminus (3' terminus means at the 3' atom of the molecule or at the most 3' moiety, e.g., the most 3' P or 2' position, as indicated by the context); (b) modification of the backbone, e.g., with the replacement of an 0 with an S, in the phosphate backbone, e.g., the provision of a phosphorothioate modification, on the U or the A or both,

[0260] 82690703v1 44Atorney Docket No.: UM9-328PC (776088)

[0261] especially on an antisense strand; e.g., with the replacement of a O with an S; (c) replacement of the U with a C5 amino linker; (d) replacement of an A with a G (sequence changes can be located on the sense strand and not the antisense strand in certain embodiments); and (d) modification at the 2', 6', 7', or 8' position. Exemplary embodiments are those in which one or more of these modifications are present on the sense but not the antisense strand, or embodiments where the antisense strand has fewer of such modifications. Yet other exemplary modifications include the use of a methylated P in a 3' overhang, e.g., at the 3' terminus; combination of a 2' modification, e.g., provision of a 2' O Me moiety and modification of the backbone, e.g., with the replacement of a O with an S, e.g., the provision of a phosphorothioate modification, or the use of a methylated P, in a 3' overhang, e.g., at the 3' terminus; modification with a 3' alkyl; modification with an abasic pyrrolidone in a 3' overhang, e.g., at the 3' terminus; modification with naproxen, ibuprofen, or other moi eties which inhibit degradation at the 3' terminus.

[0262] Heavily modified RNA silencing agents

[0263] In certain embodiments, the RNA silencing agent comprises at least 80% chemically modified nucleotides. In certain embodiments, the RNA silencing agent is fully chemically modified, i.e., 100% of the nucleotides are chemically modified.

[0264] In certain embodiments, the RNA silencing agent is 2’-O-methyl rich, i.e., comprises greater than 50% 2’-O-methyl content. In certain embodiments, the RNA silencing agent comprises at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% 2’-O-methyl nucleotide content. In certain embodiments, the RNA silencing agent comprises at least about 70% 2’-O-methyl nucleotide modifications. In certain embodiments, the RNA silencing agent comprises between about 70% and about 90% 2’-O-methyl nucleotide modifications. In certain embodiments, the RNA silencing agent is a dsRNA comprising an antisense strand and sense strand. In certain embodiments, the antisense strand comprises at least about 70% 2’-O-methyl nucleotide modifications. In certain embodiments, the antisense strand comprises between about 70% and about 90% 2’-O-methyl nucleotide modifications. In certain embodiments, the sense strand comprises at least about 70% 2’-O-methyl nucleotide modifications. In certain embodiments, the sense strand comprises between about 70% and about 90% 2’-O-methyl nucleotide modifications. In certain embodiments, the sense strand comprises between 100% 2’-O-methyl nucleotide modifications.

[0265] 82690703v1 45Atorney Docket No.: UM9-328PC (776088)

[0266] 2’-O-methyl rich RNA silencing agents and specific chemical modification patterns are further described in U.S. Patent Publication No. 2020 / 0087663 Al and U.S. Patent Publication No. 2021 / 0115442 Al, each of which is incorporated herein by reference.

[0267] Internucleotide linkage modifications

[0268] In certain embodiments, at least one internucleotide linkage, intersubunit linkage, or nucleotide backbone is modified in the RNA silencing agent. In certain embodiments, all of the intemucleotide linkages in the RNA silencing agent are modified. In certain embodiments, the modified internucleotide linkage comprises a phosphorothioate intemucleotide linkage. In certain embodiments, the RNA silencing agent comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 phosphorothioate intemucleotide linkages. In certain embodiments, the RNA silencing agent comprises 4-16 phosphorothioate intemucleotide linkages. In certain embodiments, the RNA silencing agent comprises 8-13 phosphorothioate intemucleotide linkages. In certain embodiments, the RNA silencing agent is a dsRNA comprising an antisense strand and a sense strand, each comprising a 5’ end and a 3’ end. In certain embodiments, the nucleotides at positions 1 and 2 from the 5’ end of sense strand are connected to adjacent ribonucleotides via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1 and 2 from the 3’ end of sense strand are connected to adjacent ribonucleotides via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1 and 2 from the 5’ end of antisense strand are connected to adjacent ribonucleotides via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1-2 to 1-8 from the 3’ end of antisense strand are connected to adjacent ribonucleotides via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 from the 3’ end of antisense strand are connected to adjacent ribonucleotides via phosphorothioate intemucleotide linkages. In certain embodiments, the nucleotides at positions 1-2 to 1-7 from the 3’ end of antisense strand are connected to adjacent ribonucleotides via phosphorothioate intemucleotide linkages.

[0269] In one aspect, the disclosure provides a modified oligonucleotide, said oligonucleotide having a 5’ end, a 3’ end, that is complementary to a target, wherein the oligonucleotide comprises a sense and antisense strand, and at least one modified intersubunit linkage of Formula (I):

[0270] 82690703v1 46Atorney Docket No.: UM9-328PC (776088)

[0271]

[0272] wherein:

[0273] B is a base pairing moiety;

[0274] W is selected from the group consisting of O, OCH2, OCH, CH2, and CH;

[0275] X is selected from the group consisting of halo, hydroxy, and C1-6 alkoxy;

[0276] Y is selected from the group consisting of O , OH, OR, NH , NH2, S , and SH;

[0277] Z is selected from the group consisting of O and CH2;

[0278] R is a protecting group; and

[0279] = is an optional double bond.

[0280] In an embodiment of Formula (I), when W is CH, = is a double bond.

[0281] In an embodiment of Formula (I), when W selected from the group consisting of O, OCH2, OCH, CH2, = is a single bond.

[0282] In an embodiment of Formula (I), when Y is O , either Z or W is not O.

[0283] In an embodiment of Formula (I), Z is CH2 and W is CH2. In another embodiment, the modified intersubunit linkage of Formula (I) is a modified intersubunit linkage of Formula (II):

[0284]

[0285] (II)

[0286] In an embodiment of Formula (I), Z is CH2 and W is O. In another embodiment, wherein the modified intersubunit linkage of Formula (I) is a modified intersubunit linkage of Formula (III):

[0287] 82690703v1 47Attorney Docket No.: UM9-328PC (776088)

[0288]

[0289] (HI)

[0290] In an embodiment of Formula (I), Z is O and W is CH2. In another embodiment, the modified intersubunit linkage of Formula (I) is a modified intersubunit linkage of Formula (IV):

[0291] O X

[0292] O X

[0293]

[0294] In an embodiment of Formula (I), Z is O and W is CH. In another embodiment, the modified intersubunit linkage of Formula (I) is a modified intersubunit linkage of Formula V:

[0295] O X

[0296] O X

[0297]

[0298] (V).

[0299] In an embodiment of Formula (I), Z is O and W is OCH2. In another embodiment, the modified intersubunit linkage of Formula (I) is a modified intersubunit linkage of Formula VI:

[0300] 82690703v1 48Attorney Docket No.: UM9-328PC (776088)

[0301] O X

[0302]

[0303] (VI)

[0304] In an embodiment of Formula (I), Z is CH2 and W is CH. In another embodiment, the modified intersubunit linkage of Formula (I) is a modified intersubunit linkage of Formula VII:

[0305]

[0306] (VII)

[0307] In an embodiment of Formula (I), the base pairing moiety B is selected from the group consisting of adenine, guanine, cytosine, and uracil.

[0308] In an embodiment, the modified oligonucleotide is incorporated into siRNA, said modified siRNA having a 5 ’ end, a 3 ’ end, that is complementary to a target, wherein the siRNA comprises a sense and antisense strand, and at least one modified intersubunit linkage of any one or more of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), or Formula (VII).

[0309] In an embodiment, the modified oligonucleotide is incorporated into siRNA, said modified siRNA having a 5’ end, a 3’ end, that is complementary to a target and comprises a sense and antisense strand, wherein the siRNA comprises at least one modified intersubunit linkage is of Formula VIII:

[0310] 82690703v1 49Atorney Docket No.: UM9-328PC (776088)

[0311] 0'1

[0312] D

[0313]

[0314] (VIII);

[0315] wherein:

[0316] D is selected from the group consisting of O, OCH2, OCH, CH2, and CH;

[0317] C is selected from the group consisting of O , OH, OR1, NH , NH2, S , and SH;

[0318] A is selected from the group consisting of O and CH2;

[0319] R1is a protecting group;

[0320] = is an optional double bond; and

[0321] the intersubunit is bridging two optionally modified nucleosides.

[0322] In an embodiment, when C is O , either A or D is not O.

[0323] In an embodiment, D is CH2. In another embodiment, the modified intersubunit linkage of Formula VIII is a modified intersubunit linkage of Formula (IX):

[0324] C7P

[0325] Ozl

[0326]

[0327]

[0328] In an embodiment, D is O. In another embodiment, the modified intersubunit linkage of Formula VIII is a modified intersubunit linkage of Formula (X):

[0329]

[0330]

[0331] In an embodiment, D is CH2. In another embodiment, the modified intersubunit linkage of Formula (VIII) is a modified intersubunit linkage of Formula (XI):

[0332] 82690703v1 50Attorney Docket No.: UM9-328PC (776088)

[0333] o

[0334] C7P

[0335] ozl

[0336]

[0337]

[0338] In an embodiment, D is CH. In another embodiment, the modified intersubunit linkage of Formula VIII is a modified intersubunit linkage of Formula (XII):

[0339]

[0340] (XII)

[0341] In another embodiment, the modified intersubunit linkage of Formula (VII) is a modified intersubunit linkage of Formula (XIV):

[0342]

[0343] (XIV).

[0344] In an embodiment, D is OCH2. In another embodiment, the modified intersubunit linkage of Formula (VII) is a modified intersubunit linkage of Formula (XIII):

[0345] I

[0346]

[0347] (XIII).

[0348] In another embodiment, the modified intersubunit linkage of Formula (VII) is a modified intersubunit linkage of Formula (XXa):

[0349] 82690703v1 51Atorney Docket No.: UM9-328PC (776088)

[0350]

[0351] (XXa).

[0352] In an embodiment of the modified siRNA linkage, each optionally modified nucleoside is independently, at each occurrence, selected from the group consisting of adenosine, guanosine, cytidine, and uridine.

[0353] In certain exemplary embodiments of Formula (I), W is O. In another embodiment, W is CH2. In yet another embodiment, W is CH.

[0354] In certain exemplary embodiments of Formula (I), X is OH. In another embodiment, X is OCH3. In yet another embodiment, X is halo.

[0355] In a certain embodiment of Formula (I), the modified siRNA does not comprise a 2’-fluoro substituent.

[0356] In an embodiment of Formula (I), Y is O . In another embodiment, Y is OH. In yet another embodiment, Y is OR. In still another embodiment, Y is NH . In an embodiment, Y is NH2. In another embodiment, Y is S . In yet another embodiment, Y is SH.

[0357] In an embodiment of Formula (I), Z is O. In another embodiment, Z is CH2.

[0358] In an embodiment, the modified intersubunit linkage is inserted on position 1-2 of the antisense strand. In another embodiment, the modified intersubunit linkage is inserted on position 6-7 of the antisense strand. In yet another embodiment, the modified intersubunit linkage is inserted on position 10-11 of the antisense strand. In still another embodiment, the modified intersubunit linkage is inserted on position 19-20 of the antisense strand. In an embodiment, the modified intersubunit linkage is inserted on positions 5-6 and 18-19 of the antisense strand.

[0359] In an exemplary embodiment of the modified siRNA linkage of Formula (VIII), C is O . In another embodiment, C is OH. In yet another embodiment, C is OR1. In still another embodiment, C is NH . In an embodiment, C is NH2. In another embodiment, C is S . In yet another embodiment, C is SH.

[0360] In an exemplary embodiment of the modified siRNA linkage of Formula (VIII), A is O. In another embodiment, A is CH2. In yet another embodiment, C is OR1. In still another

[0361] 82690703v1 52Atorney Docket No.: UM9-328PC (776088)

[0362] embodiment, C is NH . In an embodiment, C is NH2. In another embodiment, C is S . In yet another embodiment, C is SH.

[0363] In a certain embodiment of the modified siRNA linkage of Formula (VIII), the optionally modified nucleoside is adenosine. In another embodiment of the modified siRNA linkage of Formula (VIII), the optionally modified nucleoside is guanosine. In another embodiment of the modified siRNA linkage of Formula (VIII), the optionally modified nucleoside is cytidine. In another embodiment of the modified siRNA linkage of Formula (VIII), the optionally modified nucleoside is uridine.

[0364] In an embodiment of the modified siRNA linkage, wherein the linkage is inserted on position 1-2 of the antisense strand. In another embodiment, the linkage is inserted on position 6-7 of the antisense strand. In yet another embodiment, the linkage is inserted on position 10-11 of the antisense strand. In still another embodiment, the linkage is inserted on position 19-20 of the antisense strand. In an embodiment, the linkage is inserted on positions 5-6 and 18-19 of the antisense strand.

[0365] In certain embodiments of Formula (I), the base pairing moiety B is adenine. In certain embodiments of Formula (I), the base pairing moiety B is guanine. In certain embodiments of Formula (I), the base pairing moiety B is cytosine. In certain embodiments of Formula (I), the base pairing moiety B is uracil.

[0366] In an embodiment of Formula (I), W is O. In an embodiment of Formula (I), W is CH2. In an embodiment of Formula (I), W is CH.

[0367] In an embodiment of Formula (I), X is OH. In an embodiment of Formula (I), X is OCH3. In an embodiment of Formula (I), X is halo.

[0368] In an exemplary embodiment of Formula (I), the modified oligonucleotide does not comprise a 2’ -fluoro substituent.

[0369] In an embodiment of Formula (I), Y is O . In an embodiment of Formula (I), Y is OH. In an embodiment of Formula (I), Y is OR. In an embodiment of Formula (I), Y is NH". In an embodiment of Formula (I), Y is NH2. In an embodiment of Formula (I), Y is S . In an embodiment of Formula (I), Y is SH.

[0370] In an embodiment of Formula (I), Z is O. In an embodiment of Formula (I), Z is CH2. In an embodiment of the Formula (I), the linkage is inserted on position 1-2 of the antisense strand. In another embodiment of Formula (I), the linkage is inserted on position 6-7

[0371] 82690703v1 53Atorney Docket No.: UM9-328PC (776088)

[0372] of the antisense strand. In yet another embodiment of Formula (I), the linkage is inserted on position 10-11 of the antisense strand. In still another embodiment of Formula (I), the linkage is inserted on position 19-20 of the antisense strand. In an embodiment of Formula (I), the linkage is inserted on positions 5-6 and 18-19 of the antisense strand.

[0373] Modified intersubunit linkages are further described in U.S. Patent Publication No.

[0374] 2020 / 0385740 Al and U.S. Patent Publication No. 2022 / 0010309 Al, each of which is incorporated herein by reference.

[0375] 4) Conjugated Functional Moieties

[0376] In other embodiments, RNA silencing agents may be modified with one or more functional moieties. A functional moiety is a molecule that confers one or more additional activities to the RNA silencing agent. In certain embodiments, the functional moieties enhance cellular uptake by target cells (e.g., mammary cells). Thus, the invention includes RNA silencing agents which are conjugated or unconjugated (e.g., at its 5’ and / or 3' terminus) to another moiety (e.g. a non-nucleic acid moiety such as a peptide), an organic compound (e.g., a dye), or the like. The conjugation can be accomplished by methods known in the art, e.g., using the methods of Lambert et al., Drug Deliv. Rev.: 47(1), 99-112 (2001) (describes nucleic acids loaded to polyalkylcyanoacrylate (PACA) nanoparticles); Fattal et al., J. Control Release 53(1-3): 137-43 (1998) (describes nucleic acids bound to nanoparticles); Schwab et al., Ann. Oncol. 5 Suppl. 4:55-8 (1994) (describes nucleic acids linked to intercalating agents, hydrophobic groups, polycations or PACA nanoparticles); and Godard et al., Eur. J. Biochem.

[0377] 232(2):404-10 (1995) (describes nucleic acids linked to nanoparticles).

[0378] In a certain embodiment, the functional moiety is a hydrophobic moiety. In a certain embodiment, the hydrophobic moiety is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides and nucleoside analogs, endocannabinoids, and vitamins. In a certain embodiment, the steroid selected from the group consisting of cholesterol and Lithocholic acid (LCA). In a certain embodiment, the fatty acid selected from the group consisting of Eicosapentaenoic acid (EP A), Docosahexaenoic acid (DHA) and Docosanoic acid (DCA). In a certain embodiment, the vitamin selected from the group consisting of choline, vitamin A, vitamin E, and derivatives or metabolites thereof. In a certain embodiment, the vitamin is selected from the group consisting of retinoic acid and alpha-tocopheryl succinate.

[0379] 82690703v1 54Atorney Docket No.: UM9-328PC (776088)

[0380] In a certain embodiment, an RNA silencing agent of invention is conjugated to a lipophilic moiety. In one embodiment, the lipophilic moiety is a ligand that includes a cationic group. In another embodiment, the lipophilic moiety is attached to one or both strands of an siRNA. In an exemplary embodiment, the lipophilic moiety is attached to one end of the sense strand of the siRNA. In another exemplary embodiment, the lipophilic moiety is attached to the 3' end of the sense strand. In certain embodiments, the lipophilic moiety is selected from the group consisting of cholesterol, vitamin E, vitamin K, vitamin A, folic acid, a a cationic dye (e.g., Cy3). In an exemplary embodiment, the lipophilic moiety is cholesterol. Other lipophilic moi eties include cholic acid, adamantane acetic acid, 1 -pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyl oxy hexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.

[0381] In certain embodiments, the functional moieties may comprise one or more ligands tethered to an RNA silencing agent to improve stability, hybridization thermodynamics with a target nucleic acid, targeting to a particular tissue or cell-type, or cell permeability, e.g., by an endocytosis-dependent or -independent mechanism. Ligands and associated modifications can also increase sequence specificity and consequently decrease off-site targeting. A tethered ligand can include one or more modified bases or sugars that can function as intercal ators. These can be located in an internal region, such as in a bulge of RNA silencing agent / target duplex. The intercalator can be an aromatic, e.g., a polycyclic aromatic or heterocyclic aromatic compound. A polycyclic intercalator can have stacking capabilities, and can include systems with 2, 3, or 4 fused rings. The universal bases described herein can be included on a ligand. In one embodiment, the ligand can include a cleaving group that contributes to target gene inhibition by cleavage of the target nucleic acid. The cleaving group can be, for example, a bleomycin (e.g., bleomycin-A5, bleomycin-A2, or bleomycin-B2), pyrene, phenanthroline (e.g., O-phenanthroline), a polyamine, a tripeptide (e.g., lys-tyr-lys tripeptide), or a metal ion chelating group. The metal ion chelating group can include, e.g., an Lu(III) or EU(III) macrocyclic complex, a Zn(II) 2,9-dimethylphenanthroline derivative, a Cu(II) terpyridine, or acridine, which can promote the selective cleavage of target RNA at the site of the bulge by free metal ions, such as Lu(III). In some embodiments, a peptide ligand can be tethered to a RNA silencing agent to promote cleavage of the target RNA, e.g., at the bulge region. For example, l,8-dimethyl-l,3,6,8,10,13-hexaazacyclotetradecane (cyclam) can be conjugated to a

[0382] 82690703v1 55Atorney Docket No.: UM9-328PC (776088)

[0383] peptide (e.g., by an amino acid derivative) to promote target RNA cleavage. A tethered ligand can be an aminoglycoside ligand, which can cause an RNA silencing agent to have improved hybridization properties or improved sequence specificity. Exemplary aminoglycosides include glycosylated polylysine, galactosylated polylysine, neomycin B, tobramycin, kanamycin A, and acridine conjugates of aminoglycosides, such as Neo-N-acridine, Neo-S-acridine, Neo-C-acridine, Tobra-N-acridine, and KanaA-N-acridine. Use of an acridine analog can increase sequence specificity. For example, neomycin B has a high affinity for RNA as compared to DNA, but low sequence-specificity. An acridine analog, neo-5-acridine, has an increased affinity for the HIV Rev-response element (RRE). In some embodiments, the guanidine analog (the guanidinoglycoside) of an aminoglycoside ligand is tethered to an RNA silencing agent. In a guanidinoglycoside, the amine group on the amino acid is exchanged for a guanidine group. Attachment of a guanidine analog can enhance cell permeability of an RNA silencing agent. A tethered ligand can be a poly-arginine peptide, peptoid or peptidomimetic, which can enhance the cellular uptake of an oligonucleotide agent.

[0384] Exemplary ligands are coupled, either directly or indirectly, via an intervening tether, to a ligand-conjugated carrier. In certain embodiments, the coupling is through a covalent bond. In certain embodiments, the ligand is attached to the carrier via an intervening tether. In certain embodiments, a ligand alters the distribution, targeting or lifetime of an RNA silencing agent into which it is incorporated. In certain embodiments, a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand.

[0385] Exemplary ligands can improve transport, hybridization, and specificity properties and may also improve nuclease resistance of the resultant natural or modified RNA silencing agent, or a polymeric molecule comprising any combination of monomers described herein and / or natural or modified ribonucleotides. Ligands in general can include therapeutic modifiers, e.g., for enhancing uptake; diagnostic compounds or reporter groups e.g., for monitoring distribution; cross-linking agents; nuclease-resistance conferring moieties; and natural or unusual nucleobases. General examples include lipophiles, lipids, steroids (e.g., uvaol, hecigenin, diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, Friedelin, epifriedelanol derivatized lithocholic acid), vitamins (e.g., folic acid, vitamin A, biotin, pyridoxal), carbohydrates, proteins, protein binding agents, integrin targeting molecules, polycationics, peptides, polyamines, and peptide mimics. Ligands can include a naturally occurring substance,

[0386] 82690703v1 56Atorney Docket No.: UM9-328PC (776088)

[0387] (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); amino acid, or a lipid. The ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropyl acrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptidepolyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

[0388] Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine (GalNAc) or derivatives thereof, N-acetyl-glucosamine, multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, or an RGD peptide or RGD peptide mimetic. Other examples of ligands include dyes, intercalating agents (e.g. acridines and substituted acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine, phenanthroline, pyrenes), lys-tyr-lys tripeptide, aminoglycosides, guanidium aminoglycodies, artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g, cholesterol (and thio analogs thereof), cholic acid, cholanic acid, lithocholic acid, adamantane acetic acid, 1 -pyrene butyric acid, dihydrotestosterone, glycerol (e.g., esters (e.g., mono, bis, or tris fatty acid esters, e.g., Cio, Cn, C12, C13, C14, C15, Ci6, C17, Cis, C19, or C20 fatty acids) and ethers thereof, e.g., Cio, Cn, C12, C13, C14, C15, Ci6, C17, Cis, C19, or C20 alkyl; e.g., l,3-bis-O(hexadecyl)glycerol, l,3-bis-O(octaadecyl)glycerol), geranyl oxy hexyl group, hexadecylglycerol, borneol, menthol, 1,3 -propanediol, heptadecyl group, palmitic acid, stearic acid (e.g., glyceryl distearate), oleic acid, myristic acid, 03-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate,

[0389] 82690703v1 57Atorney Docket No.: UM9-328PC (776088)

[0390] amino, mercapto, PEG(e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport / absorption facilitators (e.g., aspirin, naproxen, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+complexes of tetraazamacrocycles), dinitrophenyl, HRP or AP. In certain embodiments, the ligand is GalNAc or a derivative thereof.

[0391] Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell. Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-kB.

[0392] The ligand can be a substance, e.g., a drug, which can increase the uptake of the RNA silencing agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, and / or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin. The ligand can increase the uptake of the RNA silencing agent into the cell by activating an inflammatory response, for example. Exemplary ligands that would have such an effect include tumor necrosis factor alpha (TNFa), interleukin-1 beta, or gamma interferon. In one aspect, the ligand is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule can bind a serum protein, e.g., human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, neproxin or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and / or (c) can be used to adjust binding to a serum protein, e.g., HSA. A lipid based ligand can be used to modulate, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to

[0393] 82690703v1 58Atorney Docket No.: UM9-328PC (776088)

[0394] target the conjugate to the kidney. In a certain embodiment, the lipid based ligand binds HSA. A lipid-based ligand can bind HSA with a sufficient affinity such that the conjugate will be distributed to a non-kidney tissue. However, it is contemplated that the affinity not be so strong that the HS A-ligand binding cannot be reversed. In another embodiment, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be distributed to the kidney. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.

[0395] In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These can be useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells. Also included are HSA and low density lipoprotein (LDL).

[0396] In another aspect, the ligand is a cell-permeation agent, such as a helical cell-permeation agent. In certain embodiments, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent can be an alpha-helical agent, which may have a lipophilic and a lipophobic phase.

[0397] The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to oligonucleotide agents can affect pharmacokinetic distribution of the RNA silencing agent, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long. A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. The peptide moiety can be an L-peptide or D-peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature 354:82-84, 1991). In exemplary

[0398] 82690703v1 59Atorney Docket No.: UM9-328PC (776088)

[0399] embodiments, the peptide or peptidomimetic tethered to an RNA silencing agent via an incorporated monomer unit is a cell targeting peptide such as an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

[0400] In certain embodiments, the functional moiety is linked to the 5’ end and / or 3’ end of the RNA silencing agent of the disclosure. In certain embodiments, the functional moiety is linked to the 5’ end and / or 3’ end of an antisense strand of the RNA silencing agent of the disclosure. In certain embodiments, the functional moiety is linked to the 5’ end and / or 3’ end of a sense strand of the RNA silencing agent of the disclosure. In certain embodiments, the functional moiety is linked to the 3’ end of a sense strand of the RNA silencing agent of the disclosure.

[0401] In certain embodiments, the functional moiety is linked to the RNA silencing agent by a linker. In certain embodiments, the functional moiety is linked to the antisense strand and / or sense strand by a linker. In certain embodiments, the functional moiety is linked to the 3’ end of a sense strand by a linker. In certain embodiments, the linker comprises a divalent or trivalent linker. In certain embodiments, the linker comprises an ethylene glycol chain, an alkyl chain, a peptide, RNA, DNA, a phosphodiester, a phosphorothioate, a phosphoramidate, an amide, a carbamate, or a combination thereof. In certain embodiments, the divalent or trivalent linker is selected from:

[0402]

[0403] In certain embodiments, the linker further comprises a phosphodiester or phosphodiester derivative. In certain embodiments, the phosphodiester or phosphodiester derivative is selected from the group consisting of:

[0404] 82690703v1 60Atorney Docket No.: UM9-328PC (776088)

[0405] (Zcl);

[0406] o

[0407] coo

[0408] © 1 ov

[0409] o

[0410] (Zc2);

[0411] O

[0412]

[0413] ; and

[0414] (Zc3)

[0415] HO. _,O ._

[0416] Ay '

[0417] OX O .

[0418] (Zc4)

[0419] wherein X is O, S or BH3.

[0420] The various functional moieties of the disclosure and means to conjugate them to RNA silencing agents are described in further detail in W02017 / 030973 Al and WO2018 / 031933 A2, incorporated herein by reference.

[0421] Dendron

[0422] The oligonucleotides described herein may be conjugated to a dendron. The dendron can have a strong reversible and non-covalent albumin binding that can be advantageously used to minimize degradation, reduce their uptake and degradation by macrophages, prevent nonspecific uptake by cells, and / or provide enhanced delivery to a tumor of the oligonucleotide conjugate. The dendron can also have a nanomolar affinity to albumin that advantageously ensures that the albumin-oligonucleotide conjugate complex remains stable throughout biodistribution, cell interactions, and / or treatment.

[0423] In some embodiments, the dendron has a structure of Formula I:

[0424] 82690703v1 61Attorney Docket No.: UM9-328PC (776088)

[0425] 0

[0426] u ■ U .£ ?

[0427] 1, i!9

[0428] ° ° ^y~O“P~O~-(BXc)

[0429]

[0430] (I) wherein:

[0431] A is an oligonucleotide (e.g., a sense strand or an antisense strand of a dsRNA);

[0432] B, for each occurrence, independently comprises one or more hydrophobic chains, amines, amides, esters, N- or O-containing heterocycles, thioethers, disulfides, and / or aromatic rings, wherein the hydrophobic chain comprises a saturated or unsaturated C1-24 alkyl chain;

[0433] C, for each occurrence, independently comprises: an hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated C1-24 alkyl chain; and / or one or more aromatic rings;

[0434] D, for each occurrence, independently is a branching unit comprising one or more alkyl chains, amides, ethers, esters, and amines, wherein the branching unit comprises 2 to 4 branches; and

[0435] m, for each occurrence, independently is 0 or 1.

[0436] In some embodiments, the dendron has a structure of Formula II:

[0437] O

[0438] (B>— o—

[0439] O I

[0440] (B>-O-P-O<D) o

[0441] 0 O’

[0442] O\D ! o

[0443] O' \ \ p (B)— O“p ‘“-o-~(^Kc)

[0444] (B>- O~P-O-(b) n

[0445] 0(B>™ O- P - O

[0446]

[0447] 6-

[0448] 82690703v1 62Attorney Docket No.: UM9-328PC (776088)

[0449] (II)

[0450] wherein:

[0451] A is an oligonucleotide (e.g., a sense strand or an antisense strand of a dsRNA);

[0452] B, for each occurrence, independently comprises one or more hydrophobic chains, amines, amides, esters, N- or O-containing heterocycles, thioethers, disulfides, and / or aromatic rings, wherein the hydrophobic chain comprises a saturated or unsaturated C1-24 alkyl chain;

[0453] C, for each occurrence, independently comprises: an hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated C1-24 alkyl chain; and / or one or more aromatic rings; and

[0454] D, for each occurrence, independently is a branching unit comprising one or more alkyl chains, amides, ethers, esters, and amines, wherein the branching unit comprises 2 to 4 branches.

[0455] In some embodiments, the dendron has a structure of Formula III:

[0456]

[0457] (HI)

[0458] wherein n, for each occurrence, independently is an integer between 1-24. In some embodiments, C is OH and n, for each occurrence, independently is 1, 6, or 12. In some embodiments, the oligonucleotide conjugate has the structure of Formula IV:

[0459] 82690703v1 63Attorney Docket No.: UM9-328PC (776088)

[0460]

[0461] In some embodiments, the dendron has a structure of Formula V:

[0462] (B)~ O -■•P-o-Mfc)

[0463] O O ■

[0464] / ’ 6- 6- (B>~0 ~P~O“-{^\C)

[0465] o O' (Ay-o-p-oXP; p

[0466] d- \

[0467] \ o p ( B)— ~o — p—o — (t$ Ffi. ) (B^O”P--O--“O-P-O-(D) Q

[0468] ® o (hj—o — p~o — Q3 / ~(C7

[0469]

[0470] wherein:

[0471] A is an oligonucleotide (e.g., a sense strand or an antisense strand of a dsRNA);

[0472] B, for each occurrence, independently comprises one or more hydrophobic chains, amines, amides, esters, N- or O-containing heterocycles, thioethers, disulfides, and / or aromatic rings, wherein the hydrophobic chain comprises a saturated or unsaturated Ci-24 alkyl chain;

[0473] C, for each occurrence, independently comprises: an hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated Ci-24 alkyl chain; and / or one or more aromatic rings; and

[0474] D, for each occurrence, independently is a branching unit comprising one or more alkyl chains, amides, ethers, esters, and amines, wherein the branching unit comprises 2 to 4 branches. In some embodiments, the oligonucleotide conjugate has a structure of Formula VI:

[0475] 82690703v1 64Attorney Docket No.: UM9-328PC (776088)

[0476] o

[0477]

[0478] wherein n, for each occurrence, independently is an integer between 1-24. In some embodiments, C, for each occurrence, independently comprises: an hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated C1-24 alkyl chain; and / or one or more aromatic rings. In some embodiments, C is OH. In some embodiments, n, for each occurrence, independently is 1, 6, or 12.

[0479] In some embodiments, the dendron has the structure of Formula VII:

[0480]

[0481] (VII) Further disclosure of dendrons for conjugation to oligonucleotides is described in U.S. Patent Publication No. 2024 / 0401042 Al, incorporated herein by reference.

[0482] 82690703v1 65Atorney Docket No.: UM9-328PC (776088)

[0483] Deliver to Tissue with :-dendron

[0484] The disclosure describes the surprising discovery that an oligonucleotide described herein, when conjugated to a dendron described herein, possesses enhanced delivery to mammary tissue relative to an oligonucleotide that is unconjugated or an oligonucleotide that is conjugated to a DCA functional moiety. This exceptional delivery to mammary tissue resulted in elevated levels of antisense strand accumulation in the mammary tissue relative to an unconjugated oligonucleotide (see, e.g., FIG. 2D).

[0485] Described herein are methods of delivering an oligonucleotide conjugate to mammary tissue of a subject, the method comprising administering the oligonucleotide conjugate to the subject, wherein the oligonucleotide conjugate comprises: i) an oligonucleotide comprising a 5’ and a 3’ end and complementarity to a target nucleic acid (e.g., IRS2 nucleic acid, such as an IRS2 mRNA); and ii) a dendron that is linked to the oligonucleotide and comprises an end group, a phosphate group, and / or a hydrophobic chain, and wherein the oligonucleotide conjugate is formulated for mammary tissue delivery.

[0486] Further described herein are methods of treating a disease or disorder of mammary tissue, comprising delivering an oligonucleotide conjugate to mammary tissue of a subject, the method comprising administering the oligonucleotide conjugate to the subject, wherein the oligonucleotide conjugate comprises: i) an oligonucleotide comprising a 5’ and a 3’ end and complementarity to a target nucleic acid (e.g., a IRS2 nucleic acid, such as an IRS2 mRNA); and ii) a dendron that is linked to the oligonucleotide and comprises an end group, a phosphate group, and / or a hydrophobic chain, and wherein the oligonucleotide conjugate is formulated for mammary tissue delivery.

[0487] In certain embodiments, the subject has cancer (e.g., breast cancer). In certain embodiments, the disease or disorder of mammary tissue is cancer (e.g., breast cancer). In certain embodiments, the oligonucleotide conjugate is administered by intravenous (IV) injection, subcutaneous (SQ) injection, intratumoral injection, or a combination thereof. In certain embodiments, the oligonucleotide conjugate is administered directly into the mammary tissue.

[0488] In certain embodiments, the end group is a hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated Ci-24 alkyl chain; and / or one or more aromatic rings.

[0489] 82690703v1 66Atorney Docket No.: UM9-328PC (776088)

[0490] In certain embodiments, the hydrophobic chain is a saturated or unsaturated C1-24 alkyl group.

[0491] In certain embodiments, the dendron comprises two branches. In certain embodiments, the dendron comprises four branches. In certain embodiments, the dendron comprises eight branches.

[0492] In certain embodiments, the dendron is linked to the 5’ end and / or 3’ end of the oligonucleotide. In certain embodiments, the oligonucleotide corresponds to an antisense oligonucleotide or a siRNA (e.g., dsRNA described herein). In certain embodiments, the siRNA comprises a sense strand and an antisense strand. In certain embodiments, the dendron is linked to the 5’ end and / or 3’ end of the sense strand or to the 5’ end and / or 3’ end of the antisense strand. In certain embodiments, the dendron is linked to the 3’ end of the sense strand.

[0493] In certain embodiments, the oligonucleotide conjugate has a structure of Formula I:

[0494]

[0495] (I) wherein:

[0496] A is an oligonucleotide;

[0497] B, for each occurrence, independently comprises one or more hydrophobic chains , amines, amides, esters, N- or O-containing heterocycles, thioethers, disulfides, and / or aromatic rings, wherein the hydrophobic chain comprises a saturated or unsaturated C1-24 alkyl chain;

[0498] C, for each occurrence, independently comprises: an hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated C1-24 alkyl chain; and / or one or more aromatic rings;

[0499] 82690703v1 67Attorney Docket No.: UM9-328PC (776088)

[0500] D, for each occurrence, independently is a branching unit comprising one or more alkyl chains, amides, ethers, esters, and amines, wherein the branching unit comprises 2 to 4 branches; and

[0501] m, for each occurrence, independently is 0 or 1.

[0502] In certain embodiments, the oligonucleotide conjugate has a structure of Formula II:

[0503] O

[0504] (^OH^-(B)-(C)

[0505] (B)”O™P~O / D) Q

[0506] / O' (B)— o— P-O-<B'HV

[0507] o i

[0508] (A)-O-P-O-(D)0

[0509] (B\~O~P~O<D) £

[0510] ! ''"N ***

[0511] (B) O -- p - o

[0512] 6"

[0513]

[0514] (II)

[0515] In certain embodiments, the oligonucleotide conjugate has a structure of Formula III:

[0516]

[0517] (HI)

[0518] wherein n, for each occurrence, independently is an integer between 1-24.

[0519] In certain embodiments, C is OH and n, for each occurrence, independently is 1, 6, or 12.

[0520] In certain embodiments, the oligonucleotide conjugate has the structure of Formula IV:

[0521] 82690703v1 68Attorney Docket No.: UM9-328PC (776088)

[0522]

[0523] O'

[0524] (IV).

[0525] In certain embodiments, the oligonucleotide conjugate has a structure of Formula V.

[0526] (B)”O ~~P~

[0527] 0 H O'

[0528] (BVO-P-O-*^

[0529] / O' O' (B}~O™P--O“(gXc)

[0530] o O' O~~P“OAPy!„0....

[0531] 6- O A-' 1 '--z

[0532] k ? - !l O" (Bt-O-P I -O-tB)- -O-P~O-(D:! X

[0533] O'0(H)— o—

[0534]

[0535] (V).

[0536] In certain embodiments, the oligonucleotide conjugate has a structure of Formula VI.

[0537]

[0538] (VI) wherein n, for each occurrence, independently is an integer between 1-24.

[0539] 82690703v1 69Atorney Docket No.: UM9-328PC (776088)

[0540] In certain embodiments, C is OH and n, for each occurrence, independently is 1, 6, or 12.

[0541] In certain embodiments, the oligonucleotide conjugate has the structure of Formula VII:

[0542] O

[0543] ii

[0544]

[0545] (VII).

[0546] VI. Branched Oligonucleotides

[0547] Two or more RNA silencing agents as disclosed supra, for example oligonucleotide constructs such as anti-IRS2 siRNAs, may be connected to one another by one or more moi eties independently selected from a linker, a spacer and a branching point, to form a branched oligonucleotide RNA silencing agent. In certain embodiments, the branched oligonucleotide RNA silencing agent consists of two siRNAs to form a di -branched siRNA (“di-siRNA”) scaffolding for delivering two siRNAs. In representative embodiments, the nucleic acids of the branched oligonucleotide each comprise an antisense strand (or portions thereof), wherein the antisense strand has sufficient complementarity to a target mRNA (e.g., IRS2 mRNA) to mediate an RNA-mediated silencing mechanism (e.g. RNAi).

[0548] In exemplary embodiments, the branched oligonucleotides may have two to eight RNA silencing agents attached through a linker. The linker may be hydrophobic. In an embodiment, branched oligonucleotides of the present application have two to three oligonucleotides. In an embodiment, the oligonucleotides independently have substantial chemical stabilization (e.g., at least 40% of the constituent bases are chemically-modified). In an exemplary embodiment, the oligonucleotides have full chemical stabilization (i.e., all the constituent bases are chemically-modified). In some embodiments, branched oligonucleotides comprise one or more single-stranded phosphorothioated tails, each independently having two to twenty nucleotides. In a non-limiting embodiment, each single-stranded tail has two to ten nucleotides.

[0549] 82690703v1 70Atorney Docket No.: UM9-328PC (776088)

[0550] In certain embodiments, branched oligonucleotides are characterized by three properties: (1) a branched structure, (2) full metabolic stabilization, and (3) the presence of a single-stranded tail comprising phosphorothioate linkers. In certain embodiments, branched oligonucleotides have 2 or 3 branches. It is believed that the increased overall size of the branched structures promotes increased uptake. Also, without being bound by a particular theory of activity, multiple adjacent branches (e.g., 2 or 3) are believed to allow each branch to act cooperatively and thus dramatically enhance rates of internalization, trafficking and release.

[0551] Branched oligonucleotides are provided in various structurally diverse embodiments. In some embodiments nucleic acids attached at the branching points are single stranded or double stranded and consist of miRNA inhibitors, gapmers, mixmers, SSOs, PMOs, or PNAs. These single strands can be attached at their 3’ or 5’ end. Combinations of siRNA and single stranded oligonucleotides could also be used for dual function. In another embodiment, short nucleic acids complementary to the gapmers, mixmers, miRNA inhibitors, SSOs, PMOs, and PNAs are used to carry these active single-stranded nucleic acids and enhance distribution and cellular internalization. The short duplex region has a low melting temperature (Tm ~37 °C) for fast dissociation upon internalization of the branched structure into the cell.

[0552] The Di-siRNA branched oligonucleotides may comprise chemically diverse conjugates, such as the functional moieties described above. Conjugated bioactive ligands may be used to enhance cellular specificity and to promote membrane association, internalization, and serum protein binding. Examples of bioactive moieties to be used for conjugation include DHA, GalNAc, and cholesterol. These moieties can be attached to Di-siRNA either through the connecting linker or spacer, or added via an additional linker or spacer attached to another free siRNA end.

[0553] The presence of a branched structure improves the level of tissue retention in the brain more than 100-fold compared to non-branched compounds of identical chemical composition, suggesting a new mechanism of cellular retention and distribution. Branched oligonucleotides have unexpectedly uniform distribution throughout the spinal cord and brain. Moreover, branched oligonucleotides exhibit unexpectedly efficient systemic delivery to a variety of tissues, and very high levels of tissue accumulation.

[0554] Branched oligonucleotides comprise a variety of therapeutic nucleic acids, including siRNAs, ASOs, miRNAs, miRNA inhibitors, splice switching, PMOs, PNAs. In some

[0555] 82690703v1 71Atorney Docket No.: UM9-328PC (776088)

[0556] embodiments, branched oligonucleotides further comprise conjugated hydrophobic moieties and exhibit unprecedented silencing and efficacy in vitro and in vivo.

[0557] Linkers

[0558] In an embodiment of the branched oligonucleotide, each linker is independently selected from an ethylene glycol chain, an alkyl chain, a peptide, RNA, DNA, a phosphate, a phosphonate, a phosphoramidate, an ester, an amide, a triazole, and combinations thereof; wherein any carbon or oxygen atom of the linker is optionally replaced with a nitrogen atom, bears a hydroxyl substituent, orbears an oxo substituent. In one embodiment, each linker is an ethylene glycol chain. In another embodiment, each linker is an alkyl chain. In another embodiment, each linker is a peptide. In another embodiment, each linker is RNA. In another embodiment, each linker is DNA. In another embodiment, each linker is a phosphate. In another embodiment, each linker is a phosphonate. In another embodiment, each linker is a phosphoramidate. In another embodiment, each linker is an ester. In another embodiment, each linker is an amide. In another embodiment, each linker is a triazole.

[0559] In an embodiment of the branched oligonucleotide, the linker has the structure of LI :

[0560]

[0561] (LI) In an embodiment of the branched oligonucleotide, the linker has the structure of L2:

[0562]

[0563] (L2)

[0564] It is to be understood that the methods described in this disclosure are not limited to particular methods and experimental conditions disclosed herein; as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0565] Furthermore, the experiments described herein, unless otherwise indicated, use conventional molecular and cellular biological and immunological techniques within the skill of the art. Such techniques are well known to the skilled worker, and are explained fully in the

[0566] 82690703v1 72Atorney Docket No.: UM9-328PC (776088)

[0567] literature. See, e.g., Ausubel, et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY (1987-2008), including all supplements, Molecular Cloning: A Laboratory Manual (Fourth Edition) by MR Green and J. Sambrook and Harlow et al., Antibodies: A Laboratory Manual, Chapter 14, Cold Spring Harbor Laboratory, Cold Spring Harbor (2013, 2nd edition).

[0568] Branched oligonucleotides, including synthesis and methods of use, are described in greater detail in WO2017 / 132669, incorporated herein by reference.

[0569] Methods of Introducing Nucleic Acids, Vectors and Host Cells

[0570] RNA silencing agents of the invention may be directly introduced into the cell (e.g., a neural cell) (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally, or may be introduced by bathing a cell or organism in a solution containing the nucleic acid. Vascular or extravascular circulation, the blood or lymph system, and the cerebrospinal fluid are sites where the nucleic acid may be introduced.

[0571] The RNA silencing agents of the invention can be introduced using nucleic acid delivery methods known in art including injection of a solution containing the nucleic acid, bombardment by particles covered by the nucleic acid, soaking the cell or organism in a solution of the nucleic acid, or electroporation of cell membranes in the presence of the nucleic acid. Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, and cationic liposome transfection such as calcium phosphate, and the like. The nucleic acid may be introduced along with other components that perform one or more of the following activities: enhance nucleic acid uptake by the cell or otherwise increase inhibition of the target gene.

[0572] Physical methods of introducing nucleic acids include injection of a solution containing the RNA, bombardment by particles covered by the RNA, soaking the cell or organism in a solution of the RNA, or electroporation of cell membranes in the presence of the RNA. A viral construct packaged into a viral particle would accomplish both efficient introduction of an expression construct into the cell and transcription of RNA encoded by the expression construct. Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, such as calcium phosphate, and the like. Thus, the RNA may be introduced along with components that perform

[0573] 82690703v1 73Atorney Docket No.: UM9-328PC (776088)

[0574] one or more of the following activities: enhance RNA uptake by the cell, inhibit annealing of single strands, stabilize the single strands, or otherwise increase inhibition of the target gene.

[0575] RNA may be directly introduced into the cell (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally, or may be introduced by bathing a cell or organism in a solution containing the RNA. Vascular or extravascular circulation, the blood or lymph system, and the cerebrospinal fluid are sites where the RNA may be introduced.

[0576] Depending on the particular target gene and the dose of double stranded RNA material delivered, this process may provide partial or complete loss of function for the target gene. A reduction or loss of gene expression in at least 50%, 60%, 70%, 80%, 90%, 95% or 99% or more of targeted cells is exemplary. Inhibition of gene expression refers to the absence (or observable decrease) in the level of protein and / or mRNA product from a target gene. Specificity refers to the ability to inhibit the target gene without manifest effects on other genes of the cell. The consequences of inhibition can be confirmed by examination of the outward properties of the cell or organism (as presented below in the examples) or by biochemical techniques such as RNA solution hybridization, nuclease protection, Northern hybridization, reverse transcription, gene expression monitoring with a microarray, antibody binding, Enzyme Linked ImmunoSorbent Assay (ELISA), Western blotting, RadioImmunoAssay (RIA), other immunoassays, and Fluorescence Activated Cell Sorting (FACS).

[0577] For RNA-mediated inhibition in a cell line or whole organism, gene expression is conveniently assayed by use of a reporter or drug resistance gene whose protein product is easily assayed. Such reporter genes include acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivatives thereof. Multiple selectable markers are available that confer resistance to ampicillin, bleomycin, chloramphenicol, gentarnycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracyclin. Depending on the assay, quantitation of the amount of gene expression allows one to determine a degree of inhibition which is greater than 10%, 33%, 50%, 90%, 95% or 99% as compared to a cell not treated according to the present invention. Lower doses of injected material and longer times after administration of RNAi agent may result in inhibition in a smaller fraction of cells (e.g., at least 10%, 20%, 50%, 75%, 90%, or 95% of targeted cells). Quantization of gene expression in a cell may show similar

[0578] 82690703v1 74Atorney Docket No.: UM9-328PC (776088)

[0579] amounts of inhibition at the level of accumulation of target mRNA or translation of target protein. As an example, the efficiency of inhibition may be determined by assessing the amount of gene product in the cell; mRNA may be detected with a hybridization probe having a nucleotide sequence outside the region used for the inhibitory double-stranded RNA, or translated polypeptide may be detected with an antibody raised against the polypeptide sequence of that region.

[0580] The RNA may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of material may yield more effective inhibition; lower doses may also be useful for specific applications.

[0581] In an exemplary aspect, the efficacy of an RNAi agent of the invention (e.g., an siRNA targeting IRS2 target sequence) is tested for its ability to specifically degrade mutant mRNA (e.g., IRS2 mRNA and / or the production of IRS2 protein) in cells, such as cells in the central nervous system. In certain embodiments, cells in the central nervous system include, but are not limited to, neurons (e.g., striatal or cortical neuronal clonal lines and / or primary neurons), glial cells, and astrocytes. Also suitable for cell-based validation assays are other readily transfectable cells, for example, HeLa cells or COS cells. Cells are transfected with human wild type or mutant cDNAs (e.g., human wild type or mutant IRS2 cDNA). Standard siRNA, modified siRNA or vectors able to produce siRNA from U-looped mRNA are co-transfected. Selective reduction in target mRNA (e.g., IRS2 mRNA) and / or target protein (e.g., IRS2 protein) is measured. Reduction of target mRNA or protein can be compared to levels of target mRNA or protein in the absence of an RNAi agent or in the presence of an RNAi agent that does not target IRS2 mRNA. Exogenously-introduced mRNA or protein (or endogenous mRNA or protein) can be assayed for comparison purposes. When utilizing neuronal cells, which are known to be somewhat resistant to standard transfection techniques, it may be desirable to introduce RNAi agents (e.g., siRNAs) by passive uptake.

[0582] VII, Methods of Treatment

[0583] In one aspect, the present invention provides for both prophylactic and therapeutic methods of treating a subject with a disease or disorder that would benefit from reduced expression of IRS2. In one embodiment, the disease or disorder is cancer.

[0584] As used herein, “treatment” or “treating”, is defined as the application or administration of a therapeutic agent (e.g., a RNA agent or vector encoding same) to a patient, or application

[0585] 82690703v1 75Atorney Docket No.: UM9-328PC (776088)

[0586] or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has the disease or disorder, a symptom of disease or disorder or a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease or disorder, the symptoms of the disease or disorder, or the predisposition toward disease.

[0587] In one aspect, the disclosure provides a method for inhibiting expression of IRS2 gene in a cell (e.g., a cell in a subject or a cell in vitro), the method comprising: (a) introducing into the cell the oligonucleotide targeting IRS2 disclosed herein, the vector disclosed herein, the rAAV disclosed herein, or the branched RNA compound disclosed herein; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the IRS2 gene, thereby inhibiting expression of the IRS2 gene in the cell.

[0588] In one aspect, the disclosure provides a method of treating or managing a disease comprising administering to a patient in need of such treatment or management a therapeutically effective amount of the oligonucleotide targeting IRS2 disclosed herein, the vector of disclosed herein, the rAAV disclosed herein, or the branched RNA compound disclosed herein. In certain embodiment, the disease is cancer. In certain embodiment, the cancer is breast cancer. In certain embodiment, the breast cancer is triple negative breast cancer (TNBC).

[0589] In certain embodiment, the oligonucleotide, the vector, the rAAV, or the branched RNA compound is administered by intravenous (IV) injection, subcutaneous (SQ) injection, intratumoral injection, or a combination thereof.

[0590] In one aspect, the invention provides a method for preventing in a subject, a disease or disorder as described above, by administering to the subject a therapeutic agent (e.g., an RNAi agent or vector or transgene encoding same). Subjects at risk for the disease can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the disease or disorder, such that the disease or disorder is prevented or, alternatively, delayed in its progression.

[0591] With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics," as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression

[0592] 82690703v1 76Atorney Docket No.: UM9-328PC (776088)

[0593] analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype," or "drug response genotype"). Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the target gene molecules of the present invention or target gene modulators according to that individual's drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

[0594] Therapeutic agents can be tested in an appropriate animal model. For example, an RNAi agent (or expression vector or transgene encoding same) as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with said agent. Alternatively, a therapeutic agent can be used in an animal model to determine the mechanism of action of such an agent. For example, an agent can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent can be used in an animal model to determine the mechanism of action of such an agent.

[0595] A pharmaceutical composition containing an RNA silencing agent of the invention can be administered to any patient diagnosed as having or at risk for developing a disease or disorder described herein.

[0596] VIII, Pharmaceutical Compositions and Methods of Administration

[0597] The invention pertains to uses of the above-described agents for prophylactic and / or therapeutic treatments as described infra. Accordingly, the modulators (e.g., RNAi agents) of the present invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, antibody, or modulatory compound and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use

[0598] 82690703v1 77Atorney Docket No.: UM9-328PC (776088)

[0599] thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0600] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, intraperitoneal, intramuscular, oral (e.g., inhalation), transdermal (topical), transmucosal, and intratumoral administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0601] The RNA silencing agents can also be administered by transfection or infection using methods known in the art, including but not limited to the methods described in McCaffrey et al. (2002), Nature, 418(6893), 38-9 (hydrodynamic transfection); Xia et al. (2002), Nature Biotechnol., 20(10), 1006-10 (viral-mediated delivery); or Putnam (1996), Am. J. Health Syst. Pharm. 53(2), 151-160, erratum at Am. J. Health Syst. Pharm. 53(3), 325 (1996).

[0602] For example, compositions can include one or more species of an RNA silencing agent and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, intratumoral injection, intrathecal, or intraventricular (e.g., intracerebroventricular) administration.

[0603] It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods described herein may be made using suitable equivalents without departing from the scope of the embodiments disclosed herein. Having now described certain embodiments in detail, the same will be more clearly understood by reference to the

[0604] 82690703v1 78Atorney Docket No.: UM9-328PC (776088)

[0605] following example, which is included for purposes of illustration only and is not intended to be limiting.

[0606] EXAMPLES

[0607] Example 1. Materials and Methods of the Examples.

[0608] Sex as a biological variable

[0609] The mice utilized in this study were female because human cancer largely affects female patients.

[0610] Cell Culture

[0611] MDA-MB-231, 4T1, and FL83B cells were obtained from ATCC Cell Biology Collection. PyV-MT mammary tumor cells were isolated from female FVB MMTV-PyV-MT:Irslfl / fl Irs2fl / fl mice,_and PyV-MT -.Irsl / Irs2- / - cells were generated by infection with adenoviral Cre recombinase as.previously described (Landis et al. J Biol Chem. 2014; 289(26): 18603-13). MDA-MB-231 and 4T1 cells were grown in RPMI media (Gibco) containing 10% FBS, FL83B cells were grown in F-12K media (Gibco) containing 10% FBS, and PyV-MT cells were grown in DMEM media containing 10% FBS. All cells were grown at 37 °C with 5% CO2 supply and tested negative for mycoplasma by PCR (Abm).

[0612] Antibodies

[0613] Primary antibodies used for immunoblots include rabbit anti-IRS2 (Cell Signaling Technology, Cat# 4502), rabbit anti-IRSl (Bethyl Laboratories, Cat# A301-158A), mouse antiactin (Thermo Fisher Scientific, Cat# MA5-11869), mouse anti-tubulin (Cell Signaling Technology Cat#3873), and mouse anti-GAPDH (Santa Cruz Biotechnology, Cat# sc-32233). Anti-vimentin antibodies (Proteintech, clone 6K21, Rosemont, IL, USA) were used for immunohistochemical analysis. Immunofluorescence was performed using a mouse anti-CD31 antibody (Cell Signaling Technology Cat# 77699) or rabbit anti-F4 / 80 (Cell Signaling Technology #70076). Fluorochrome-labeled antibodies against mouse CD326 (G8.8), CD45 (30-F11), CD206 (C068C2), CD8a (53-6.7), I-A / I-E (M5 / 114.15.2), CD4 (RM4-5), CDllc (N418), TCRb (H57-597), and F4 / 80 (BM8) were purchased from Biolegend and used for flow cytometric analysis.

[0614] 82690703v1 79Atorney Docket No.: UM9-328PC (776088)

[0615] Design of human-specific, mouse-specific, and cross-reactive siRNAs targeting IRS2

[0616] The siRNAs of the disclosure were designed based on a 21 -nucleotide targeting sequence from human IRS2 (accession number NM 003749.3) and mouse Irs2 (accession number NM_001081212.2). Exclusion criteria for sequences included: 1) >56% GC content, 2) single-nucleotide stretches of four or more, or 3) perfect homology to miRNA seeds at position 2-7 of the antisense strand. Sequences were also excluded if position 2-17 of the antisense strand had full complementarity to non-target mRNAs to minimize off-target effects. Cross-species targeting was determined based on perfect homology of positions 2-17 within the target sequence to both species. siRNAs were named based on the position in the target sequence from which they were extracted (e.g., human IRS2 siRNA 5967 was extracted from positions 5967-5988 of NM_003749.3).

[0617] Oligonucleotide synthesis,

[0618]

[0619] One set of 48 fully-chemically modified antisense and sense strands was synthesized for in vitro screening at a 1 pmol scale using standard solid-phase phosphoramidite chemistry on a Dr. Oligo 48 high-throughput oligonucleotide synthesizer (Biolytic, Fremont, CA). Compounds for in vivo studies were synthesized on diverse scales using a MerMade 12 synthesizer (Biosearch Technologies, Novato, CA). RNA 2'-O-methyl, 2'-fluoro modifications were applied to improve siRNA stability. Extended nucleic acid (exNA)-modified RNA (exNA) was used at the 3 ’ terminus of the guide strands in compounds used for in vivo tumor silencing studies (Yamada et al. Nat Biotechnol. 2024.10.1038 / s41587-024-02336-7). Phosphoramidites were purchased from Chemgenes, Wilmington, MA and Hongene Biotech, Union City, CA.

[0620] Sense strands of in vitro compounds were synthesized on a cholesterol-conjugated solid support (Chemgenes). DCA and PCDCA conjugated sense strands were synthesized on custom-functionalized controlled pore glass (CPG) supports as previously described (Biscans et al. Nucleic Acid Res. 2019; 47(3): 1082-96), containing a (dT)2 cleavable linker between the oligonucleotide and the conjugate. Synthesis of the amphiphilic dendrimer-conjugated sense strand was carried out on Unylinker CPG (ChemGenes) and commercially available amidites were used to build the dendritic moiety on the 5' end as previously described (Lacroix et al. J Controlled Release. 2020; 324: 34-46; Lacroix et al. J Am Chem Soc. 2017; 139(21): 7355-62). Cy3 -phosphoramidites (GenePharma) were used for fluorescence labeling of the 5’ of sense strands for in vivo studies. For Cy3-labeled dendrimer strands, Cy3-DMT-phosphoramidite (Chemgenes) was placed in between the conjugate and the sense strand.

[0621] 82690703v1 80Atorney Docket No.: UM9-328PC (776088)

[0622] Antisense strands were synthesized on Unylinker CPG (Chemgenes), bis-cyanoethyl-N, N-diisopropyl CED phosphoramidite (Chemgenes) was used to introduce a 5 ’-mono-phosphate for in vitro experiments, and 5’-(E)-vinylphosphonate-2’-O-Me-Uridine phosphoramidite (Hongene) was applied for in vivo studies.

[0623] In vitro strands were cleaved and deprotected on synthesis columns (on-column) with ammonia gas (Airgas Specialty Gases) for 90min at 65°C followed by on-column ethanol precipitation and elution with nuclease-free water. In vivo sense strands were cleaved and deprotected using 28% aqueous ammonium hydroxide solution for 20 hours at 55 °C. In vivo antisense strands were cleaved and deprotected using 3% diethylamine in aqueous ammonium hydroxide solution for 20 hours at 35°C, while a 1 : 1 mixture of ammonium hydroxide and 40% aqueous monomethylamine was used for the sense strands for 120min at 25°C. The controlled pore glass was subsequently filtered and rinsed with 50% ethanol in water and dried overnight under vacuum. Oligonucleotides for in vivo experiments were HPLC-purified using an Agilent 1290 Infinity II system (Agilent Technologies, Santa Clara CA) with a PRP-C18 column for Cy3 labeled and lipid-conjugated sense strands and an ion-exchange column for antisense and dendrimer-conjugated sense strands. Purified oligonucleotides were desalted by size-exclusion chromatography and characterized by LC-MS analysis on an Agilent 6530 accurate-mass quadrupole time-of-flight (Q-TOF) LC / MS (Agilent Technologies).

[0624] Identification of IRS2 selective siRNAs

[0625] For in vitro screening of siRNA candidates, cells were treated with candidate cholesterol-conjugated siRNAs for 72hr in a 50 / 50 mixture of complete growth media supplemented with 6% FBS and Opti-MEM (Gibco). Screening concentrations for MDA-MB-231 (0.1875uM), FL83B (1.5uM), and 4T1 (1.5uM) cells served as maximal dose for doseresponse assays. Cells were then lysed using lysis mixture (Invitrogen #13228) diluted 1 :2 with water containing 0.2mg / mL proteinase K (Invitrogen, #25530-049) and heated at 55 °C for 30 minutes before measuring gene expression.

[0626] Human IRS2 and mouse Irs2 mRNA levels were determined using the Quantigene 2.0 assay (Affymetrix). Cells were lysed in 250 pL homogenizing solution (Invitrogen Cat. QG0517) containing 0.2mg / mL proteinase K (Invitrogen, #25530-049). Samples were heated at 65 °C for 30min and then centrifuged at 568xg for 5min at room temperature to remove debris. Supernatants were combined with diluted probe sets (mouse Irs2; SB-29780, human IRS2; SA- 10203; ThermoFisher), added to the capture plate and signal was amplified and

[0627] 82690703v1 81Atorney Docket No.: UM9-328PC (776088)

[0628] detected according to manufacturer’s protocol. Luminescence was detected using a SpectraMax M5 microplate reader and SoftMax Pro 6.3 software (Molecular Devices).

[0629] For protein analysis, cells were solubilized at 4 °C in lysis buffer (20 mM Tris buffer, pH 7.4, 1% Nonidet P-40, 0.137 M NaCl, 10% glycerol) containing protease inhibitors (Roche) and phosphatase inhibitors (Roche).

[0630] In vivo siRNA studies

[0631] Mice were housed in a pathogen-free animal facilities at UMass Chan Medical School with 12 hour light / 12 hour dark cycle and free access to food and water. Female BALB / c mice (Charles River Laboratories) were used for all experiments and were 7- to 9-weeks old of age at the initiation of each study. For all animal studies, mice were injected with either phosphate buffered saline (PBS control) or fully chemically modified (unconjugated, lipid-conjugated, or dendrimer-conjugated) siRNA that was suspended in IxPBS for a final siRNA concentration of 40 mg / kg (150 pL injection volume). Mice were housed in pathogen-free animal facilities at UMass Chan Medical School.

[0632] To confirm in vivo silencing efficacy of / / '.s2-targ eting siRNAs, naive mice were subcutaneously injected once with either PBS or 40mg / kg siRNA. Animals were euthanized 2 weeks post-injection, and tissues were collected and either placed in RNAlater and stored at 4 °C or flash frozen and stored at -80 °C. Two 2mm punches were collected from tissues stored in RNAlater, placed into QIAGEN Collection Microtubes holding 3mm tungsten beads and lysed in 300 pL homogenizing solution containing 0.2 mg / mL proteinase K using a QIAGEN TissueLyser II. mRNA levels were determined using the Quantigene 2.0 assays (Affymetrix). For protein analysis, frozen tissues were homogenized in RIPA buffer containing protease and phosphatase inhibitors.

[0633] For mammary tissue siRNA delivery studies, naive mice were subcutaneously injected once with either PBS or 40 mg / kg siRNA labeled with a Cy3 fluorophore. Animals were euthanized 48hr post-injection, and tissues were collected and fixed in 10% neutral buffered formalin overnight at 4 °C. A separate cohort of naive mice were subcutaneously injected once with either PBS or 40 mg / kg siRNA labeled with Cy3 to assess siRNA mammary tissue silencing efficacy and antisense accumulation. Animals were euthanized 2 weeks post-injection and tissues were collected and placed in RNAlater and stored at 4 °C. Relative RNA expression levels were measured by the Quantigene 2.0 assay (Affymetrix) and antisense strand concentration was quantified by Stemloop RT-PCR.

[0634] 82690703v1 82Atorney Docket No.: UM9-328PC (776088)

[0635] To determine the optimal siRNA conjugation strategy for mammary tumor delivery, 4T1 cells (1.6xl05) suspended in 30 pLPBS were orthotopically injected into the #4 mammary fat pad of 7- to 9-week-old female BALB / c mice. Animals were palpated daily to detect tumor initiation, and palpable tumors were measured daily with calipers to monitor tumor growth. When tumors reached -200 mm3in volume, mice were injected either subcutaneously (150 pL) or intratum orally (50 pL) with either phosphate buffered saline or 40 mg / kg siRNA. Animals were euthanized 48 hours post-injection, and tissues were collected for fluorescence microscopy analysis.

[0636] To investigate the role of Irs2 silencing in mammary tumor progression, 4T1 cells (IxlO5) were injected into the #2 mammary fat pad and palpable tumors were measured daily with calipers. When tumors reached ~200mm3in volume, the mice were randomized into groups and injected subcutaneously with either PBS or 40 mg / kg siRNA, and again 72 hours after the first injection. Mice were euthanized 72 hours after the second injection and tissues were collected to measure tumor and secondary tissue siRNA delivery, gene silencing, and histopathology. Tumor volumes were calculated from caliper measurements using the equation (W2*L) / 2 to track tumor growth in vivo, and terminal tumor volumes were calculated using the equation V=(4 / 3)TI*(L / 2)*(W / 2)*(D / 2) (Tomayko et al. Cancer Chemother Pharmacol. 1989; 24:148-54; Faustino-Rocha et al. In Vivo. 2016; 30(4): 465-72). Tumor measurements were confirmed by an individual who was blinded to experimental intervention.

[0637] Fluorescence

[0638]

[0639] A portion of tumors and secondary tissues were paraffin-embedded and sectioned by the Morphology Research Core Facility at UMass Chan Medical School. Sections were stained with 4',6-diamidino-2-phenylindole (DAPI) to visualize nuclei and fluorescent images were acquired with a Leica DMi8 inverted microscope (Leica Microsystems) and a Nikon Al confocal microscope (Nikon). Whole-tissue images were taken using a 10X objective and confocal images were taken using a 60X oil immersion objective. The denoise. ai algorithm was used to process confocal images in FIG. 2C using NIS-Elements Advanced Research software (Nikon). Images were adjusted for equal brightness and contrast to compare the degree of siRNA biodistribution.

[0640] Immunofluorescence

[0641]

[0642] Formalin-fixed, paraffin-embedded tissue sections mounted on glass slides were deparaffinized with xylene and rehydrated using the following series of 5 minute ethanol

[0643] 82690703v1 83Atorney Docket No.: UM9-328PC (776088)

[0644] washes: 100%, 95%, 70%, and 50%, with a final wash with deionized water. An antigen retrieval step was performed using heat and sodium citrate unmasking solution (Cell Signaling Technology #14746S). After antigen retrieval, slides were briefly washed with PBS and placed in blocking solution of PBS containing 0. l%Triton-X 100 (PBST) and 1% bovine serum album (BSA) for 1 hour at room temperature. Slides were then incubated in blocking solution containing an anti-CD31 or anti-F4 / 80 antibody overnight at 4o C. Sections were washed with PBST, then incubated in blocking solution containing secondary antibodies for 1.5 hours at room temperature. Slides were again washed with PBST, incubated in DAPI diluted in PBS to visualize nuclei, and coverslipped using Prolong Glass mounting medium (ThermoFisher Cat#P36984). Slides were allowed to cure overnight and then imaged with a 20X objective using a Leica DMi8 microscope or a 60X objective using a Nikon Al confocal microscope. For analysis of tumor vascularization, three representative images were taken per tumor, and blood vessel density and cross-sectional area were quantified and confirmed by three individuals who were blinded to experimental intervention using ImageJ software.

[0645] Flow Cytometry

[0646] A portion of collected tumors that were stored in Crytostor CS10 media (Sigma-Aldrich) were dissociated into a single cell suspension using the Miltenyi mouse tumor dissociation kit (Miltenyi Biotec Cat# 130-096-730) according to manufacturer’s protocol. Cell suspensions were treated with TruStain FcX PLUS (anti-CD 16 / 32) antibody (Biolegend #156603) for 5min at 4 °C, then stained with primary antibodies suspended in PBS + 1% FBS supplemented with Brilliant Stain Buffer (BD Biosciences #659611). After washing with PBS, cells were stained with a Fixable Viability Dye (Invitrogen #65-0865-14) and fixed using a formaldehyde-based fixative (Miltenyi Cat# 130-090-477). Samples were run on a Cytek Aurora flow cytometer and analyzed using Flow Jo vlO software. Single-stained cell suspensions and UltraComp eBeads Plus (ThermoFisher #01-3333-42) compensation beads were used as compensation controls.

[0647] Stem -loop RT-PCR

[0648] Biodistribution levels of siRNA in mammary fat pad, tumor, pancreas, and liver tissue were quantified using Stem-loop RT-PCR (Castellanos-Rizaldos et al. Nucleic Acid Ther. 2020; 30(3): 133-42; Landesman et al. Silence. 2010; 1(16)). Tissues were lysed in homogenizing solution (Invitrogen) containing 0.2 mg / mL proteinase K, heated to 65 °C for 30min, and spun down to remove debris. Stock tissue supernatants were diluted 1:60 with nuclease-free water

[0649] 82690703v1 84Atorney Docket No.: UM9-328PC (776088)

[0650] for downstream analysis. An 8-point standard curve ranging from O-lOOnM was generated using diluted control tissue supernatants spiked with either unconjugated, lipid-conjugated, or dendrimer-conjugated siRNAs as a template for cDNA synthesis. Standard curve and experimental samples were heated to 95 °C for 20 minutes and combined with 1 pM RT primers, lOmM dNTPs (New England Biolabs; N0447L), 10X M-MuLV RT reaction buffer (New England Biolabs; B0253S), and M-MuLV reverse transcriptase (New England Biolabs; M0253L) for cDNA synthesis. Synthesis of cDNA was performed using the following protocol: 16 °C for 30 min for primer annealing, 42 °C for 30 min for reverse transcription, and then 70 °C for 15 min for enzyme inactivation. For the qPCR reaction setup, a master-mix consisting of 5 pL of Power-Up SYBR qPCR Mastermix (Applied Biosystems), 0.05 pL forward primer at 100 pM , 0.05 pL universal reverse primer at 100 pM, and 2.9pL water was mixed with 2 pL of cDNA template diluted 1 : 1 with nuclease-free water. The thermal cycling program was set as followed: 2 min incubation at 50 °C, a 2 min denaturation at 95 °C, then 50 cycles of 10 sec at 95 °C and 20 sec at 60 °C. The primers used are recited below in Table A:

[0651] Table A - Primer sequence

[0652] Primer Sequence

[0653] HtRT GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATAC GACAAATATCA

[0654] Irs2 RT GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATAC GACAATTCTTT

[0655] Jakl RT GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATAC GACAAACATCA

[0656] Ht forward CCGCCTACCGTGGTTAATCTCTTTACTG

[0657] Irs2 forward ACCGTGGTAAACATGTACCCAA

[0658] Jakl forward CCTACCGTGGTATCGCTTGTAGCTGAT

[0659]

[0660] Universal reverse CGTGCAGGGTCCGAGGT

[0661] RNA Preparation and Real-time PCR

[0662] Total RNA was extracted from PyN-M Irsl / Irs2 / - cells stably expressing either a FLAG-tagged Irs2 or an empty vector control using the RNeasy Mini kit (Qiagen). cDNA was synthesized using an AzuraQuant cDNA synthesis kit (Azura Genomics). qRT-PCR was performed in an Applied Biosystems QuantStudio 6 Flex apparatus using AzuraView GreenFast qPCR Blue Mix (Azura Genomics). The delta-delta Ct method was used to determine relative mRNA expression. Primers for mouse vimentin and mouse P-actin (housekeeping gene) were synthesized by Azenta Life Sciences and were as follows: Vim forward, 5’-TTTGCTGACCTCTCTGAGGC-3’; Vim reverse, 5’-

[0663] 82690703v1 85Atorney Docket No.: UM9-328PC (776088)

[0664] CTCCAGGGACTCGTTAGTGC-3’; P-actin forward 5’-AGGTGACAGCATTGCTTCTG-3’; P-actin reverse 5’-GCTGCCTCAACACCTCAAC-3’.

[0665] Serum Glucose Analysis

[0666] Whole blood was collected from mice via the facial vein at time of euthanasia and serum was isolated using serum separator tubes (BD #365967). Serum glucose concentrations were then measured using a glucose colorimetric detection kit (ThermoFisher Scientific Cat# EIAGLUC) according to manufacturer’s protocol.

[0667] Immunoblotting

[0668] Cell or tissue extracts containing equivalent amounts of protein were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked for 1 hour at room temperature in 50 mM Tris buffer, pH 7.5 with 0.15 MNaCl and 0.1% Tween-20 (TBST) and 5% (wt / vol) dry milk, incubated overnight at 4 °C in TBST containing 3% (wt / vol) bovine serum albumin (BSA) and primary antibodies. Membranes were washed with TBST, and then incubated for 1-2 hours at room temperature in 5% blocking buffer with milk containing peroxidase-conjugated secondary antibodies. Bands were detected by chemiluminescence using a ChemiDoc XRS+system (Biorad) and quantified by densitometry using ImageJ. Signals were normalized to total housekeeping genes to compare relative protein expression levels.

[0669] Tumor and Pancreas Histopathology and Immunohistochemistry

[0670] Pancreas tissue and a portion of tumor samples were processed, paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E) by the Morphology Research Core Facility atUMass Chan Medical School using standard protocols. To determine pancreatic islet cell mass, the total number and cross-sectional area of all islets were compared between experimental groups. Tumor tissue was evaluated for histomorphologic characterization and determination of the percent neoplastic composition of the tissue, percent necrotic composition of the neoplastic population, and the number of mitotic figures per ten contiguous high-powered fields (HPFs; 2.37mm2). Immunolabeling of FFPE sections of all tumor specimens was performed by using 5 pm sections with a recombinant anti-vimentin antibody using standard protocols. Antigen retrieval was performed using sodium citrate solution. Normal murine teste and adipose tissue were used as positive controls while primary antibody was removed in negative controls. Stained specimens were scored as having no (0), weak (1),

[0671] 82690703v1 86Atorney Docket No.: UM9-328PC (776088)

[0672] moderate (2), or strong (3) immunoreactivity, and the percentage of neoplastic cells that stained positive was recorded. An h-score was calculated by multiplying the staining intensity score by the percentage (by decile) of positively labeled tumor cells. All histologic evaluations and immunohistochemical scoring were performed by a board-certified veterinary pathologist who was blinded to experimental intervention.

[0673] Transwell Migration Assays

[0674] PyV-M Irsl / Irs2- / - cells stably expressing either a FLAG-tagged Irs2 or an empty vector control were transfected with shRNAs targeting either GFP or vimentin (TRCN0000089828; TRCN0000089830) using Lipofectamine 3000 for 24 hours. Cells were plated into the top chamber of 6.5 mm Transwells (8 pm pore size) (Coming) and 3T3-conditioned media was added to the bottom chamber, and cells were allowed to migrate for 5 hours at 37 °C. Cells that had migrated to the lower surface of the filters were fixed in methanol for 10 minutes and mounted on glass slides using a Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA). Migration was quantified by counting the number of stained nuclei in four independent fields in each Transwell.

[0675] Statistical Analysis

[0676] All data were analyzed using GraphPad Prism 10 software (GraphPad Software, Inc., San Diego, CA, USA). Student’s t-test was applied and p-value of <0.05 was considered to indicate statistical significance when comparing 2 groups. For comparison of more than 2 groups, one-way or two-way ANOVA followed by Tukey ’ s multiple comparisons was applied.

[0677] Study Approval

[0678] All animal experiments were performed in accordance with animal care ethics approval and guidelines of the University of Massachusetts Chan Medical School Institutional Animal Care and Use Committee. All procedures were approved under the Protocol #201900333 (Shaw Laboratory) and #202000010 (Khvorova Laboratory) and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals

[0679] Example 2. In vitro identification of IRS2-targeting oligonucleotides.

[0680] IRS2 is expressed in both primary tumor cells and in cells of the tumor microenvironment (TME) and may play distinct roles in these compartments to drive tumor

[0681] 82690703v1 87Atorney Docket No.: UM9-328PC (776088)

[0682] progression. In tumor models in which human cancer cell lines are orthotopically injected into mice, identification of species-specific siRNAs would enable the silencing of IRS2 exclusively in tumor cells or in stromal cells of the TME and allow the dissection of these distinct roles. As neoplastic cells and non-neoplastic TME cells both contribute to tumor progression and impact response to therapy, identifying species cross-reactive siRNAs that silence IRS2 in both compartments would also allow the assessment of the impact of silencing IRS2 on tumor progression in both immunodeficient mouse tumor models as well as in syngeneic mouse models. Human-specific, mouse-specific, and human / mouse cross-reactive siRNA sequences targeting IRS2 were tested.

[0683] A panel of 48 siRNA sequences were generated to silence IRS2 (14 human, 14 mouse, and 20 human / mouse cross-reactive) and were specific to the open reading frame or 3’ untranslated regions (UTR) of IRS2 mRNA transcripts were synthesized. The 3’ end of the siRNA sense strands were conjugated to cholesterol to enable passive uptake for in vitro screening. IRS2 is highly expressed in TNBC. Thus, TNBC cell lines were used to identify siRNA sequences that silence IRS2 expression. We screened candidate siRNAs using MDA-MB-231 human breast carcinoma cells and 4T1 murine mammary tumor cells and found two human / mouse cross-reactive siRNAs (sil 110 and si6530), one human-specific siRNA (si5967) and two mouse-specific siRNAs (si6548 and si6696) that silenced IRS2 / Irs2 mRNA expression by approximately 50% (FIG. 1A and FIG. IB). The median inhibition concentration (IC50) values were then determined for these siRNA candidates using seven-point dose-response studies (FIG. 1C and FIG. ID). Predicted mouse-specific siRNAs did not silence IRS2 mRNA expression in MDA-MB-231 cells (FIG. 1A), and the predicted human-specific siRNA did not silence Irs2 mRNA expression in 4T1 cells (FIG. IB).

[0684] We next evaluated the impact of siRNA-silencing on protein expression in both MDA-MB-231 and 4T1 cells using the lead sequences we identified from the mRNA screen. The degree of IRS2 protein silencing was consistent with mRNA silencing (approximately 50% reduction) in MDA-MB-231 cells after treatment with si5967 and si6530, but not sil 110, or the mouse-specific siRNAs (FIG. IE). In 4T1 cells, both si6530 (species cross-reactive) and si6548 (mouse-specific) silenced Irs2 protein expression to a greater extent than mRNA expression, with an approximately 80% reduction in Irs2 protein expression observed (FIG. IF). We validated the silencing efficacy of our species cross-reactive and mouse-specific siRNA sequences using the FL83B mouse hepatocyte cell line, which highly expresses Irs2 (FIG. 1 J). Importantly, treatment of all cell lines with si5967, si6530, and si6548 did not

[0685] 82690703v1 88Atorney Docket No.: UM9-328PC (776088)

[0686] silence IRS1 protein expression, indicating that these top siRNA candidates selectively silence IRS2 / Irs2.

[0687] After identifying species-selective and cross-reactive siRNA sequences, we assessed dose-dependent protein silencing and in vivo silencing efficacy of our lead mouse-specific compound, si6548. Four-point dose response studies in 4T1 cells confirmed robust, dosedependent Irs2 protein silencing in vitro (FIG. IK). To confirm in vivo efficacy of our lead compound, naive mice were subcutaneously injected with 40 mg / kg of si6548 in 150 pL PBS, and mRNA and protein silencing was evaluated after 2 weeks. si6548 silenced Irs2 mRNA expression in skeletal muscle (FIG. 1G) when covalently conjugated to the lipid docosanoic acid (DCA). Irs2 protein expression was evaluated in the liver and was suppressed by si6548 by approximately 75% (FIG. 1H). Given these results, we selected si6548 (hereafter referred to as silrs2) for subsequent in vivo tumor studies.

[0688] Example 3. Dendritic conjugation improves siRNA delivery to mammary tumors.

[0689] A barrier to the use of siRNA therapeutics in cancer is delivery of oligonucleotides to tumors. Previous studies have shown that lipid conjugation improves functional siRNA delivery to extrahepatic tissues upon systemic administration (Biscans et al. Nucleic Acid Res.

[0690] 2019; 47(3): 1082-96). Primary breast tumors arise from epithelial cells of the mammary gland, which are localized within the adipocyte-rich environment of the healthy mammary tissue. We hypothesized, therefore, that conjugated siRNAs with improved biodistribution and efficacy in mammary tissue could also have enhanced delivery to mammary tumors. We tested the impact of two different lipid conjugates, docosanoic acid (DCA-siRNA), a 22-carbon chain saturated fatty acid, and DCA modified with a phosphocholine group (PCDCA-siRNA) (FIG.2A), both of which have shown improved extrahepatic distribution profiles compared to other lipid conjugates, on siRNA mammary tissue delivery, accumulation, and silencing. Cy3-fluorescently labeled unconjugated, DCA-, and PCDCA-siRNAs targeting the ubiquitously expressed gene Huntingtin (Htt) were subcutaneously injected into mice to investigate siRNA delivery to and silencing in mammary tissue (FIG. 2E). Fluorescence imaging of isolated mammary fat pads revealed that both DCA- and PCDCA-siRNAs distributed to mammary tissue to a greater extent than unconjugated siRNAs (FIG.2F). Antisense strand accumulation in mammary tissue was significantly increased in mice treated with DCA-siRNA and increased, though not statistically significantly, in mice treated with PCDCA-siRNA, compared with animals treated with unconjugated siRNA (FIG. 2G). Furthermore, mice treated with

[0691] 82690703v1 89Atorney Docket No.: UM9-328PC (776088)

[0692] unconjugated and PCDCA-, but not DCA-conjugated, siRNAs exhibited significant Htt silencing when compared with each respective NTC siRNA and untreated (UNT) control animals (FIG.2H). Taken together, our data suggest that DCA and PCDCA conjugation indeed improves productive siRNA delivery to and silencing of target genes in mammary tissue.

[0693] We next assessed the delivery of DCA- and PCDCA-siRNAs to mammary tumors. We also investigated siRNAs with a third conjugate, an amphiphilic dendrimeric structure (dendrimer) that has high binding to albumin (Fakih et al. Mol Ther Nucleic Acids. 2023; 34:102080) (FIG. 2A). We hypothesized that this dendrimer conjugate would improve mammary tumor delivery because albumin has been previously used as a carrier for breast cancer therapies (Untch et al. J Clin Oncol. 2019; 37(25): 2226-34). Moreover, dendrimer-conjugated siRNAs are internalized by glioblastoma after intracerebroventricular injection into the ventricle or striatum (Sarli et al. Nucleic Acids Res 2024; 52(9): 4799-8117). Syngeneic mice were injected with 4T1 tumor cells orthotopically into the #4 mammary fat pad and palpated daily until tumor volumes were approximately 200mm3. Mice were then administered Cy3-labeled unconjugated, DCA-, PCDCA-, or dendrimer-siRNAs targeting Htt. Oligonucleotides were injected both locally (intratumoral) and systemically (subcutaneous) to determine the administration route that most uniformly distributed siRNAs within tumors. Tumors and adjacent mammary tissue were collected 48 hours post-injection to assess siRNA biodistribution by fluorescence microscopy (FIG. 2B, FIG. 2C, FIG. 21, FIG. 2J). Cy3 fluorescence distributed throughout tumors in mice injected subcutaneously with siRNA, but fluorescence was largely confined to the site of injection following intratumoral injection. Whereas the fluorescence signal was high in tumor-associated mammary tissue from mice injected with DCA- and PCDCA-siRNAs, as we had observed previously, fluorescence was largely undetectable in the mammary tumors in these mice, suggesting minimal tumor biodistribution. In contrast to the low uptake in normal mammary tissue, tumor fluorescence was relatively increased in mice administered unconjugated siRNA when compared to the tumor fluorescence in mice injected with DCA- and PCDCA-siRNAs. However, tumors from mice treated with dendrimer-siRNA showed the greatest fluorescence distribution, with robust, uniform Cy3 fluorescence observed throughout the tumors. Antisense strand concentrations in tumor tissues reflected the microscopy findings (FIG. 2D), leading to our conclusion that albumin-binding dendrimer conjugation significantly improves siRNA delivery to mammary tumors.

[0694] Tumors are a heterogenous microenvironment of primary neoplastic cells, immune cells, and stromal cells, and target gene silencing in one or more of these cellular compartments

[0695] 82690703v1 90Atorney Docket No.: UM9-328PC (776088)

[0696] may impact tumor biology. To assess the cell-type specificity of siRNA uptake in the tumor microenvironment, we performed multicolor flow cytometry on mammary tumor cell suspensions from mice treated with PBS control and either Cy3-labeled unconjugated NTC siRNA (siNTC) or dendrimer-conjugated siNTC. Mice were injected with 4T1 cells into the #2 mammary fat pad and all tumors formed in mice at the same time and tumor growth rates were similar prior to treatment (FIG. 3F and FIG.3G). Mice were injected subcutaneously with 40 mg / kg siRNAs in PBS when tumors were ~200mm3. A second injection was given 72 hours later, and the mice were sacrificed after an additional 72 hours, at which time tumors were isolated, and a single cell suspension was prepared for flow cytometry analysis (FIG. 3A).

[0697] An 11-color panel was used to distinguish neoplastic cells, tumor-associated immune cells, and nonimmune stromal cells in order to characterize cell populations that internalized Cy3-labelled siRNAs (FIG. 3B). Primary tumor cells, defined by high expression of EpCAM, as well as non-tumor stromal cells in the CD45 negative (CD45-) population exhibited Cy3 fluorescence, indicative of siRNA internalization (FIG.3C). Both adaptive and innate immune cell populations (CD45+ populations) also displayed varying degrees of Cy3 fluorescence. Ml-like macrophage populations, defined by high expression of F4 / 80, CD11c, and MHC class II, and M2 -like macrophages, defined by high expression of F4 / 80 and CD206, had greater siRNA uptake than T cell populations, dendritic cells, and other immune populations. Dendrimer conjugation enhanced siRNA delivery to all identified cell populations, as both the degree of Cy3 fluorescence within each population (FIG. 3D) and the percentage of cells that were Cy3 fluorescent (FIG. 3E) was increased in tumors treated with dendrimer-siRNA compared to unconjugated siRNA. Taken together, our results demonstrate that dendrimer conjugation promotes efficient delivery of siRNAs to both neoplastic and non-neoplastic cells of the TME after systemic siRNA administration.

[0698] Example 4. siRNA-mediated silencing of Irs2 reduces mammary tumor growth.

[0699] Previous studies have implicated Irs2 in multiple aspects of breast cancer progression, including tumor initiation and sternness, tumor cell migration and invasion, and metastasis using Irs2 knockout transgenic and orthotopic mouse tumor models (Nagle et al. Mol Cell Biol.

[0700] 2004; 24(22): 9726-35; Lee et al. Cell Rep. 2022; 41(10): 111759; Mercado-Matos et al. Mol Cell Biol. 2018; 38(14); Jackson et al. Oncogene. 2001; 20:7318-25). To investigate the impact of acute siRNA-mediated Irs2 silencing on mammary tumor growth and progression, we selected dendrimer-conjugation for further tumor studies due to the enhanced tumor uptake that we observed in the pilot studies. Dendrimer-conjugated silrs2 and siNTC were administered to

[0701] 82690703v1 91Atorney Docket No.: UM9-328PC (776088)

[0702] mice bearing 4T1 mammary tumors following the same siRNA injection protocol as performed for the flow cytometry studies (FIG. 3A). A cohort of tumor-bearing mice were also injected with a previously validated, dendrimer-conjugated siRNA that silences the inflammatory mediator Jakl (siJakl) to further control for non-specific impacts of siRNA sequence on tumor silencing. Following the first siRNA injection, tumors within mice administered silrs2 exhibited a slower growth rate than tumors in mice administered siNTC and this slower growth rate persisted after the second injection (FIG. 4A and FIG. 4B). Terminal tumor volumes at sacrifice were approximately 20% smaller in mice treated with silrs2 than those from mice treated with siNTC (FIG. 4C). No differences in tumor growth rate or terminal tumor volumes were observed for mice injected with siJakl (FIG. 4 J and FIG. 4K).

[0703] To confirm siRNA delivery, tumor sections were evaluated for Cy3 fluorescence by imaging and by analysis of antisense strand accumulation in tumor extracts. Similar to our pilot study results with dendrimer-conjugated Htt siRNA, siNTC, silrs2, and siJakl were robustly delivered to mammary tumors when conjugated to dendrimer (FIG. 4D). Both the center and periphery of tumors contained substantial concentrations of antisense strand (FIG. 4E, FIG.

[0704] 4L), suggesting penetration of siRNA throughout the tumor tissue. As expected, siRNAs were robustly delivered to the liver. Irs2 and Jakl mRNA silencing was assessed in biopsies sampled from non-necrotic areas of the mammary tumors. Administration of silrs2 led to approximately 30% Irs2 gene silencing (FIG. 4F) and administration of siJakl led to a -20-30% reduction in Jakl mRNA expression (FIG. 4M).

[0705] A major concern regarding therapeutic silencing of components of the IIS signaling pathway is disruption of the insulin-dependent regulation of glucose uptake in metabolic tissues, resulting in hyperglycemia. IRS2 is required for pancreatic islet cell viability and mice lacking Irs2 expression exhibit loss of islet mass and develop insulin resistance which leads to hyperglycemia (Withers et al. Nature. 1998; 391). While we observed some accumulation of silrs2 in the pancreas (FIG. 4E), the amount detected was lower than in mammary tumors or liver. Analysis of terminal serum glucose levels revealed that systemic treatment of mice with silrs2 did not cause an elevation in serum glucose levels relative to mice treated with PBS or siNTC (FIG. 4G), and there was no correlation between Irs2 expression and serum glucose levels in siRNA-treated mice (FIG. 5H, FIG. 51). Further histological evaluation of pancreas tissue also indicated that neither the number nor size of pancreatic islets were decreased in mice treated with silrs2 compared to PBS or siNTC (FIG. 4H, FIG. 41). These data support that administration of Irs2-selective siRNA can achieve productive gene silencing in tumors without perturbing systemic glucose homeostasis.

[0706] 82690703v1 92Atorney Docket No.: UM9-328PC (776088)

[0707] Histopathological comparison of siNTC and silrs2-treated tumors revealed similar histological features typical of 4T1 tumors (FIG. 5J). Neoplastic cells were polygonal to slightly spindled with poorly defined cytoplasmic borders and large nuclei containing variably distinct nucleoli and condensed to vesicular chromatin. Throughout the tumors there were numerous foci of small aggregates of lymphocytes and plasma cells. Rarely, degranulating eosinophils were observed. No difference in relative necrosis was observed between the two groups of tumors as the percentage of non-necrotic neoplastic cells was similar between groups (FIG. 5K). However, a trend (p=0.0534) towards decreased mitotic counts in tumors from silrs 2 -treated mice compared to mice treated with siNTC was observed (FIG. 5A).

[0708] Irs2 is expressed in tumor cells as well as in some stromal / immune cell populations of the TME. This raises the possibility that the suppression of tumor growth by silrs2 may be the result of both tumor cell intrinsic and extrinsic functions of Irs2. For example, IRS2 is a signaling adapter for the IL-4 receptor that drives macrophage polarization to the M2 phenotype (FIG. 5B) (Heller et al. Sci Signaling. 2008; 1(51)). IRS2 is also expressed in stromal endothelial cells and fibroblasts (Hashimoto et al. Diabetes. 2015; 64(3): 876-86; Sadagurski et al. Journal of Biological Chemistry. 2005; 280(15): 14536-44). To further examine the mechanism by which silrs2 inhibits mammary tumor growth, we compared the immune populations of primary tumors from mice treated with silrs2 and siNTC, because changes in Irs2 expression could alter the composition of the TME to impact tumor cell growth. Flow cytometric analysis revealed that the proportion of dendritic cells, T cells, and other, undefined immune populations within the tumor immune compartment did not differ between treatment groups (FIG. 5C). Although the frequency of total macrophages within the tumor immune compartment was similar in silrs2- and siNTC-treated mice, the frequency of macrophages that highly express CD206 (M2 -like) was decreased in tumors from silrs2-treated mice (FIG. 5D). As a result, the ratio of macrophages that highly expressed CD11c (Ml -like) to those that highly express CD206 (M2-like) was significantly increased in tumors from mice treated with silrs2 compared to siNTC (FIG. 5E).

[0709] M2-like tumor associated macrophages (TAMs) are a key driver of tumor angiogenesis, a process necessary to provide nutrients and oxygen to sustain tumor expansion and spread (Fu et al. Cell Immunol. 2020; 353: 104119; Du et al. Cancer Cell. 2008; 13(3): 206-10; Sierra et al. J Exp Med. 2008; 205(7): 1673-85). Moreover, Irs2 is upregulated under hypoxic conditions in tumor cells and has been shown to promote the expression of major regulators of neovascularization (Mardilovich et al. Cancer Res. 2009; 69(23): 8894-901). To determine the impact of Irs2 suppression on tumor angiogenesis, the density and average area of blood

[0710] 82690703v1 93Atorney Docket No.: UM9-328PC (776088)

[0711] vessels, identified by expression of CD31, were measured to assess the tumor vascular network (FIG. 5F). While blood vessel density was similar in tumors across groups, vessel cross sectional area was significantly decreased in tumors from mice treated with silrs2, indicating less extensive vascularization / reduced perfusion of the tumors. To evaluate if the reduction in angiogenesis was the result of suppression of Irs2 expression in endothelial cells, tumor sections were stained with CD31 and evaluated for Cy3 expression by fluorescence microscopy (FIG. 5G). Co-localization of Cy3 and CD31 staining was not observed, revealing that dendrimer-conjugated siRNAs are not internalized efficiently by endothelial cells. In contrast, macrophages identified by F4 / 80 staining showed significant uptake of Cy3, confirming the flow cytometry data (FIG. 3). Taken together, our data support a cell extrinsic regulation of angiogenesis by Irs2.

[0712] Example 5. siRNA-mediated silencing of Irs2 reduces mammary tumor metastasis.

[0713] To investigate whether acute targeting of Irs2 by siRNA treatment impacts tumor dissemination, lung metastatic burden in silrs2- and .s / A7C-treated mice was evaluated. A similar percentage of mice developed metastases in all groups (8 out of 10 mice), and there was no significant difference in the number of metastatic lesions across two different lung lobes (FIG. 6A). However, in .s / 7 / '.s2-treated mice, a trend toward a decrease in the size of metastatic lesions was observed (FIG. 6B). Multiple studies have reported that increased Irs2 expression and activity are associated with increased tumor cell migration and invasiveness, key functions associated with metastatic tumor cells (Zhu et al. JCI Insight. 2018; 3(8); Mercado-Matos et al., supra; Jackson et al., supra). Invasion involves remodeling of the cytoskeleton and upregulation of mesenchymal features through epithelial to mesenchymal transition (EMT) (Wang et al. Chin J Cancer. 2011; 30(9)). We evaluated the expression of one mesenchymal marker that is upregulated in cells that undergo an EMT, the cytoskeletal protein vimentin, in tumors from silrs2- and siNTC- treated mice. Vimentin immunolabeling demonstrated increased expression by neoplastic cells with more fusiform morphology within the leading edge of the tumors. Fewer malignant cells expressed vimentin in tumors from silrs2-treated mice, and the intensity of vimentin expression was decreased in these cells (FIG. 6C). We further examined the tumor cell-intrinsic role of Irs2 in regulating vimentin expression, and the contribution of vimentin expression to Irs2-dependent tumor cell behavior. Restoration of Irs2 expression in PyV-MT : Irsl Irs-2 - cells that lack expression of both Irsl and Irs2 increased both vimentin mRNA and protein expression (FIG.6D-E). Knockdown of vimentin expression using 2 different shRNAs in PyV-MT: Irsl / Irs-2- / - cells stably expressing Irs2 reduced cell

[0714] 82690703v1 94Atorney Docket No.: UM9-328PC (776088)

[0715] migration (FIG.6F-G). These results demonstrate that Irs2 is sufficient for tumor cell-intrinsic regulation of vimentin expression, and that this mesenchymal marker is necessary for migration / invasion mediated by Irs2 in malignant cells. Taken together, our data support that siRNA-mediated silencing of Irs2 elicits changes in tumor cells and immune cell populations of the TME that contribute to the inhibition of mammary tumor growth and progression.

[0716] An exemplary Irs2 siRNA was administered to BALB / c mice to demonstrate tissue accumulation and safety. Accumulation of Cy3-labeled siRNA targeting Irs2 in small intestine, colon, liver, pancreas, muscle, and abdominal fat tissue from BALB / c mice 2 weeks after subcutaneous administration of PBS or 40 mg / kg dendrimer-.s / 7 / '.s2 (n = 10 mice / group) was measured (FIG. 7A). The data demonstrates that the dendrimer conjugated siRNA leads to uptake in the tested tissues. The body weight of the same mice was measured to demonstrate safety of the dendrimer conjugated siRNA (FIG. 7B).

[0717] Sequences

[0718] 45-nucleotide and 20-nucleotide target sequences are recited below in Table 1A (human IRS2) and Table 2A (Mouse and human cross-reactive Irs2). The siRNA antisense and sense strands are recited below in Table IB (human IRS2) and Table 2B (mouse and human cross-reactive Irs2). The following siRNA chemical modification pattern was employed for select above recited examples:

[0719] Antisense strand, from 5’ to 3’ (21 -nucleotides in length):

[0720] VP(mX)#(fX)#(mX)(fX)(fX)(fX)(mX)(fX)(mX)(fX)(mX)(fX)(mX)(fX)#(mX)#(fX)#(mX)#( mX)#(mX)#(fX)#(mX)

[0721] Sense strand, from 5’ to 3’ (16-nucleotides in length):

[0722] (mX)#(mX)#(mX)(fX)(mX)(fX)(mX)(fX)(mX)(fX)(mX)(mX)(mX)(fX)#(mX)#(mX) “m” corresponds to a 2’-O-methyl modification; “f” corresponds to a 2’-fluoro modification; “X” corresponds to any nucleotide of A, U, G, or C; “#” corresponds to a phosphorothioate internucleotide linkage; and “VP” corresponds to a 5’-(E)-vinylphosphonate.

[0723] In some embodiments, the 3’ end of the sense strand is conjugated to a hydrophobic moiety, such as cholesterol, docosanoic acid (DC A), or PC-docosanoic acid (PCDCA), or the conjugate of a dendrimer (as shown in FIG.2A). In some embodiments, the 3’ end of the sense

[0724] 82690703v1 95Attorney Docket No.: UM9-328PC (776088)

[0725] strand is conjugated to the hydrophobic moiety or the dendrimer via a polyethylene glycol linker, such as tri ethylene glycol or tetra ethylene glycol linker.

[0726] Table 1A. Human IRS2 Sequences (Accession Number NM_003749)

[0727] ID Gene region Target mRNA Sequence Target CTGTACATTTCACAAAAAGGCATATGCAAT AAAGGCAUAUGCAAUAU IRS2-6583 ATTTACATTTTTAAT UUA AAATATTTTTTGCTATATAAACTTTAACAGT UAUAAACUUUAACAGUU IRS2-6731 TATTAAACAGTGTT AUU TTTTGCTATATAAACTTTAACAGTTATTAAA UUUAACAGUUAUUAAAC IRS2-6738 CAGTGTTTTCTTTT AGU GTATTGTTTCTGGATATCAAGATGTTAAAT AUCAAGAUGUUAAAUA IRS2-6790 ATATTTCTTGCTATT UAUU ATCATGGATGCCCTCCTTAATAGCCATATG CUUAAUAGCCAUAUGCA IRS2-6967 CAATAAAATAAAGTA AUA TTTGCTATATAAACTTTAACAGTTATTAAA UUAACAGUUAUUAAACA IRS2-6739 CAGTGTTTTCTTTTT GUG AACCTCAACAACAACAACAACAACAACAA AACAACAACAACAACCA IRS2-600 CCACAGCGTGCGCAAG CAG CTCAACAACAACAACAACAACAACAACCA AACAACAACAACCACAG IRS2-603 CAGCGTGCGCAAGTGC CGU GGCTCAGGCACCCCGGGCACCAGCAGCGA GGCACCAGCAGCGACAG IRS2-3420 CAGCCGGCAGCGGTCT CCG GGACTTTGAAGACGGATTACTAAATAATAA AUUACUAAAUAAUAAU IRS2-5238 TTATTATATGTAACT (SEQ ID NO: 3) UAUU (SEQ ID NO: 20) ATATAATAGATATCTATCGCTATAGAATAA AUCGCUAUAGAAUAAUG IRS2-6040 TGCATTAATAAAATG (SEQ ID NO: 6) CAU (SEQ ID NO: 23)

[0728] CTTTGCCCTAAAATGATAGTCATGTAATAA AUAGUCAUGUAAUAAU IRS2-8097 TGTGTGTGTTATCTT GUGU GGCCATATAATGTTAGCTGGAAGGTCAATT GCUGGAAGGUCAAUUUC IRS2-6279 TCAGTGTATGATATA (SEQ ID NO: 7) AGU (SEQ ID NO: 24)

[0729] GGAAGCCAAAAAATACCTGCCAGATAACA CCUGCCAGAUAACAACA IRS2-7170 ACATTTATGAAAAGTA UUU ATGTTTATGTAGGTACTTCACATTGCAAAC CUUCACAUUGCAAACGC IRS2-5405 GCCTTTTATTCTATT (SEQ ID NO: 4) CUU (SEQ ID NO: 21)

[0730] TATATTTCTTGCTATTGTGATATGACAAGA UGUGAUAUGACAAGAG IRS2-6819 GACTTAACTTATCTT (SEQ ID NO: 8) A CUU (SEQ ID NO: 25) GCAATTCCAGGGTGGTCCGGGTTTGGCAGA UCCGGGUUUGGCAGAUU IRS2-5526 TTTGATTTTTAAAAA UGA CTTGTCGAAAAAATTCCGGACAAGACTACC CCGGACAAGACUACCCU IRS2-5745 CTTGTTTTATGTTTT (SEQ ID NO: 5) UGU (SEQ ID NO: 22)

[0731] GGTTACACTAATTCATTGGAGATGTAAGTT UUGGAGAUGUAAGUUG IRS2-5967 GTTGGTTTTGTTTTG (SEQ ID NO: 1) UUGG (SEQ ID NO: 18) ATAAAGTACATTATTTATGAAATGAATACA UAUGAAAUGAAUACAG IRS2-7004 GTCCTGAAGATTTTT UCCU CTGAATATGGACCCTGCTGAAAGCAGTGTA GCUGAAAGCAGUGUAUU

[0732]

[0733] IRS2-6426 TTGACGCATATTTAA GAC

[0734] 82690703v1 96Attorney Docket No.: UM9-328PC (776088)

[0735] TTCCCGGATGGGGCATTCATCATTGTGCTG UUCAUCAUUGUGCUGUU IRS2-4755 TTTGCGTTTTGTTTT (SEQ ID NO: 2) UGC (SEQ IDNO: 19)

[0736] ATGCTAAGAGACTTGTGTGAGAGCACACA UGUGAGAGCACACAGUC

[0737]

[0738] IRS2-7391 GTCCATGAGTGGTAAA CAU

[0739] Table IB. Human IRS2 Targeting siRNA Sequences

[0740] ID Antisense Strand Sense Strand

[0741] IRS2-6583 UAAAUAUUGCAUAUGCCUUU GGCAUAUGCAAUAUUU IRS2-6731 AAUAACUGUUAAAGUUUAUA AAACUUUAACAGUUAU IRS2-6738 ACUGUUUAAUAACUGUUAAA AACAGUUAUUAAACAG IRS2-6790 AAUAUAUUUAACAUCUUGAU AAGAUGUUAAAUAUAU IRS2-6967 UAUUGCAUAUGGCUAUUAAG AAUAGCCAUAUGCAAU IRS2-6739 CACUGUUUAAUAACUGUUAA ACAGUUAUUAAACAGU IRS2-600 CUGUGGUUGUUGUUGUUGUU AACAACAACAACCACA IRS2-603 ACGCUGUGGUUGUUGUUGUU AACAACAACCACAGCG IRS2-3420 CGGCUGUCGCUGCUGGUGCC ACCAGCAGCGACAGCC AAUAAUUAUUAUUUAGUAAU ACUAAAUAAUAAUUAU IRS2-5238 (SEQ ID NO: 39) (SEQ ID NO: 40)

[0742] AUGCAUUAUUCUAUAGCGAU GCUAUAGAAUAAUGCA IRS2-6040 (SEQ ID NO: 45) (SEQ ID NO: 46)

[0743] IRS2-8097 ACACAUUAUUACAUGACUAU GUCAUGUAAUAAUGUG ACUGAAAUUGACCUUCCAGC GGAAGGUCAAUUUCAG IRS2-6279 (SEQ ID NO: 47) (SEQ ID NO: 48)

[0744] IRS2-7170 AAAUGUUGUUAUCUGGCAGG GCCAGAUAACAACAUU AAGGCGUUUGCAAUGUGAAG CACAUUGCAAACGCCU IRS2-5405 (SEQ ID NO: 41) (SEQ ID NO: 42)

[0745] AAGUCUCUUGUCAUAUCACA GAUAUGACAAGAGACU IRS2-6819 (SEQ ID NO: 49) (SEQ ID NO: 50)

[0746] IRS2-5526 UCAAAUCUGCCAAACCCGGA GGGUUUGGCAGAUUUG ACAAGGGUAGUCUUGUCCGG GACAAGACUACCCUUG IRS2-5745 (SEQ ID NO: 43) (SEQ ID NO: 44)

[0747] CCAACAACUUACAUCUCCAA GAGAUGUAAGUUGUUG IRS2-5967 (SEQ ID NO: 35) (SEQ ID NO: 36)

[0748] IRS2-7004 AGGACUGUAUUCAUUUCAUA GAAAUGAAUACAGUCC IRS2-6426 GUCAAUACACUGCUUUCAGC GAAAGCAGUGUAUUGA GCAAACAGCACAAUGAUGAA AUCAUUGUGCUGUUUG IRS2-4755 (SEQ ID NO: 37) (SEQ ID NO: 38)

[0749]

[0750] IRS2-7391 AUGGACUGUGUGCUCUCACA GAGAGCACACAGUCCA

[0751] Table 2A. Mouse and human cross-reactive IRS2 Sequences (Accession Number NM_001081212)

[0752] ID Gene region Target mRNA Sequence Target AAATTTAAACTATTTTTTGCTATATAAACTTTA UUUGCUAUAUAAACU

[0753]

[0754] Irs2-6512 ACAGTTATTAAA (SEQ ID NO: 15) UUAAC (SEQ ID NO: 32)

[0755] 82690703v1 97Atorney Docket No.: UM9-328PC (776088)

[0756] ATTTAAACTATTTTTTGCTATATAAACTTTAAC UGCUAUAUAAACUUU

[0757] Irs2-6514 AGTTATTAAACA AACAG GCTATATAAACTTTAACAGTTATTAAACAGTG ACAGUUAUUAAACAG

[0758] Irs2-6530 TTTTCTTTGGGTA (SEQ ID NO: 9) UGUUU (SEQ ID NO: 26)

[0759] CATTTCAAGAAGAGCAGGCATATGCAATATTT AGGCAUAUGCAAUAU

[0760] Irs2-6373 ACATCCTTAATTT (SEQ ID NO: 14) UUACA (SEQ ID NO: 31)

[0761] TATTGACCATGGATGCCCTCCTTAATAGCCAT CCCUCCUUAAUAGCC

[0762] Irs2-6742 ATGCAATAAAATA AUAUG GTAGAAGAAGGCTGTATTGCAAGACAAAGTT AUUGCAAGACAAAGU

[0763] Irs2-5984 GAATGTAAATTGAT (SEQ ID NO: 13) UGAAU (SEQ ID NO: 30)

[0764] GCGCTCGACTGCTGTCTGAACATCAACAAGCG CUGAACAUCAACAAG

[0765] Irs2-794 CGCGGACGCCAAG (SEQ ID NO: 11) CGCGC (SEQ ID NO: 28)

[0766] TGAAACCTAAGGGACTGGGCCAGAGCAAGAA UGGGCCAGAGCAAGA

[0767] Irs2-1110 CCTGACTGGTGTAT (SEQ ID NO: 10) ACCUG (SEQ ID NO: 27)

[0768] CCGTCTACCGCGAGGTGTGGCAGGTGAACCT UGUGGCAGGUGAACC

[0769] Irs2-1080 GAAACCTAAGGGAC UGAAA CGCCGCTGCGGCCACTCGGACAGCTTCTTCTT UCGGACAGCUUCUUC

[0770] Irs2-1241 CATCGAGGTGGGC UUCAU TGGAAGTGGTCAAATCTGGTATTTACTGGCTT CUGGUAUUUACUGGC

[0771] Irs2-4902 ACAGTCAAAACTA (SEQ ID NO: 12) UUACA (SEQ ID NO: 29)

[0772] ATAACAACAACAACAACAACAACCACAGCGT ACAACAACCACAGCG

[0773] Irs2-576 GCGCAAGTGCGGCT UGCGC TTGGGATGTATATATATATATATATATATGTG AUAUAUAUAUAUAUG

[0774] Irs2-5826 TCACTATAGAATA UGUCA GCATCTTAAGCAGTTTGGGCCACATAGCACTG UGGGCCACAUAGCAC

[0775] Irs2-6077 TGTGTGCTATCCT UGUGU AGCAATTCTACATTTTGAGACTTCTGTGAATT UGAGACUUCUGUGAA

[0776] Irs2-4621 AGATAAGGAACCA UUAGA ATTGTTTTGTTTTTGTTTGGGATGTATATATAT UUUGGGAUGUAUAUA

[0777] Irs2-5810 ATATATATATAT UAUAU TTGTACATTTTGCTTGACTTAATCTTAAATTTA GACUUAAUCUUAAAU

[0778] Irs2-6486 AACTATTTTTTG UUAAA CTACACTAATAACTCTTGGAAATGTGAGTTGC UUGGAAAUGUGAGUU

[0779] Irs2-5761 TGGTTTATTTTTT GCUGG GTTATTAAACAGTGTTTTCTTTGGGTACATGTT UUUCUUUGGGUACAU

[0780] Irs2-6548 TCCTGGATACCA (SEQ ID NO: 16) GUUUC (SEQ ID NO: 33)

[0781] TACACTAATAACTCTTGGAAATGTGAGTTGCT UGGAAAUGUGAGUUG

[0782] Irs2-5762 GGTTTATTTTTTA CUGGU AAGACAAGAATAAACTGGAGTAGATTAGTTT UGGAGUAGAUUAGUU

[0783] Irs2-6696 GCTGTATTTAGTCT (SEQ ID NO: 17) UGCUG (SEQ ID NO: 34)

[0784] TATATATATATATGTGTCACTATAGAATAATG GUCACUAUAGAAUAA

[0785] Irs2-5842 CATTGGTAAGGTA UGCAU ATATTCTCCGTGGGATTGGACTTGAAGATGGA UUGGACUUGAAGAUG

[0786] Irs2-5113 TTAATCCTAAAAA GAUUA TCTGTTGTCAGTGTTCTGGAAATGTCAGTGTT CUGGAAAUGUCAGUG

[0787] Irs2-5587 GTGGAACTGTTTC UUGUG TACCCAGAGGACTATGGAGACATTGAGATTG GGAGACAUUGAGAUU

[0788]

[0789] Irs2-2384 GTTCTCACAAGAGT GGUUC

[0790] 82690703v1 98Attorney Docket No.: UM9-328PC (776088)

[0791] Table 2B. Mouse and human cross-reactive IRS2 Targeting siRNA Sequences

[0792] ID Antisense Strand Sense Strand GUUAAAGUUUAUAUAGCAAA GCUAUAUAAACUUUAA

[0793] Irs2-6512 (SEQ ID NO: 63) (SEQ ID NO: 64)

[0794] Irs2-6514 CUGUUAAAGUUUAUAUAGCA UAUAUAAACUUUAACA AAACACUGUUUAAUAACUGU GUUAUUAAACAGUGUU

[0795] Irs2-6530 (SEQ ID NO: 51) (SEQ ID NO: 52)

[0796] UGUAAAUAUUGCAUAUGCCU CAUAUGCAAUAUUUAC

[0797] Irs2-6373 (SEQ ID NO: 61) (SEQ ID NO: 62)

[0798] Irs2-6742 CAUAUGGCUAUUAAGGAGGG UCCUUAAUAGCCAUAU AUUCAACUUUGUCUUGCAAU GCAAGACAAAGUUGAA

[0799] Irs2-5984 (SEQ ID NO: 59) (SEQ ID NO: 60)

[0800] GCGCGCUUGUUGAUGUUCAG AACAUCAACAAGCGCG

[0801] Irs2-794 (SEQ ID NO: 55) (SEQ ID NO: 56)

[0802] CAGGUUCUUGCUCUGGCCCA GCCAGAGCAAGAACCU

[0803] Irs2-1110 (SEQ ID NO: 53) (SEQ ID NO: 54)

[0804] Irs2-1080 UUUCAGGUUCACCUGCCACA GGCAGGUGAACCUGAA Irs2-1241 AUGAAGAAGAAGCUGUCCGA GACAGCUUCUUCUUCA UGUAAGCCAGUAAAUACCAG GUAUUUACUGGCUUAC

[0805] Irs2-4902 (SEQ ID NO: 57) (SEQ ID NO: 58)

[0806] Irs2-576 GCGCACGCUGUGGUUGUUGU ACAACCACAGCGUGCG Irs2-5826 UGACACAUAUAUAUAUAUAU UAUAUAUAUAUGUGUC Irs2-6077 ACACAGUGCUAUGUGGCCCA GCCACAUAGCACUGUG Irs2-4621 UCUAAUUCACAGAAGUCUCA GACUUCUGUGAAUUAG Irs2-5810 AUAUAUAUAUACAUCCCAAA GGGAUGUAUAUAUAUA Irs2-6486 UUUAAAUUUAAGAUUAAGUC UUAAUCUUAAAUUUAA Irs2-5761 CCAGCAACUCACAUUUCCAA GAAAUGUGAGUUGCUG GAAACAUGUACCCAAAGAAA CUUUGGGUACAUGUUU

[0807] Irs2-6548 (SEQ ID NO: 65) (SEQ ID NO: 66)

[0808] Irs2-5762 ACCAGCAACUCACAUUUCCA AAAUGUGAGUUGCUGG CAGCAAACUAAUCUACUCCA AGUAGAUUAGUUUGCU

[0809] Irs2-6696 (SEQ ID NO: 67) (SEQ ID NO: 68)

[0810] Irs2-5842 AUGCAUUAUUCUAUAGUGAC ACUAUAGAAUAAUGCA Irs2-5113 UAAUCCAUCUUCAAGUCCAA GACUUGAAGAUGGAUU Irs2-5587 CACAACACUGACAUUUCCAG GAAAUGUCAGUGUUGU

[0811]

[0812] Irs2-2384 GAACCAAUCUCAAUGUCUCC GACAUUGAGAUUGGUU

[0813] Incorporation by Reference

[0814] The contents of all cited references (including literature references, patents, patent applications, and websites) that maybe cited throughout this application are hereby expressly incorporated by reference in their entirety for any purpose, as are the references cited therein. The disclosure will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology and cell biology, which are well known in the art.

[0815] 82690703v1 99Attorney Docket No.: UM9-328PC (776088)

[0816] Equivalents

[0817] The disclosure may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the disclosure. Scope of the disclosure is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced herein.

[0818] 82690703v1 100

Claims

Atorney Docket No.: UM9-328PC (776088)ClaimsWhat is claimed:

1. An oligonucleotide compound that is between 15 and 50 bases in length comprising substantial complementary to any one of SEQ ID NOs: 1-17.

2. The oligonucleotide compound of claim 1, comprising substantial complementary to any one of SEQ ID NOs: 18-34.

3. The oligonucleotide compound of claim 1 or 2, wherein the oligonucleotide compound is a double stranded RNA (dsRNA), an antisense oligonucleotide (ASO), a microRNA (miRNA), or a short hairpin RNA (shRNA).

4. The oligonucleotide compound of any one of claims 1-3, wherein the oligonucleotide compound is a dsRNA comprising an antisense strand with substantial complementary to any one of SEQ ID NOs: 1-34 and a sense strand.

5. The dsRNA of claim 4, wherein the antisense strand comprises no more than 3 mismatches with any one of SEQ ID NOs: 1-34.

6. The dsRNA of claim 4, wherein the antisense strand comprises full complementarity with any one of SEQ ID NOs: 1-34.

7. The dsRNA of claim 4, wherein no more than 2 mismatches are present between nucleotides 1-8 from the 5’ end the antisense strand and any one of SEQ ID NOs: 1-34.

8. The dsRNA of any one of claims 4-7, wherein the antisense strand is 15 nucleotides to 25 nucleotides in length, optionally 20, 21, or 22 nucleotides in length.

9. The dsRNA of any one of claims 4-8, wherein the sense strand is 15 nucleotides to 25 nucleotides in length, optionally 15, 16, 18, or 20 nucleotides in length.

10. The dsRNA of any one of claims 4-9, wherein the dsRNA comprises a doublestranded region of 15 base pairs to 20 base pairs, optionally 15, 16, 18, or 20 base pairs.82690703v1 101Atorney Docket No.: UM9-328PC (776088)11. The dsRNA of any one of claims 4-10, wherein the dsRNA comprises a blunt-end.

12. The dsRNA of any one of claims 4-11, wherein the dsRNA comprises at least one single stranded nucleotide overhang, optionally about a 2-nucleotide to 5-nucleotide single stranded nucleotide overhang.

13. The dsRNA of any one of claims 4-12, wherein the dsRNA comprises at least one modified nucleotide.

14. The dsRNA of claim 13, wherein the modified nucleotide comprises a 2'-O-methyl modified nucleotide, a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, or a mixture thereof.

15. The dsRNA of any one of claims 4-14, wherein the dsRNA comprises at least one modified internucleotide linkage.

16. The dsRNA of claim 15, wherein the modified intemucleotide linkage comprises a phosphorothioate intemucleotide linkage.

17. The dsRNA of any one of claims 4-16, comprising 4-16 phosphorothioate intemucleotide linkages.

18. The dsRNA of any one of claims 4-16, comprising 8-13 phosphorothioate intemucleotide linkages.

19. The dsRNA of any one of claims 4-18, wherein the nucleotides at positions 1-2 to 1- 7 from the 3’ end of the antisense strand are connected to each other via phosphorothioate intemucleotide linkages.

20. The dsRNA of any one of claims 4-19, wherein the nucleotides at positions 1-2 from the 5’ end of the antisense strand are connected to each other via phosphorothioate82690703v1 102Atorney Docket No.: UM9-328PC (776088)internucleotide linkages.

21. The dsRNA of any one of claims 4-20, wherein the nucleotides at positions 1-2 from the 5’ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages.

22. The dsRNA of any one of claims 4-21, wherein the nucleotides at positions 1-2 from the 3’ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages.

23. The dsRNA of any one of claims 4-22, wherein the dsRNA comprises at least 80% chemically modified nucleotides.

24. The dsRNA of any one of claims 4-23, wherein the dsRNA is fully chemically modified.

25. The dsRNA of any one of claims 4-24, wherein the antisense strand comprises a 5’ phosphate, a 5 ’-alkyl phosphonate, a 5’ alkylene phosphonate, or a 5’ alkenyl phosphonate.

26. The dsRNA of claim 25, wherein the antisense strand comprises a 5’ vinyl phosphonate.

27. The dsRNA of any one of claims 4-26, wherein:i) the antisense strand comprises or consists of the sequence of SEQ ID NO: 35, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 36, or a chemically modified variant thereof;ii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 37, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 38, or a chemically modified variant thereof;iii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 39, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 40, or a chemically modified variant thereof;iv) the antisense strand comprises or consists of the sequence of SEQ ID NO: 41, or a chemically modified variant thereof, and the senses strand comprises or consists of the82690703v1 103Atorney Docket No.: UM9-328PC (776088)sequence of SEQ ID NO: 42, or a chemically modified variant thereof;v) the antisense strand comprises or consists of the sequence of SEQ ID NO: 43, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 44, or a chemically modified variant thereof;vi) the antisense strand comprises or consists of the sequence of SEQ ID NO: 45, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 46, or a chemically modified variant thereof;vii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 47, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 48, or a chemically modified variant thereof;viii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 49, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 50, or a chemically modified variant thereof;ix) the antisense strand comprises or consists of the sequence of SEQ ID NO: 51, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 52, or a chemically modified variant thereof;x) the antisense strand comprises or consists of the sequence of SEQ ID NO: 53, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 54, or a chemically modified variant thereof;xi) the antisense strand comprises or consists of the sequence of SEQ ID NO: 55, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 56, or a chemically modified variant thereof;xii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 57, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 58, or a chemically modified variant thereof;xiii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 59, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 60, or a chemically modified variant thereof;xiv) the antisense strand comprises or consists of the sequence of SEQ ID NO: 61, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 62, or a chemically modified variant thereof;xv) the antisense strand comprises or consists of the sequence of SEQ ID NO: 63, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 64, or a chemically modified variant thereof;82690703v1 104Atorney Docket No.: UM9-328PC (776088)xvi) the antisense strand comprises or consists of the sequence of SEQ ID NO: 65, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 66, or a chemically modified variant thereof; orxvii) the antisense strand comprises or consists of the sequence of SEQ ID NO: 67, or a chemically modified variant thereof, and the senses strand comprises or consists of the sequence of SEQ ID NO: 68, or a chemically modified variant thereof.

28. The dsRNA of any one of claims 4-27, wherein a functional moiety is linked to the 5’ end and / or 3’ end of the antisense strand.

29. The dsRNA of any one of claims 4-28, wherein a functional moiety is linked to the 5’ end and / or 3’ end of the sense strand.

30. The dsRNA of any one of claims 4-29, wherein a functional moiety is linked to the 3’ end of the sense strand.

31. The dsRNA of any one of claims 28-30, wherein the functional moiety comprises a dendron that comprises an end group, a phosphate group, and / or a hydrophobic chain.

32. The dsRNA of claim 31, wherein the end group is a hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated Ci-24 alkyl chain; and / or one or more aromatic rings.

33. The dsRNA of claim 31 or 32, wherein the hydrophobic chain is a saturated or unsaturated Ci-24 alkyl group.

34. The dsRNA of any one of claims 31-33, wherein the dendron comprises two branches.

35. The dsRNA of any one of claims 31-33, wherein the dendron comprises four branches.

36. The dsRNA of any one of claims 31-33, wherein the dendron comprises eight branches.82690703v1 105Atorney Docket No.: UM9-328PC (776088)37. The dsRNA of any one of claims 31-36, wherein the dendron is linked to the 5’ end and / or 3’ end of the oligonucleotide.

38. The dsRNA of any one of claims 31-37, wherein the dendron has a structure of Formula I:(I) wherein:A is the sense or antisense strand of the dsRNA;B, for each occurrence, independently comprises one or more hydrophobic chains , amines, amides, esters, N- or O-containing heterocycles, thioethers, disulfides, and / or aromatic rings, wherein the hydrophobic chain comprises a saturated or unsaturated Ci-24 alkyl chain;C, for each occurrence, independently comprises: an hydrophilic group comprising hydroxide, amine, phosphate, sulfur, and / or sugar; an hydrophobic group comprising amine, amide, ether, ester, N- or O-containing heterocycles, thiol, thioether, and / or saturated or unsaturated Ci-24 alkyl chain; and / or one or more aromatic rings;D, for each occurrence, independently is a branching unit comprising one or more alkyl chains, amides, ethers, esters, and amines, wherein the branching unit comprises 2 to 4 branches; andm, for each occurrence, independently is 0 or 1.

39. The dsRNA of claim 38, wherein the dendron has a structure of Formula II:82690703v1 106Attorney Docket No.: UM9-328PC (776088)o(B)-O“P-O4BX^)(B)~~ O-P-O-(D) o / O~~ P-O-@-@Q j. ' 0- (^0-p-0{b)00‘ \ fg)_\ Q A-^ i ■— ‘(BX-O-’P-O^) 20^B)--O . p--O“--{S)~(c)O’(II)40. The dsRNA of claims 39, wherein the dendron has a structure of Formula III:(HI)wherein n, for each occurrence, independently is an integer between 1-24.

41. The dsRNA of claim 40, wherein C is OH and n, for each occurrence, independently is 1, 6, or 12.

42. The dsRNA of any one of claims 38-41, wherein the dendron has the structure of Formula IV:82690703v1 107Attorney Docket No.: UM9-328PC (776088)43. The dsRNA of any one of claims 38-41, wherein the dendron has a structure of Formula(BFo-P-O-fW)p - 9 6'(B)~ O~P~O-(B)~-O-- P - O -(pi) 0 / O" O'o J. - A.(AVO~P“O^PJ pV o o J® ■° . Fo-€>'@(B)-O-P-O^O-P-O^ 2A- ’ ■°0(B)-0"P”O”(BXC)44. The dsRNA of claim 43, wherein the dendron has a structure of Formula VI:82690703v1 108Atorney Docket No.: UM9-328PC (776088)(VI)wherein n, for each occurrence, independently is an integer between 1-24.

45. The dsRNA of claim 44, wherein C is OH and n, for each occurrence, independently is 1, 6, or 12.

46. The dsRNA of claim 45, wherein the oligonucleotide conjugate has the structure of Formula VII:(VII).

47. The dsRNA of any one of claims 28-30, wherein the functional moiety comprises a hydrophobic moiety.

48. The dsRNA of claim 47, wherein the hydrophobic moiety is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides, nucleoside analogs, endocannabinoids, vitamins, and a mixture thereof.

49. The dsRNA of claim 48, wherein the fatty acid selected from the group consisting of Docosanoic acid (DCA), Eicosapentaenoic acid (EP A), and Docosahexaenoic acid (DHA).

50. The dsRNA of claim 48, wherein the steroid selected from the group consisting of cholesterol and lithocholic acid (LA).82690703v1 109Atorney Docket No.: UM9-328PC (776088)51. The dsRNA of claim 48, wherein the vitamin is selected from the group consisting of choline, vitamin A, vitamin E, and derivatives or metabolites thereof.

52. The dsRNA of claim 48, wherein the vitamin is selected from the group consisting of retinoic acid and alpha-tocopheryl succinate.

53. The dsRNA of any one of claims 28-52, wherein the functional moiety is linked to the antisense strand and / or sense strand by a linker.

54. The dsRNA of claim 53, wherein the linker comprises an ethylene glycol chain, an alkyl chain, a peptide, an RNA, a DNA, a phosphodiester, a phosphorothioate, a phosphoramidate, an amide, a carbamate, or a combination thereof.

55. A vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes an RNA molecule substantially complementary to a IRS2 nucleic acid sequence of SEQ IDNOs: 1-34.

56. The vector of claim 55, wherein said RNA molecule inhibits the expression of said IRS2 gene by at least 20%57. The vector of claim 55, wherein said RNA molecule inhibits the expression of said IRS2 gene by at least 50%.

58. A cell comprising the vector of any one of claims 55-57.

59. A recombinant adeno-associated virus (rAAV) comprising the vector of any one of claims 55-57and an AAV capsid.

60. A branched RNA compound comprising two or more oligonucleotides of any one of claims 1-54, wherein the two or more oligonucleotides are connected to one another by one or more moieties independently selected from a linker, a spacer and a branching point.82690703v1 110Atorney Docket No.: UM9-328PC (776088)61. The branched RNA compound of claim 60, wherein the linker comprises an ethylene glycol chain, an alkyl chain, a peptide, an RNA, a DNA, a phosphate, a phosphonate, a phosphoramidate, an ester, an amide, a triazole, or combinations thereof.

62. The branched RNA compound of claim 60 or 61, wherein the linker comprises tetra ethylene glycol.

63. The branched RNA compound of claim 61 or 62, wherein the linker is of structure LI :HNOH64. The branched RNA compound of claim 61 or 62, wherein the linker is of structure L2:O / / OH (L2).

65. The branched RNA compound of any one of claims 60-64, wherein the linker is attached to the 3’ end of a first sense strand and the 3’ end of a second sense strand.

66. A pharmaceutical composition for inhibiting the expression of insulin receptor substrate 2 (IRS2) gene in an organism, comprising the oligonucleotide of any one of claims 1-54, the vector of any one of claims 55-57, the rAAV of claim 59, or the branched RNA compound of any one of claims 60-65, and a pharmaceutically acceptable carrier.

67. The pharmaceutical composition of claim 66, wherein the oligonucleotide inhibits the expression of the gene by at least 25%.

68. A method for inhibiting expression of IRS2 gene in a cell, the method comprising:82690703v1 111Atorney Docket No.: UM9-328PC (776088)(a) introducing into the cell the oligonucleotide of any one of claims 1-54, the vector of any one of claims 55-57, the rAAV of claim 59, or the branched RNA compound of any one of claims 60-65; and(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the IRS2 gene, thereby inhibiting expression of the IRS2 gene in the cell.

69. A method of treating or managing a disease comprising administering to a patient in need of such treatment or management a therapeutically effective amount of the oligonucleotide of any one of claims 1-54, the vector of any one of claims 55-57, the rAAV of claim 59, or the branched RNA compound of any one of claims 60-65.

70. The method of claim 69, wherein the disease is cancer.

71. The method of claim 70, wherein the cancer is breast cancer.

72. The method of claim 71, wherein the breast cancer is triple negative breast cancer (TNBC).

73. The method of any one of claims 69-72, wherein the oligonucleotide is administered by intravenous (IV) injection, subcutaneous (SQ) injection, intratumoral injection, or a combination thereof.82690703v1 112